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RATIONALE:  Our  laboratories  birthed  the  field  of  human  immunodeficiency  virus  (HIV)  
theranostics.  The  new  field  allows  simultaneous  detection  (diagnostics)  and  treatment  
(therapeutic)  for  the  identification,  treatment  and  inevitable  elimination  of  virus  in  cell  and  
tissue  compartments.    By  employing  theranostics,  antiretroviral  drugs  (ARVs)  can  be  
tracked  in  lymph  nodes,  gut,  spleen  and  liver.  Cellular  viral  reservoirs  including  CD4+  T  
cell  populations  and  mononuclear  phagocytes  (MP;;  monocytes,  macrophages,  microglia  
and  dendritic  cells)  along  with  subcellular  endosomal  structures  can  now  be  targeted  for  
drug  delivery  bringing  therapeutics  to  areas  where  virus  replicates.  The  overarching  idea  
rests  in  improving  precision  targeted  ARV  delivery.  Bringing  ART  to  anatomically  
privileged  tissues  can  be  visualized  and  confirmed  through  single  photon  emission  
computed  tomography  (SPECT)  imaging  facilitated  by  multimodal  antiretroviral  drug  
(ARV)  nanoprobes.  To  deploy  such  technologies,  we  have  successfully  placed  rilpivirine  
into  a  theranostic  nano  system,  taking  advantage  of  state  of  the  art  physical  and  
chemical  properties  of  nano-­sized  particles  for  maximal  biodistribution  to  viral  sites.  This  
allowed  measurements  of  optimal  antiretroviral  responses.  To  achieve  this  outcome,  we  
made  particles  with  combinations  of  bioimaging  detectors  and  ARV  deliverers.    This  
platform,  in  future  studies,  will  utilize  LASER  ART  and  HIV-­1  excision  payloads  (for  
example,  CRISPR  Cas9)  for  the  inevitable  elimination  of  viral  infection.    Our  overall  goal  
is  to  facilitate  long-­acting  slow  effective  release  antiretroviral  therapy  (LASER  ART)  
development.  To  this  end,  in  a  first  step  analysis  we  created  “multimodal  imaging  
theranostic  nanoprobes”  with  the  hydrophobic  antiretroviral  drug  rilpivirine  (RPV).  These  
unique  nanoprobes  allowed  combined  bioimaging,  drug  pharmacokinetics  and  tissue  
biodistribution  tests  in  animal  models.  Combination  of  SPECT/CT  and  MR  imaging  
modalities  resulted  in  a  highly  accurate  and  sensitive  nanoprobe.  Because  of  this  
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combination,  the  imaging  data  acquired  from  these  nanoprobes  after  administration  in  
mice  proved  predictive  of  future  drug  pharmacokinetics  and  biodistribution.  
METHODS:  111Indium  (111In)  and  Europium  (Eu3+)-­doped  cobalt  ferrite  (CF)  rilpivirine  
(RPV)-­loaded  (111InEuCF-­RPV)  nanoparticles  were  synthesized  then  fully  characterized  
based  on  their  size,  shape  and  stability.  The  particles  were  tested  in  vitro  for  uptake,  
retention  and  antiretroviral  efficacy  in  human  monocyte-­derived  macrophages  (MDMs)  
along  with  the  intracellular  location  of  particles.  These  were  then  used  as  platforms  for  
nanoformulated  drug  biodistribution.  For  multimodal  imaging  and  biodistribution  studies;;  
111InEuCF-­RPV,  ultra-­small  lipid  coated  177LuEuCF  and  NRPV  particles  were  injected  
intravenously  into  mice  at  various  concentrations  of  drug  or  radioisotope.  One  group  was  
treated  with  ultra-­small  lipid-­coated  177LuEuCF  particles  at  ∼  74  MBq  (2000  μCi)  to  
assess  the  effect  of  particle  size  on  biodistribution.  Drug  levels  were  quantified  in  plasma  
and  tissues  by  UPLC-­MS/MS  and  cobalt  levels  were  quantified  by  ICP-­MS.  Pearson’s  
correlations  were  used  to  assess  the  predicative  potential  of  imaging  data  and  future  
ARV  biodistribution  and  pharmacokinetics.  
RESULTS:  111InEuCF-­RPV  particles  were  synthesized  and  were  shown  to  be  of  
consistent  size  and  were  stable  in  a  variety  of  different  media  conditions  for  over  a  week.  
Physiochemical  characterizations  and  TEM  imaging  confirmed  the  structure  and  
components  of  the  system  were  correct.  Formed  theranostic  particles  were  shown  to  be  
non-­toxic  to  MDMs  and  at  high  concentrations  were  much  less  cytotoxic  than  native  
RPV.  Particles  demonstrated  excellent  intracellular  relaxivity  values  of  r2  =  732.8  mM-­1s-­1  
and  thus  served  as  excellent  MRI  contrast  agents.  Drug  particles  were  detected  in  
macrophage  Rab  compartments  by  dual  fluorescence  labeling.  Replicate  particles  
elicited  sustained  antiretroviral  responses  similar  to  nanoformulated  RPV.  After  
administration  to  Balb/c  mice  particles  could  be  localized  to  the  spleen,  liver,  as  well  as  
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popliteal  and  axillary  lymph  nodes.  Imaging  showed  that  nanoparticles  accumulated  in  
the  spleen  over  5  days  and  gradually  left  the  liver  as  confirmed  by  ex  vivo  
autoradiographic  imaging  and  gamma  scintillation  spectrometry.  Imaging  data  acquired  
up  to  5  days  proved  predicative  of  drug  biodistribution  and  pharmacokinetics  up  to  28  
days  post  administration.    
CONCLUSIONS:  We  conclude  that  this  novel  nano  system  can  be  used  broadly  
for  theranostic  antiretroviral  drug  biodistribution.    In  particular,  in  the  not  so  
distant  future,  it  will  enable  the  merger  of  LASER  ART  with  detection  methods  to  
realize  the  long  term  goal  of  improving  patient  outcomes  by  assessing  where  and  
to  what  levels  antiretroviral  drugs  are  delivered  into  viral  compartments.    The  
long  term  goals  are  to  best  prevent  new  infections,  achieve  viral  elimination,  and  











1.1  Global  significance  of  HIV    
Human   Immunodeficiency   virus   (HIV)   is   a   progressive   retrovirus   of   the  
human   immune  system  which,   if   left  untreated,  can  eventually   lead   to  acquired  
immunodeficiency   syndrome   (AIDS).   This   virus   represented   a   global   pandemic  
shortly  after  its  discovery  in  the  early  1980’s  and  at  the  time  an  HIV  diagnosis  was  
practically  a  death  sentence.  However  since  its  discovery,  HIV  has  been  a  major  
focus   of   medical   research   for   several   decades,   with   the   molecular   structure,  
function,   regulation,   tropism,   and   means   of   viral   persistence   having   been  
documented  [1-­3].  Regardless  of  such  efforts,  more  than  70  million  people  have  
been  infected  with  HIV  since  its  discovery  and  35  million  people  have  succumbed  
to  the  virus  after  initial  infection  [4].  Additionally,  in  2018  there  were  approximately  
38  million  people  living  with  HIV,  with  1.7  million  people  becoming  newly  infected  
in   2018.   Treatment   and   management   of   patients   infected   with   the   virus   has  
become  and  continues  to  be  one  of  the  greatest  challenges  of  the  modern  medical  
era.  
Development  of  treatment  options  for  patients  infected  with  HIV  is  arguably  
one  of   the  most  significant  victories   in  pharmaceutical   research,  with  dozens  of  
effective   antiretroviral   therapies   (ART)   being   brought   to   market   since  
azidothymidine  (AZT)  was  first  approved  in  1987  [5,  6].  There  is  no  cure  for  HIV  
infection.  However,  effective  antiretroviral  (ARV)  drugs  can  control  the  virus  and  
help  prevent  transmission  so  that  people  with  HIV,  and  those  at  substantial  risk,  
can  enjoy  healthy,  long  and  productive  lives.  Furthermore,  more  recent  innovations  
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in  ART  technology  have  allowed  concurrent  administration  of  multiple  antiretroviral  
compounds   to   patients,   drastically   increasing   their   effectiveness   in   limiting  HIV  
replication   and   inhibiting   viral   resistance.   Combination   ART   (cART)   markedly  
reduces  HIV  replication  such  that  HIV  RNA  is  undetectable  within  plasma,  which  
halts  further  loss  of  CD4+  T  cells  and  prevents  progression  to  AIDS  [7,  8].  However,  
despite   such   pharmacological   advances   and   sustained   viral   suppression,   ART  
cannot   eliminate   viral   infection.   Complete   viral   eradication   will   require   the  
development  of  novel  drug  technologies,  with   improvements   in  drug  design  and  
delivery  being  at  the  forefront  of  significance    
  
  1.2  HIV-­1  virology    
1.2.1  Structure  of  HIV  
HIV  is  a  retrovirus,  whose  genome  encodes  its  own  reverse  transcriptase  
which,  after  translation  by  the  host  cell,  is  used  to  transcribe  single  stranded  viral  
RNA  into  a  double  stranded  DNA  that  can  be  integrated  into  the  host  genome.    HIV  
isolates  are  currently  grouped  into  two  types,  HIV-­type  1  (HIV-­1)  and  HIV-­type  2  
(HIV-­2)   [9,   10].   The   worldwide   main   agent   of   AIDS   is   HIV-­1,   while   HIV-­2   is  
restricted   to   some   regions   of   Western   and   Central   Africa   [11].   However,   both  
tropisms   share   many   similarities   in   terms   of   genetics   and   structure.   HIV   is   a  
genetically   related   member   of   the   lentivirus   genus   of   the   retroviridae   family.  
Infections  with  lentiviruses  typically  show  a  chronic  course  of  the  disease,  with  a  
long  period  of  clinical  latency,  persistent  viral  replication,  and  involvement  of  the  
central  nervous  system  [12].    
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Two   identical   copies  of   single  stranded  RNA   reside  within   the  cylindrical  
capsid  of  the  virus  and  are  characterized  by  the  presence  of  structural  genes  gag,  
pol,  env  [1,  13].  The  group-­specific  antigen  gene,  or  gag,  encodes  the  proteins  that  
comprise  viral  core  and  matrix,  such  as  viral  capsid  proteins  HIV  p24,  p6  and  p7.  
Gag  also  encodes  matrix  protein  HIV  p17  [14].  The  env  gene  encodes  proteins  
that   form   the   viral   envelope,   specifically   glycoprotein   120   (HIV   gp120)   and  
transmembrane  glycoprotein  41  (HIV  gp41).  The  pol  gene  encodes  for  enzymes  
crucial  for  viral  replication,  which  are  the  reverse  transcriptase  that  converts  viral  
RNA   into   DNA,   the   integrase   that   incorporates   the   viral   DNA   into   host  
chromosomal  DNA  (the  provirus),  and  the  protease  that  cleaves  large  gag  and  pol  
protein  precursors  into  their  functional  proteins.  [15].  All  three  genes  are  critical  for  
the  propagation  of  HIV  within  an  infected  host,  and  as  such  these  genes  and  the  
proteins  they  encode  have  become  biological  targets  of  antiretroviral  drug  (ARV)  
therapy.    
In  addition   to   these  enzymes,  several  genes   that  encode  accessory  and  
immune-­regulatory  proteins  play  a  vital   role   in  viral   infectivity.  Trans-­activator  of  
transcription,  or  Tat,  causes  substantially  increased  levels  of  reverse  transcription  
to  occur  after  a  small  number  of  RNA  transcripts  are  made  via  a  positive  feedback  
loop  [14].    Regulator  of  viral  protein  expression,  or  Rev,  dictates  the  movement  of  
RNA  from  cytoplasm  to  nucleus.  Other  necessary  proteins  include  viral  protein  R  
(Vpr),  viral  infectivity  factor  (Vif),  negative  regulatory  factor  (Nef),  and  HIV-­1p7  [16].  
While   the   biological   mechanism   in   which   Vpr,   Vif,   and   Nef   influence   HIV-­1  
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replication  are  not  completely  known,  it  has  been  established  that  these  proteins  
positively  affect  HIV-­1  replication.    
HIV   viral   particles   have  a   diameter   of   100   nm  and  are   surrounded  by   a  
lipoprotein-­rich  membrane.   Each   viral   particle   membrane   includes   glycoprotein  
heterodimer  complexes  composed  of  trimers  of  the  external  surface  gp120  and  the  
transmembrane  spanning  gp41  glycoproteins  bound  together  [17,  18].  During  the  
process  of  budding  from  the  infected  cell  (discussed  in  the  next  section),  the  virus  
may   also   incorporate   into   its   membrane   different   proteins   from   the   host   cell  
membrane,   such   as  HLA   class   I   and   II   proteins,   or   adhesion   proteins   such   as  
ICAM-­1  that  may  facilitate  adhesion  to  other  target  cells  [19].    
The   primary   target   of   progeny   infectious  HIV-­1   and   the  most   commonly  
infected   cell   is   the  CD4+   T   lymphocyte   [20,   21].   This   was   shown   by   isolation,  
propagation  and  molecular  analyses  of  the  viral  genome  in  HIV-­1  infected  patients  
[22,  23].  These  investigations  definitively  showed  that  proviral  DNA  is  integrated  
within   the   genomes   of   CD4+   T   cells   and   to   more   limited   degree   monocyte-­
macrophages   [24].   Indeed,   impaired   immune   response   is   characteristic   of   all  




1.2.2   The  HIV  replication  cycle  
The  HIV  replication  cycle  can  be  summarized  in  six  steps;;  1)  binding  and  
entry;;  2)  uncoating;;  3)  reverse  transcription;;  4)  provirus  integration;;  5)  virus  protein  
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synthesis  and  assembly  and  6)  budding.  The  entry  process  of  HIV-­1  and  HIV-­2  
can  be  divided   into   three  major  events:   virus  binding   to   the  cell,   activation  and  
fusion.  The  viral  envelope  trimeric  complex,  composed  of  the  heterodimer  proteins  
gp120  and  gp41,  is  essential  for  virus  recognition  and  entry  into  target  cells  [26].  
HIV  gp120  binds  a  58  kDa  monomeric  glycoprotein,  designated  as  CD4,  which  is  
expressed  on  the  cell  surface  of  circulating  T-­lymphocytes,  on  T-­cell  precursors  
within   the   bone   marrow   and   thymus,   monocytes/macrophages,   eosinophils,  
dendritic  cells  and  microglial  cells  of  the  central  nervous  system  [27-­30].  The  CD4  
molecule   normally   functions   as   a   co-­receptor   of   the   major   histocompatibility  
complex  class  II  molecule  during  T-­cell  recognition  of  a  foreign  antigen  [31].  Upon  
gp120   binding   with   the   CD4   protein,   the   virus   envelope   complex   undergoes   a  
structural  change,  exposing  a  specific  domain  in  the  gp120  protein  that  is  able  to  
bind   chemokine   receptors,   which   function   as   viral   “co-­receptors”,   on   the   cell  
membrane.  The  most  common  co-­receptors  used  by  HIV  are  CCR5  and  CXCR4,  
but  other  potential  co-­receptors  have  been  described  [32,  33].  The  double  binding  
of  gp120   to  both  CD4  and  one  chemokine   receptor  creates  a  more  stable   two-­
pronged   attachment   of   the   virus,   which   in   turns   allows   the   N-­terminal   fusion  
peptide  gp41  to  penetrate  the  cell  membrane,  eventually  leading  to  fusion  of  the  
cell  and  viral  membranes  [34].  
Following  membrane  fusion,   the  virus  core  uncoats   into   the  cytoplasm  of  
the  target  cell  freeing  the  viral  RNA  (uncoating).  The  conversion  of  viral  RNA  into  
proviral  DNA  takes  place  because  of  the  action  of  the  reverse  transcriptase  [35].  
The  integration  of  proviral  DNA  is  accomplished  via  the  integrase  enzyme  and  the  
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expression  of  the  provirus  requires  that  the  target  cell  is  in  an  activated  state  [36,  
37].   Monocytes/macrophages,   microglial   cells,   and   latently   infected   quiescent  
CD4+   T-­cells   contain   integrated   provirus   and   are   important   long-­living   cellular  
reservoirs  of  HIV   [38].  Upon  cell   activation,   transcription  of   proviral  DNA   into  a  
messenger   RNA   occurs.   Transcription   process   initially   results   in   the   early  
synthesis  of  regulatory  HIV  proteins  such  as  Tat  and  Rev.  Tat  binds  to  the  TAR  
site  (Transactivation  Response  Element)  at  the  beginning  of  the  HIV  RNA  in  the  
nucleus   and   stimulates   the   transcription   and   the   formation   of   longer   RNA  
transcripts.  Rev  also   facilitates   the   transcription  of   longer  RNA  transcripts  but   it  
also   induces   expression   of   structural   and   enzymatic   genes  while   inhibiting   the  
production  of  regulatory  proteins,  therefore  promoting  the  formation  of  mature  viral  
particles  [39-­41].  
Viral  messenger  RNA  coding  for  large  precursor  proteins  migrates  into  the  
cytoplasm,  where  structural  proteins  of  new  virions  are  synthesized.  The  proteins  
coded  by  pol  and  gag  genes  form  the  nucleus  of  the  maturing  HIV  particle  and  the  
gene  products  coded  by   the  env   gene   form   the  glycoprotein  spikes  of   the  viral  
envelope   [42-­44].  Large  gp160  precursor  molecules  are  cleaved  by   the  cellular  
proteases  into  gp120  and  gp41  [45].  The  viral  protease,  integrase,  RNase  H,  and  
reverse  transcriptase  (RT)  are  always  expressed  within  the  context  of  a  Gag-­Pol  
fusion  protein,  the  gag-­pol  precursor  (gp160).    
The  cleavage  of  the  precursor  molecules  by  the  HIV  protease  is  necessary  
for  the  generation  of  infectious  viral  particles.  The  formation  of  new  viral  particles  
is  a  stepwise  process:  two  viral  RNA  strands  associate  together  with  replication  
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enzymes,  while  core  proteins  assemble  over  them  forming  the  virus  capsid.  This  
immature   particle   migrates   towards   the   cell   surface.   Large   precursor   env  
molecules  are  then  cleaved  by  the  HIV  protease,  resulting  in  new  infectious  viral  
particles,   which   bud   through   the   host   cell   membrane   thus   acquiring   a   new  
envelope   [46].   During   the   budding   process,   the   virus   lipid   membranes   may  
incorporate  various  host  cell  proteins  and  become  enriched  with  phospholipids  and  
cholesterol.  Ultimately,  the  massive  release  of  HIV  virion  leads  to  the  death  of  the  
CD4+  T  cells  [47].    
Importantly,  reverse  transcription  is  completed  by  HIV  enzymes  utilizing  the  
infected  host  cell’s  deoxynucleotides.  Viral  DNA  synthesis  occurs  concurrently  with  
the  degradation  of  the  original  viral  RNA,  as  the  reverse  transcriptase  enzyme  also  
has  RNase  activity.  During   each   iteration   of  RNA   to  DNA   reverse   transcription  
within  an  infected  host  cell,  the  probability  of  a  random  mutation  is  relatively  high  
due  to  reverse  transcriptase’s  relatively  poor  proof  reading  capabilities  [48].  This  
is   what   allows   HIV   to   develop   viral   mutations   over   time   that   potentially   are  
beneficial  to  its  propagation  within  the  host,  such  as  developing  ART  resistance.  
Reverse   transcription   is   performed   twice   to   produce   a   double   stranded   DNA  
molecule,  after  which  there  is  binding  to  the  viral  integrase  enzyme.  Integrase  can  
then  transport  the  double  stranded  viral  DNA  into  the  nucleus  of  the  host  cell  as  
well  as  creating  a  cut  within  the  host  cell  genome  for  viral  DNA  integration  [49].    
1.3  Viral  transmission  
Transmission  occurs  by  separate  routes  (through  contaminated  needles,  by  
transfusion  of  blood  and  blood  products,   from  mother   to   fetus  and  by   receptive  
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anal  or  vaginal   intercourse)  [50].  The  actual  process  ensues  through  cells  or  by  
the  virus  itself.    As  per  the  latter,  HIV  is  released  to  float  freely  within  plasma  until  
they   come   in   contact   and   interact   with   a   host   cell   suitable   for   entrance   and  
infection.   “Cell-­to-­cell   transmission”   is   the   alternative   mechanism   for   the  
progression  of  HIV  infection,  in  which  direct  contact  between  an  infected  cell  with  
an   uninfected   naïve   cell   results   in   HIV   transmission.   Cell-­to-­cell   transmission  
occurs  during  the  fusion  of  HIV  infected  cells  with  that  of  uninfected  susceptible  
cells;;   the   fusion  process   causes   the   viral   components   to   be  deposited   into   the  
uninfected  cell,  subsequently  causing  multinucleated  giant  cells  [51,  52].    
1.4  Immune  Response  to  HIV-­1  
AIDS  occurs  as  a  consequence  of  progressive  viral  infection  and  CD4+  T  
cell  depletion.    It  is  classified  as  patients  infected  with  HIV-­1  that  have  CD4+  T  cell  
counts  below  200  per  µl,  which  compromises  cell-­mediated  immunity.  This  lack  of  
cell-­mediated  immunity  leaves  patients  extremely  vulnerable  to  opportunistic  viral,  
fungal,  parasitic  and  mycobacterial  infections  as  well  as  immune  related  cancers  
that   are   strongly   associated   with   advanced   HIV   infection   [16,   53].   Ultimately,  
patients  succumb  to  HIV  not  directly  from  the  virus  itself,  but  rather  indirectly  as  
opportunistic  infections  take  advantage  of  a  weakened  and  dysfunctional  immune  
system.   However,   the   progression   of   the   HIV   disease   state,   from   initial  
infection/transmission  to  complete  immune  failure,  is  a  process  taking  many  years  
or  even  decades,  and  is  characterized  into  several  distinct  stages  defined  by  the  
current  immune  response  [54].  These  four  stages  are:  primary  infection,  a  clinically  
asymptotic  period,  symptomatic  HIV  infection,  and  HIV  to  AIDS  progression.  Each  
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infected  individual  varies  in  their  respective  length,  severity,  and  symptoms  of  each  
stage;;   it   is   of   importance   to   mention   that   patients   consistently   taking   ARV  
medication  generally  will  not  progress  to  the  later  stages  of  the  disease  [54].    
Primary  infection  is  the  beginning  of  HIV  disease  progression  as  the  virus  
establishes  itself  within  the  host  body.  This  stage  typically  lasts  only  a  few  weeks  
after  initial  transmission.  Within  the  first  24  hours  after  infection,  HIV  virions  infect  
dendritic  cells  within   the  mucous  membrane;;  after  about  5  days,   these   infected  
dendritic   cells   are   recruited   to   lymph   nodes   and   the   peripheral   blood,   where  
replication   rates   dramatically   increase.   The   primary   infection   stage   is  
characterized   by   substantially   decreasing   CD4+   T   cells   and   exponentially  
increasing  levels  of  viremia,  often  millions  of  virus  copies  per  milliliter  of  plasma  
[55].  Such  a  large  number  of  HIV  viral  particles  within  the  blood  allows  for  systemic  
infection  of  peripheral  lymphoid  organs.  Regardless  of  this  viral  spike,  the  body’s  
immune  response  during  primary  infection  eventually  results  in  reduction  of  virus  
levels  within  the  peripheral  blood.  Virus  specific  cytotoxic  T  lymphocytes  (CTLs)  
appear   early   in   infection   and   potentially   downregulate   HIV   replication   [56,   57].  
CD8+   T   cells   are   also   credited   in   controlling   the   initial   viremia   peak   that   is  
characteristic   of   primary   infection;;   activated   and  mature  CD8+  T   cells   possess  
different  anti-­HIV  processes.  Specifically,  CD8+  T-­cells  can  release  cytokines  such  
as  RANTES,  MIP-­1  alpha,  and  MIP-­1  beta  that  can  effectively  block  the  entry  of  
HIV  into  host  cells  by  competing  for  or  downregulating  cellular  co-­receptor  CCR5  
[56,  57].  Following  a  severe  reduction  in  plasma  viremia  and  a  small  rebound  in  
CD4+  T-­cell  populations,  patients  progress  to  the  clinically  asymptomatic  stage.    
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The   period   of   time   between   the   initial   primary   infection   stage   and   the  
development  of  AIDS  is  classified  as  the  clinically  asymptomatic  stage.  After  the  
initial  viremia  peak  and  subsequent  decrease  in  HIV  plasma  characteristic  of  the  
primary   infection   stage,   HIV   continues   to   replicate   within   infected   cells   and   is  
readily  detected  in  almost  all  lymphoid  tissue  [58,  59].  Consistent  viral  replication  
results  in  chronic  immune  stimulation;;  this  strain  on  the  immune  system  is  thought  
to  be  responsible  for  its  eventual  deterioration  as  well  as  the  progressive  death  of  
lymphoid   tissue   [60].   Despite   continual   propagation   of   the   virus   and   gradually  
decreasing  CD4+  T-­cell  populations,  infected  patients  generally  don’t  exhibit  any  
clinical  symptoms  at  this  stage,  as  immunodeficiency  has  not  progressed  enough  
to  compromise  cell-­mediated  immune  function.    
The  final  phase  includes  both  the  stage  of  symptomatic  HIV  infection  as  well  
as   the   progression   of  HIV-­1   to   AIDS.  While   the   immunological   hallmark   of   the  
progression   from   the   asymptomatic   stage   is   gradual   loss   of   CD4+   T-­cells,   the  
symptomatic  stage  is  defined  by  a  steeper  decline  in  CD4+  T  cell  populations  and  
overall  increase  in  systemic  viral  load  [61].  This  is  due  to  systemic  viral  replication  
at  multiple   sites   in   addition   to   the   high   amount   of   replication   happening  within  
lymphoid   tissue.   The   amount   of   time   required   for   the   development   of   clinical  
immunodeficiency   from   the   asymptomatic   stage   is   variable   among   infected  
individuals:  indeed,  the  complexity  of  host  and  viral  factor  interactions  are  integral  
to   the   eventual   outcome   of   the   disease   [54].   Overall,   low   amounts   of   viral  
replication   and   retention   of   immune   function   favors   a   slow   progression   of   HIV  
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infection,  while  high  viremia  and  immune  dysfunction  leads  to  a  more  rapid  disease  
progression.     
1.5  HIV-­1  reservoirs  
The  establishment  and  maintenance  of  HIV  reservoirs  that  lead  to  persistent  
viremia   in  patients  on  antiretroviral  drugs   remains   the  greatest  challenge  of   the  
HAART   era.      Cellular   reservoirs   include   resting  memory   CD4+   T   lymphocytes,  
which  are  implicated  as  the  major  HIV  reservoir  [62].  Some  anatomical  reservoirs  
that  may  harbor  such  cells  include  the  central  nervous  system,  the  gastrointestinal  
tract   and   the   gut-­‐associated   lymphoid   tissue,   other   lymphoid   organs,   and   the  
genital   tract   [63,  64].  The  presence  of   immune  cells  and  other  HIV  susceptible  
cells,   occurring   in   differing   compositions   in   anatomical   reservoirs,   coupled  with  
variable  and  poor  drug  penetration  that  results  in  suboptimal  drug  concentrations  
in  some  sites,  are  all  likely  factors  that  fuel  the  continued  low-­‐level  replication  and  
persistent  viremia  during  treatment  [65,  66].  Latently,  HIV-­‐  infected  CD4+  T  cells  
harboring  replication-­‐competent  virus,  HIV  cell-­‐to-­‐cell  spread,  and  HIV-­‐  infected  T  
cell  homeostatic  proliferation  due  to  chronic  immune  activation  represent  further  
drivers  of  this  persistent  HIV  viremia  during  highly  active  antiretroviral  therapy  [67].  
1.5.1  Genital  tract  
   Evidence   suggests   that   both   male   and   female   genital   tracts   may   be  
important   reservoirs   of   HIV.   In   the   male   genital   tract,   drug   resistance   persists  
longer   than   in   blood   that   may   indicate   local   drug   penetration   barriers   and  
independent   selection   pressures   although   antiretroviral   therapy   can   effectively  
reduce   HIV-­‐1   levels   in   semen   [68].   Even   with   antiretroviral   therapy,   irregular  
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seminal  HIV  shedding  can  occur  [69].  This  may  be  due  to  the  presence  of  both  the  
virus   and   CD4+   T   lymphocytes   in   semen,   which   support   and   provide   an  
environment  for  continued  replication  within  the  seminal  tract  [70].  In  females,  HIV  
is  also  archived  in  the  genital  tract  early  in  infection  and  has  been  detected  in  some  
women  with  undetectable  levels  in  blood.  Mutation  patterns  from  blood  and  genital  
tract   specimens   may   differ   and   even   within   the   genital   tract,   viruses   from  
cervicovaginal   lavage   specimens   exhibited   genetically   distinct   characteristics  
when  compared  to  viruses  from  endocervical  secretions  which  supports  the  theory  
of  this  tissue  acting  as  a  viral  reservoir  [71].  Low-­‐level  HIV  replication  in  the  male  
and   female   genital   tract   remains   a   possible   explanation   for   persistent   viremia  
during  HAART  possibly  because  of  poor  drug  penetration  and  suboptimal  drug  
concentrations  and  the  presence  of  infected  long-­‐lived  cells  in  these  compartments  
[72].  
Additionally,  activated  cells  in  the  genital  tract  mucosa  are  very  important  
for   the   initial   establishment   of   infection   and   the   spread   of   virus   to   different  
reservoirs.   Dendritic   cells   (DCs)   in   the   genital   tract   mucosa   are   the   main   HIV  
targets   during   sexual   transmission   [73,   74].   Dendritic   cells   express   the   HIV  
receptors   CD4,   chemokine   receptors   CCR5   and   CXCR4   together   with   CD209  
protein,   also   known  as   dendritic   cell–specific   intercellular   adhesion  molecule-­‐3-­‐
grabbing  nonintegrin  (DC-­‐SIGN)  [75].  The  DC-­‐SIGN  enhances   infection  through  
high  affinity  binding  to  the  HIV  glycoprotein  gp120,  aiding  transmission  of  the  virus  
to  T  lymphocytes  [76].  HIV  particles  in  DC-­‐SIGN–positive  cells  are  not  degraded  
and  can  remain  stable  and  infectious  for  more  than  9  months  [76,  77].    
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1.5.2  Lymphoid  Organs  
   After   initial   exposure   to   antigen   presenting   DC-­‐SIGN–positive   DCs   at  
mucosal   surfaces,   the   virus   is   internalized,   processed,   and   presented   to   T  
lymphocytes  initiating  an  adaptive  immune  response  [55].  HIV  takes  advantage  of  
immature   DCs   in   the   genital   tract,   which   capture   the   virus   to   gain   access   to  
lymphoid  tissue  compartmentalized  CD4+  T  cells.  HIV  then  replicates  in  CD4+  T  
cells  in  the  lymph  nodes  before  infected  T  cells  and  free  viruses  enter  the  thoracic  
duct   and   spread   into   the   bloodstream,   to   other   lymphoreticular   tissues   and  
immune-­‐associated   organs   such   as   the   thymus,   bone   marrow,   gut-­‐associated  
lymphoid  tissue  (GALT),  and  spleen,  and  CNS  [55,  78,  79].  Persistent  replication  
in  lymph  nodes  and  lymphatic  tissues  despite  HAART  and  lower  concentrations  of  
the  antiretroviral  (ARV)  drugs  compared  to   levels   in  peripheral  blood  provides  a  
“hiding   place”   for   HIV   in   this   compartment   [80].   Animal   model   studies   have  
demonstrated   that   the   lymph  nodes  may  harbor   viral   reservoirs   responsible   for  
virological   failure   if   treatment   is   terminated   whereas   some   drugs   such   as  
nonnucleoside  reverse  transcriptase  inhibitor  efavirenz,  the  nucleoside/nucleotide  
reverse  transcriptase  inhibitor  drugs  tenofovir  and  emtricitabine,  and  atazanavir  a  
protease  inhibitor  have  all  been  shown  to  have  much  lower  levels  in  lymph  nodes  
compared  to  peripheral  blood.  
   Spleen  and  bone  marrow  may  also  be  important  HIV  reservoirs  with  studies  
showing   increased   splenic   inflammatory   activity   in   HIV-­‐   infected   individuals  
compared   to   noninfected   individuals.   Abnormalities   in   hematopoietic   progenitor  
cells   (HPCs)  due   to  bone  marrow   infection  and   the  establishment  of   latent  HIV  
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infection  have  also  been  reported.  Not  much  is  known  about  the  importance  of  the  
thymus  as  an  HIV  reservoir,  but  in  vitro  infection  of  thymocytes  by  HIV  has  been  
reported   [79].   In   vivo   studies   show   that   HIV   can   infect   the   thymus   and   is  
accompanied  by  increased  activation  and  depletion  of  CD4+  T  cells  [81].  Animal  
model   studies   using   bone   marrow-­‐liver-­‐thymus–humanized   mice   demonstrated  
that   ARV   drugs   adequately   penetrated   the   human   thymic   organoid   but   did   not  
eliminate  HIV  replication   in   this   tissue  or  other   tissues   including   the  spleen  and  
lymph  nodes,  further  highlighting  these  tissues  as  possible  reservoirs  and  sources  
of  persistent  viremia  during  HAART  [82].  
1.5.3  Gastrointestinal  Tract  
The  GIT  contains  a  high  proportion  of   the   total   lymphocytes   in   the  body  
through   the   GALT   that   also   harbors   numerous   innate   immune   cells   such   as  
macrophages  and  DCs  making  this  a  favorable  site  for  both  HIV  acquisition  and  
replication   [83,   84].   Prolonged   immune   activation   results   in   depletion   of   GALT  
lymphocytes  early  in  infection  and  levels  remain  depressed  for  the  duration  of  the  
disease   with   incomplete   restoration   during   HAART   despite   undetectable   virus  
levels  in  the  blood  [85].  Early  initiation  of  HAART  also  does  not  seem  to  completely  
restore  and  prevent  CD4+  T  cell  activation  and  depletion  in  the  GALT  although  it  
may  aid  in  maintaining  homeostasis  in  the  GALT  mucosa  [86,  87].  
The   HIV   persistence   in  GALT   even   after   10   years   of   therapy   has   been  
reported  with   evidence  of   peripheral   blood  mononuclear   cell   infection   from   this  
reservoir   [85].   As   a  major   site   of  HIV   replication,   a  mechanism  underlying  HIV  
persistence  in  the  GIT  and  GALT  may  be  the  persistent  immune  activation  caused  
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by  antigenic  stimulation  of  resting  T  and  B  cells  resulting  in  their  proliferation  and  
increased  turn-­  over  providing  HIV  with  a  constantly  available  source  of  susceptible  
cells  [88].  In  addition  to  CD4+  T  lymphocytes,  the  GIT  macrophages  and  follicular  
DCs  may  also  significantly  contribute  to  the  reservoir  size  of  the  GIT.  Considering  
the  large  size  of  the  GIT-­‐associated  mucosa,  these  cells  have  been  reported  as  a  
significant  source  of  viral  RNA  in  this  reservoir  [83].  
1.5.4  Central  Nervous  System  
Different  routes  have  been  proposed  by  which  HIV  can  invade  the  brain,  and  these  
include  access  through  the  blood-­‐brain  barrier,  the  choroid  plexus,  and  the  CSF  
[89,  90].  On  entering  the  CNS,  HIV  has  access  to  susceptible  microglial  cells  and  
macrophages,  which  express  the  CD4  primary  receptor  and  CCR5  chemokine  co-­
receptor   [91].   Other   CNS   cells   not   bearing   the   primary   CD4   receptor   such   as  
astrocytes  can  also  be  infected  by  HIV,  but  the  mechanisms  involved  are  still  not  
well  understood  [92].  The  virus  may  remain  detectable  in  the  CSF  10  years  after  
initiation  of   therapy,  and   there   is  strong  evidence  of   the  CNS  acting  as  an  HIV  
reservoir  and  site  that  supports  low-­‐level  replication  [93,  94].  Suboptimal  ARV  drug  
levels   in   the  CNS  most   likely  result   in  continued  replication   in   this  compartment  
leading  to  the  selection  for  neurotropic  variants  and  development  of  neurological  
symptoms   in  patients  with  undetectable  plasma  virus   levels   [95-­97].   In   line  with  
this,  drugs  with  better  CNS  penetration  seem  to  result  in  improved  outcomes  [98,  
99].  
1.5.5  Cellular  Reservoirs  
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   Resting  memory  CD4+  T  lymphocytes  are  the  major  cellular  HIV  reservoir,  
and   this  source   is  considered  a  major  barrier   to  HIV  eradication  during  HAART  
[100].  These  cells  harbor  inactivated  HIV  proviral  DNA  that  persists  for  long  periods  
despite  treatment.  This  reservoir  is  suspected  to  be  the  source  of  persistent  low-­‐
level  viremia  in  patients  on  HAART  who  otherwise  seem  to  have  suppressed  the  
virus   [101].   Macrophages   are   also   a   source   of   persistent   HIV   viremia   during  
HAART   although   their   exact   role   is   still   controversial   [102].   These   cells   can  
withstand  the  cytopathic  effects  of  viral  infection,  which  gives  them  an  extended  
period   of   existence   during   which   they   produce   and   release   large   numbers   of  
viruses  [103,  104].  Follicular  DCs  are  also  a  potential  cellular  reservoir  as  they  can  
trap  infectious  HIV  on  their  surfaces  for  months  and  lead  to  CD4+  T  lymphocyte  
infection  [105].  HIV  can  also  infect  hematopoietic  precursor  cells  that  include  mast  
cell  progenitors,  multipotent  HPCs,  and  monocytes  which  suggests  that  HPCs  can  
act  as  a  cellular  reservoir  [79,  106-­108].  
   Cellular   reservoirs   in   the   brain   may   include   non-­‐CD4+   cells   such   as  
astrocytes  and  microglia  [109].  The  HIV  replication   in  astrocytes   is  known  to  be  
very   low   and   only   a   few   astrocytes   are   infected,   but   since   astrocytes   are   an  
abundant  cell  type  in  the  brain,  the  infection  of  a  small  percentage  of  these  cells  
may  have  significant  results   in  regards  to  neurotoxicity  and  brain  cells  damage.  
The   slow   turnover   of   glial   cells   also  means   that   infected   cells   could   potentially  
harbor  the  virus  for  several  years  [110,  111].  
  
1.6  Antiretroviral  therapy  (ART)      
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   The  natural  progression  of  HIV  infection  that   is  described   in  the  previous  
section   is   dependent   on   infected   individuals   not   being   administered   any   HIV  
specific   treatment   during   their   infection.   This   is   representative   of   the   clinical  
landscape  in  the  decade  following  the  discovery  of  HIV-­1  in  1983,  in  which  medical  
professionals  knew  very  little  about  the  virus  and  its  pathology.  Treatment  options  
were   limited   if   not   non-­existent   during   this   period;;   testing   positive   for   HIV  was  
universally   fatal,   with   survival   time   directly   dependent   on   the   individual’s   own  
progression  from  initial  infection  to  AIDS.        
   This   changed   in   1987   with   the   development   and   testing   of   a  
dideoxynucleoside   reverse   transcriptase   inhibitor   (NRTI),  azidothymidine   (AZT),  
the  first  antiretroviral  drug  used  to  treat  HIV  [6].  Benefits  of  AZT  treatment  were  
limited;;  greater  survival  times  were  found  in  patients  at  24  weeks,  but  this  effect  
was  short-­lived  and  by  48  weeks’  time,  survival  benefits  were  no  longer  observed  
[112,  113].  Additionally,  AZT   treatment  showed  side  effects  of   transient  anemia  
and  malaise   due   to   off   target   toxicities,   particularly   in   high   doses   given   to  HIV  
patients  shortly  after  approval.  Regardless  of  AZT’s  limitations,  the  effects  seen  on  
the   survivability   of   HIV   patients   spurred   medical   research   to   investigate   the  
potential  of  antiretroviral   therapy.  Three  additional  NRTIs  were   then  released   in  
quick  succession:  zalcitabine  (ddC),  didanosine  (ddI),  and  stavudine  (d4T).       All  
three   medications   had   particular   toxicities   and   as   of   present   none   are   widely  
administered   within   the   clinic   [114,   115].   However,   the   development   and  
administration  of   these  early  antiretroviral  drugs,  and   their  associated   toxicities,  
inevitably   led   physicians   to   give   treatment   sequentially   or   to   alternate   between  
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different  therapies,  a  strategy  that  would  serendipitously  prove  effective  as  more  
antiretrovirals  became  developed   [116].  Patients  continued   to   fare  poorly  within  
the   clinic,   but  with   small   reductions   in   the   rate   of   adverse   reactions   there  was  
optimism  antiretroviral  research  was  heading  in  the  right  direction.    
   Combination  NRTI  therapy,  in  which  two  or  more  antiretrovirals  are  given  
as  a  treatment  concurrently,  was  another  clinical  concept  that  showed  encouraging  
results  in  the  early  1990s.  The  development  of  lamivudine  (3TC),  a  cytidine  analog,  
allowed  for  another  drug  to  be  used  in  combination  with  other  NRTIs  and  proved  
to  be  synergistic  with  the  other  compounds  [117].  But  despite  such  progressions,  
the  quality  of   life  for  HIV  patients  continued  to  be  poor.  Triple  drug  combination  
strategies  were   the  only  cases  showing  any  sign  of  significantly  controlling  HIV  
infection,   and   early   NRTIs,   particularly   thymidine   analogs,   continued   to   have  
issues  with  toxicity  [115].    
   The   development   of   different   classes   of   ARVs   was   perhaps   the   most  
substantial  advancement  of  HIV-­1  therapeutics.  Groups  of  drugs  that  have  a  direct  
effect  on  HIV  viremia  but  do  so  via  different  biological  mechanisms;;  when  given  in  
combination,   have   proved   effective   at   limiting   viral   resistance  while   decreasing  
viral  plasma  levels.  Saquinavir  became  the  first  protease  inhibitor  (PI)  approved  in  
1995,  but  initial  formulations  struggled  with  poor  bioavailability  and  deactivation  by  
enzymatic  metabolization  [115].  Ritonavir,  another  PI,  was  developed  shortly  after  
saquinavir.  Ritonavir  was   found   to   be  a  potent   inhibitor   of   one  of   the  enzymes  
responsible   for   deactivating   saquinavir,   and   when   given   in   combination,   dual  
saquinavir   and   ritonavir   administration   was   found   to   be   quite   effective   at   HIV  
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suppression,  though  tolerability  was  low  [118].  Eventually  it  was  determined  that  
high-­dose   saquinavir   and   low-­dose   ritonavir      in   combination   was   optimal   for  
effective   protease   inhibition,   and   still   represents   the   recommended   usage   for  
protease  inhibition  in  the  clinic  at  present  [115].    Nevirapine  became  the  first  non-­
nucleoside  reverse  transcriptase  inhibitor  (NNRTI)  to  be  approved  in  1996,  and  it  
was   found   that   if   given   as   a   monotherapy   that   resistance   develops   relatively  
quickly.   But   with   nevirapine   given   as   part   of   three-­drug   regimen,   in   which   two  
NRTIs  are  also  administered,  HIV  was  found  to  be  nearly  completely  suppressed  
and  proved  superior  to  dual  therapy  NRTI  control  groups  in  the  Italy,  Netherlands,  
Canada,  Australia  Study  (INCA  Study)  [119].    
   Different   classes   of   ARV   medications,   which   in   turn   could   be   given   to  
patients   in   a   variety   of   different   combinations,   ultimately   proved   the   key   in  
defeating  HIV  conferred  drug  resistance.  Such  drug  regimens  become  referred  to  
as  “highly  active  antiretroviral  therapy”  (HAART)  and  truly  marked  a  turning  point  
in  the  battle  against  the  HIV  pandemic.  A  substantial  decrease  in  HIV  associated  
morbidity  and  mortality  associated  with  HAART  administration  changed  the  world:  
the  leading  cause  of  death  among  young  people  within  developed  countries  had  
become  augmented  to  a  chronic  but  manageable  affliction  [120].    Perpetual  variety  
in  HAART  treatment  not  only  prevents  HIV  for  developing  resistance  to  specific  
ARVs  but  also  prevents  HIV  replication  to  the  point  where  plasma  viral  levels  are  
undetectable   [121].   To   date,   there   are   five   different   classes   of   antiretroviral  
medications:  NRTIs,  NNRTIs,  PIs,  entry/fusion  inhibitors,  and  integrase  inhibitors.    
•   Nucleoside/Nucleotide  reverse   transcriptase   inhibitors   (NRTIs)  work  
to  inhibit  the  enzyme  responsible  for  the  transcription  of  the  viral  RNA  into  
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DNA   for   integration.   This   is   accomplished   by   NRTIs   being   nucleoside  
analogs;;   they   compete   with   natural   deoxynucleotides   within   the   cell   for  
incorporation   into   the   growing   DNA   strand   during   reverse   transcription.  
Such  analogs  lack  the  3’  OH  group  needed  to  successful  chain  elongation.  
When   the   next   deoxynucleotide   is   incorporated   into   the   growing   DNA  
chain,  the  5’  to  3’  phosphodiester  bond  needed  for  continuation  cannot  be  
formed.    Failure  to  form  this  bond  halts  the  process,  effectively  preventing  
viral  RNA  from  being  reverse  transcribed  [122].  Currently  approved  NRTIs  
used   in   treatment   of   HIV   include:   Zidovudine,   Didanosine,   Zalcitabine,  
Stavudine,  Lamivudine,  Abacavir,  and  Tenofovir.   It   should  be  noted   that  
Tenofovir  is  a  unique  type  of  NRTIs.  Nucleoside  analogs  normally  undergo  
phosphorylation  to  be  converted  into  nucleotides,  which  become  active  for  
incorporation.   Tenofovir   is   administered   as   an   already   chemically   active  
nucleotide   analog,  with   no   need   for   activation   via   phosphorylation   [123,  
124].    
•     Non-­nucleoside   reverse   transcriptase   inhibitors   (NNRTIs)   again  
inhibit   the   transcription   of   viral  RNA   into  DNA  but   do   so   by  more   direct  
means.   NNRTIs   non-­competitively   bind   to   an   allosteric   site   on   reverse  
transcriptase,   resulting   in   a   confirmation   change   and   inactivation   of   the  
enzyme  [125].  If  given  as  a  monotherapy,  HIV-­1  resistance  to  NNRTIs  can  
be   established   fairly   quickly   due   to   mutations   in   reverse   transcriptase  
during  continual  iterations  of  replication;;  mutations  in  which  NNRTIs  cannot  
bind  to  the  RT  allosteric  site  are  positively  selected  for  [126,  127].  Because  
of  this,  NNRTIs  are  commonly  given  in  conjunction  with  one  or  two  other  
NRTIs.   Currently   approved   NNRTIs   include:   Nevirapine,   Delavirdine,  
Efavirenz,  Emtricitabine,  Etravirine,  and  Rilpivirine  [128,  129].    
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•   Protease  Inhibitors  (PIs)  effectively  prevent  the  maturation  and  release  of  
newly  synthesized  viral  proteins  by  inhibiting  the  enzyme  needed  for  their  
cleavage  and  subsequent  activation  [130].  As  described  above,  once  viral  
RNA  has  been  reverse  transcribed  into  DNA  and  integrated  into  the  host  
genome,  viral  proteins  are  transcribed  by  host  cell  machinery  to  produce  
new  viral  particles.  Newly  synthesized  viral  proteins  must  become  cleaved  
by  the  viral  protease  to  become  fully  activated  and  infectious.  PIs  bind  to  
the  active  site  of  viral  proteases,  preventing  them  from  having  enzymatic  
activity   and   inhibiting   the   completion   of   HIV-­1   life   cycle   [131].   Currently  
approved   PIs   include:   Saquinavir,   Ritonavir,   Nelfinavir,   Amprenavir,  
Lopinavir,   Atazanavir,   Fosamprenavir,   Tipranavir,   and   Darunavir   [132,  
133].  
•     Entry  and  fusion  inhibitors  are  a  relatively  new  class  of  ARV  drugs  with  
only  3  compounds  currently  being  approved  for  HIV  treatment:  Enfuvirtide,  
approved  in  2003,  Maraviroc,  approved  in  2007,  and  Ibalizumab  in  2018  
[134,   135].   For   entrance   of   HIV   into   a   host   cell,   viral   envelope   surface  
glycoproteins   must   interact   with   membrane   surface   receptors.   HIV  
envelope   glycoproteins   are   normally   a   heterotrimer   consisting   of   three  
molecules  of  gp120  and  three  molecules  of  gp41.  Binding  of  viral  gp120  to  
the  CD4   receptor   of   a   host   cell   causes   a   conformational   change   in   the  
glycoprotein,   allowing   interaction   with   host   cell   co-­receptors   CCR5   or  
CXCR4.  Co-­receptor  binding  ultimately  allows  fusion  between  the  host  cell  
membrane   and   portions   of   gp41   within   viral   envelope.   Enfuvirtide   is   a  
synthetic  oligopeptide  whose  sequence  corresponds   to   that  of   the  HR-­2  
region  of   the  HIV-­1  envelope  gp41  subunit.  Binding  of  enfuvirtide   to   the  
trimeric  HR-­1  complex  prevents  the  association  of  HR-­1  with  HR-­2,  thereby  
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inhibiting   fusion   and   blocking   virus   entry   [136].   Maraviroc   is   a   small  
molecule   with   high   affinity   for   the   co-­receptor   CCR5,   binding   to   it   and  
preventing  association  with  gp41,  effectively  inhibiting  entry  into  cells  with  
the   CCR5   co-­receptor   [137].   Ibalizumab   is   a   recombinant   humanized  
monoclonal   antibody,   and   represents   the   first   novel   agent   for   HIV-­1  
management  in  over  a  decade  and  is  the  first  monoclonal  antibody  for  the  
treatment  of  multi-­drug  resistant  (MDR)  HIV-­1  infection  in  combination  with  
other  forms  of  antiretroviral  therapy  in  heavily  treatment-­experienced  adults  
who  are   failing   their  current  antiretroviral   regimen  [138,  139].   Ibalizumab  
has  a  novel  mechanism  of  action  that  is  worth  discussing.  Ibalizumab  binds  
to  the  CD4  T  cell  extracellular  domain  on  the  interface  between  domains  1  
and  2  of  human  CD4,  on  a  surface  opposite  of  the  site  where  gp120  and  
the  major  histocompatibility  complex  II  (MHC-­II)  molecule  bind  on  domain  
1  [135].  Traditionally,  when  the  HIV  envelope  gp120  binds  to  CD4  T  cell  
extracellular  domain  1,  a  conformational  shift  occurs   that  causes   the  V1  
and  V2   loops   to  expose   the  V3   loop,  which  converts   the   trimer   from  the  
closed  state  to  an  open  state  [140,  141].  Ibalizumab  binding  prevents  these  
conformational  changes  and  subsequently  inhibits  the  interaction  of  gp120  
with   CCR5   and   CXCR4   co-­receptors   via   the   V3   loop.   It   also   prevents  
conformational   changes   in   gp41   that   are   needed   for   membrane   fusion  
[142].  This  novel  mechanism  of  action  makes  ibalizumab  effective  against  
CXCR4-­   and   CCR5-­tropic   strains   and   led   to   its   classification   as   a  
parenteral  CD4-­directed  post-­attachment  inhibitor  [138,  143].    
•   Integrase  inhibitors  were  developed  to  block  the  enzyme  responsible  for  
the  integration  of  newly  synthesized  HIV  DNA  into  the  host  cell  genome.  
Integrase  catalyzes  two  reactions  within  the  HIV  replication  life  cycle.  The  
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first  is  3’  end  processing  in  which  two  nucleotides  are  removed  from  one  or  
both  of  the  3’  ends  of  the  viral  DNA,  while  the  second  is  the  “stand  transfer  
reaction”   in   which   the   processed   3’   ends   are   covalently   bound   to   host  
chromosomal   DNA.   Inhibition   of   integrase   prevents   these   steps   from  
occurring,   effectively   preventing   the   infection   of   the   host   cell   [144-­146].  
Currently   approved   integrase   inhibitors   are:   Raltegravir,   Dolutegravir,  
Elvitegravir,  and  Bictegravir  [146,  147].  
Despite   such   significant   advancements   in   the   development   of   HIV-­1  
treatment   options,   complete   eradication   of   HIV-­1   remains   an   extremely   active  
subject   of   research.   Though   HAART   can   reduce   plasma   viral   levels   to  
undetectable   levels  and  allow  patients   to   live  decades  after   their   initial   infection  
and  diagnosis,  HIV-­1  continues  to  persist  throughout  the  world.  
1.6.1  LASER  ART  
   ART  has  transformed  the  prognosis  of  HIV  infection  from  certain  death  to  a  
manageable  chronic  disease  by  reducing  plasma  viral  loads  to  undetectable  limits  
and   preventing   CD4+   T   cell   depletion.   However,   achieving   this   requires   strict  
adherence   to   drug   regimens  as  prolonged  or   frequent   deviations   from   this   can  
result  in  viral  rebound,  and  in  some  cases  viral  mutations  that  render  the  current  
treatment  ineffective.  In  fact,  adherence  to  antiretroviral  medications  continues  to  
be  a  major  predictor  of  treatment  success  (and  source  of  variability  in  outcomes  in  
clinical  practice  and  research  studies)  [148].  It  is  true  that  newer  medications  have  
become  safer  and  easier  to  take;;  most  of  them  are  now  co-­formulated  in  a  single  
tablet   that   is   taken  once-­a-­day.  However,  ART  adherence   is  still   challenged  by  
multiple   individual   (i.e.,   education,   health   literacy,   poverty,   substance   use)   and  
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community  or  structural  (i.e.,  stigma,  disclosure,  access  to  care)  barriers  that  limit  
its  durability  [149].    
   With  the  goal  of  improving  regimen  adherence  and  thus  treatment  outcomes  
researchers   have   been   actively   developing   long-­acting   ARVs   [150-­154].  
Generally,   ART   medication   has   been   given   as   oral   medication   and   thus   drug  
design   has   focused   on   aqueous   solubility   of   drugs.   Long-­acting   ARVs   are   not  
designed  for  oral  administration  and  therefore  hydrophobicity  and  lipophilicity  are  
enhanced  in  order  to  affect  bioavailability  and  pharmacokinetics.  In  fact  this  idea  
is  already  being  tested  by  major  healthcare  companies.  In  2017,  ViiV  Healthcare  
announced   results   from   their   Phase   IIb   Long-­Acting   antiretroviral   Treatment  
Enabling   trial   in  which   two   long-­acting  ARVs,  cabotegravir   (CAB)  and   rilpivirine  
(RPV)  were  used   in   the  treatment  of  HIV   infection.  Although  CAB  and  RPV  are  
hydrophobic  in  their  native  active  forms,  chemical  modifications  were  employed  to  
further   improve   their   long-­acting   profiles.   When   placed   in   an   aqueous  
nanosuspension  with  polysorbate  20,  polyethylene  glycol  3350,  and  mannitol,  CAB  
demonstrates  a  long  half-­life.  Similarly,  RPV  LA  is  stabilized  by  poloxamer  338  in  
aqueous  suspensions.  The  two-­drug  combination  of  all-­injectable,  long-­acting  CAB  
plus  RPV  every  4  weeks  or  every  8  weeks  was  as  effective  as  daily  three-­drug  oral  
therapy  at  maintaining  HIV-­1  viral   suppression   through  96  weeks  and  was  well  
accepted  and  tolerated  [155].  These  drugs  were  moved  to  a  Phase  III  trial,  named:  
Antiretroviral   Therapy   as   Long-­acting   Suppression   (ATLAS)   study  
(clinicaltrials.gov  identifier:  NCT02951052).    Both  drugs  formulations  are  produced  
top-­down  and  using  wet  milling  techniques,  until  drug  particles  of  around  200  nm  
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are   formed.   The   drug   formulations   were   administered   intramuscularly   which  
formed  depots  in  the  muscle  tissue  (injection  site),  resulting  in  a  sustained  release  
of   drug   and   dosing   was   performed   once   a   month.      CAB   and   RPV   LA   are  
administered  at  800  and  1200  mg  doses,  respectively,  as  2  ml  gluteal  injections.  
Thus,   the  high  dosing  volume  requirement  and   resultant   injection  site   reactions  
represent  significant  limitations.  These  limitations,  together  with  limited  formulation  
access   to   ‘putative’   cell   and   tissue   viral   reservoirs,   open   up   opportunities   for  
improvements  [156,  157].  
   Our  laboratory  has  sought  to  overcome  these  limitations  through  chemical  
modifications  of  native  ARVs  to  generate  lipophilic  and  hydrophobic  prodrugs  into  
Long-­Acting  Slow  Effective  Release  antiretroviral  therapy  (LASER  ART).  LASER  
ART  is  defined  as  hydrophobic  prodrug  crystals  stabilized  by  lipids  or  surfactants  
enabling   sustained   release   of   therapeutic   drug   concentrations   in   plasma   and  
transfer  across  biological  barriers  and  into  anatomical  viral  reservoirs  [158].  The  
inactive,  lipophilic  LASER  ART  prodrug  easily  crosses  these  barriers  and  once  in  
cellular   targets   it   is   metabolized   into   the   native   active   drug   by   enzymatic   or  
chemical  hydrolysis  of   the   ‘prodrug  moiety.  Prodrugs  are  a  major  component  of  
LASER  ART  and  enable  high  drug  loading  with  improved  membrane  permeability.  
The  advantages  of  LASER  ART  are   in  permitting  rapid  drug  penetration  across  
physiological  barriers,   slow  drug  dissolution,  poor  aqueous  solubility,   enhanced  
bioavailability,  and  reduced  systemic  toxicities  [159-­161].  
   Our  laboratory  has  created  ester  prodrugs  of  abacavir  (ABC),  Lamivudine  
(3TC),  DTG  and  CAB  through  myristolyation  [154].  After  uptake  by  macrophages  
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and  other  cells,   intracellular  esterases  convert   inactive  prodrug  into  active  drug.  
The  rate  of  which  can  be  affected  by  the  steric  hindrance  afforded  by  the  prodrug  
moiety.  As  seen  with  NMDTG,  this  results  in  enhancements  in  macrophage  drug  
uptake,  prolonged  retention,  and  drug  efficacy  for  up  to  1  month.  Pharmacokinetic  
(PK)  tests  in  Balb/cJ  mice  showed  blood  and  tissue  DTG  levels  at,  or  above,  the  
protein-­adjusted  90%  inhibitory  concentration  (PA-­IC90)  for  up  to  56  days  after  a  
single  45  mg/kg   intramuscular   injection  without  adverse  events   [151].  Similarly,  
intramuscular   administration  of   nanoformulated  CAB  prodrug  at   45  mg/kg  CAB  
equivalents  provided  plasma  drug  levels  four  times  above  the  PA-­IC90  for  56  days  
in  rhesus  macaques  [162].  These  data  demonstrate  that  thoughtfully  engineered  
prodrugs   can   improve   PK   and   ARV   biodistribution   (BD)   over-­encapsulation   of  
native  drug.  
1.7  Pharmacokinetic  Modeling  
   The   prediction   of   drug   pharmacokinetics   after   dosing   is   sometimes  
accomplished  through  using  mathematical  modeling.  Models  are  designed  to  best  
represent   plasma   drug   and   tissue   drug   levels   over   time   while   attempting   to  
incorporate   physiochemical   properties   and   in   vivo   behavior   of   drug   molecules  
[163-­168].  Physiologically  based  pharmacokinetic  (PBPK)  models  take  this  a  step  
further   by   taking   into   account   drug   movement   through   individual   anatomical  
compartments  [169].  However,  there  are  several  limitations  to  PBPK  modeling  in  
the  context  of  LASER  ART  that  include  complex  formulation  and  prodrug  design,  
variant  in  vivo  drug  biodistribution,  metabolism,  and  transport.  Nanoparticle  size,  
shape,  and  surface  characteristics  all  affect  nanoparticle  distribution.    While  some  
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nanoparticles  are  designed  for  uptake  by  the  reticuloendothelial  system,  others  are  
carried   through   the   lymphatic  system   [170,  171].  Thus  a  one-­size   fits  all  PBPK  
model   is   not   realistic.   PBPK   modeling   requires   significant   clinical   and   in   vivo  
experiment   data   related   to   physiologic   conditions,   biochemical   changes,   and  
tissue-­specific  enzymes  that  may  be  seen  in  some  patients.  This  data  may  simply  
not  be  available.  Moreover,  variation  in  the  number  and  type  of  drug  transporters,  
type   and   species   specificity   of   cell   receptors,   drug   permeability,   surfactant   or  
excipient  modulation  of  the  activity  enzymes  such  as  cytochrome  p450,  can  result  
in   inaccurate   predictions   [172-­174].   Additionally,   the   kinetics   associated   with  
various  routes  of  administration,  differences  between  animals  and  humans,  and  
gender  specific  differences  introduce  ambiguity  into  the  models  [175-­177].  Lastly,  
the   PKs   of   highly   hydrophobic   drugs   with   different   sizes   and   shapes   of  
nanoformulations   are   difficult   to   predict   due   to   high   drug-­protein   binding   and  
difficulty  in  mimicking  the  exact  plasma  environment  [178].  These  limitations  could  
be  overcome  through  the  development  of  ARV  theranostics.  
1.8  Theranostics  
Over   recent   decades,   nanotechnology   has   garnered   a   considerable   amount   of  
interest  within  the  scientific  community,  with  medical  research  being  no  exception.  Indeed,  
the  ability  to  reliably  and  consistently  produce  materials  with  dimensions  and  tolerances  
of  less  than  100  nm  has  proven  extremely  useful  across  a  diverse  multitude  of  research  
fields.  The  impact  nanotechnology  has  had  on  medicine,  both  in  research  laboratories  and  
within  the  clinical  landscape,  cannot  be  understated.    Constant  innovation  in  the  synthesis  
and  characterization  of  nanoscale  materials  has  resulted  in  products  with  high  amounts  of  
utility.    
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However,   until   recently,   nanotechnology   developed   for   medical   purposes   has  
largely  been  one-­dimensional.  Development  and  production  of  nanomaterials  were  done  
for  the  utilization  of  a  single  function;;  to  diagnose  and/or  provide  information  on  a  disease  
state,  or  to  provide  therapy  for  the  treatment  of  a  disease  state  [179].  These  nanoscale  
diagnostic   agents   and   nanomedicines   have   proven   to   be   independently   useful,   with  
particular  success  being   found   in  sequential  utilization  of   their  single   functions.  To   first  
make   a   diagnosis   and   acquire   details   on   the   progression   of   a   disease,   and   then   to  
administer   specific,   personalized   treatments   to   abrogate   and   possibly   eliminate   said  
disease  based  on  previously  acquired  diagnostic  information,  has  proven  useful  in  patient  
management.   But   these   independent   functions,   diagnosis   and   therapy,   have   required  
independent  nanomaterials.  Such  a  two-­part  strategy  has  proven  ineffectual  for  disease  
states  with  diverse  presentations  within  the  clinic  and  complicated  underlying  pathology.  
Furthermore,   the   most   significant   diseases   impacting   humanity   today   have   complex  
disease  progressions.  
The  term  “theranostics”  was  coined  from  the  concept  of  combining  both  therapeutic  
and  diagnostic  nanomaterials  into  a  single  platform  [180].  Such  combination  would  allow  
both   nanomaterials   to   be   delivered   together,   allowing   for   concurrent   treatment   and  
monitoring   of   a   disease   state.   Theranostics   is   a   cornerstone   strategy   for   personalized  
medicines,  allowing  for  identification  of  subgroups  of  patients  with  specific  clinical  profiles  
that  are  most   likely   to   respond   to  specific   therapies,  while  also   identifying  within   those  
same   subgroups   patients   that   would   have   adverse   reactions   to   these   same   therapies  
[179].    
We  developed   theranostic   nanoparticles   for   real-­time   tracking  of   therapy  
biodistribution  in  the  treatment  of  HIV-­1.  Termed  “multi-­modal  imaging  theranostic  
nanoprobes”,   such   nanotechnology   allowed   combined   bioimaging,   drug  
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pharmacokinetics,   and   tissue   biodistribution   tests   in   animal   models   [179].  
Individual   components   include   3   diagnostic   components;;   1)   a   paramagnetic  
contrast   agent   in   cobalt   ferrite   (CF),   2)   an   intrinsically   doped,   gamma-­emitting  
radionucleotide,  111Indium,  3)  a  fluorescent  component  in  incorporated  Europium  
(Eu3+),  and  nanoformulated  rilpivirine  (RPV)  as  the  therapeutic  component.  These  
particles   were   constructed   to   take   advantage   of   magnetic   resonance   imaging  
(MRI)  and  single  photon  emission  computed  tomography/computed  tomography  
(SPECT/CT)  imaging  modalities  in  order  to  correlate  imaging  data  with  long  term  
drug  pharmacokinetics  
1.8.1  Paramagnetic  and  superparamagnetic  contrast  agents  
     MRI   has   proven   to   be   a   powerful   and   non-­invasive   diagnostic  modality  
since   it’s   development   in   the   1970’s   [181].  MRI   utilizes   strong  magnetic   fields,  
magnetic  field  gradients,  and  radio  waves  for  interaction  with  the  protons  within  a  
living   organism,   allowing   for   generation   of   internal   images.   Specifically,   MRI  
generates  contrast  based  on  intrinsic  differences  between  different  tissue  regions  
such  as  T1  (spin-­lattice)  and  T2  (spin-­spin)  relaxation  times,  and  proton  density.  
In  some  disease  states,  it  is  possible  to  differentiate  diseased  tissue  from  healthy  
tissue   based   on   disease’s   effect   on   these   intrinsic   differences.   However,   often  
times   the   effect   of   disease   pathology   on   these   factors   is   too   limited   for   any  
meaningful   diagnostic   information   to   be   discerned   from   the   resulting   images.  
Because   of   this,   multiple   “contrast   agents”   have   been   developed   that   can  
drastically  change  the  intrinsic  relaxation  times  of  specific  tissues.    
 48 
   “Paramagnetic”  materials  can  be  defined  as  those  that  are  weakly  attracted  
by   an   external  magnetic   field   and   form   internal,   induced  magnetic   fields   in   the  
direction   of   a   specific   applied  magnetic   field   [182,   183].  Paramagnetic   contrast  
agents  include  manganese  (Mn2+)  and  gadolinium  (Gd)  that  substantially  shorten  
T1  relaxation  of  water  protons,  creating  a  brightened  contrast  in  T1  MR  images.  
Superparamagnetic   contrast   agents   such   iron   oxide   particles   or   cobalt   ferrite  
nanoparticles  shorten  T2  relaxation  times  of  water  protons,  creating  a  “darkening”  
effect  on  T2  weighted  MR  images  [184].  Additionally,  superparamagnetic  contrast  
agents   show   much   more   magnetic   susceptibility   compared   that   paramagnetic  
contrast  agents,  leading  to  an  increase  in  magnetic  sensitivity.  In  our  case,  cobalt  
ferrite  particles  show  exceptional  magnetic  sensitivity  and  thus  are  used  in  the  core  
of  our  particles.    
1.8.2  Single-­photon  emission  computed  tomography  
   SPECT   is   a   nuclear   medicine   tomographic   technique   that   uses   emitted  
gamma   rays   to  generate  3D   images  of   radionucleotide   location  and  quantity   in  
vivo.  The  technique  requires  delivery  of  a  gamma-­emitting  radioisotope  such  as  
Technetium-­99m,   Iodine-­123,  or   Indium-­111  [185].   In   the  case  of  nanoparticles,  
radioisotopes  are  most  often  attached  to  the  particles  by  use  of  various  chelators  
such  as  DOTA  or  NOTA  creating  a  “radioligand”  [186].  This  allows  for  visualization  
of   radioisotope   concentration   and   location   in   the   body.   SPECT   imaging   is  
performed  by  using  a  gamma  camera  to  acquire  multiple  2D  images  (also  called  
projections),  from  multiple  angles.  A  computer  is  then  used  to  apply  a  tomographic  
reconstruction  algorithm  to   the  multiple  projections,  yielding  a  3D  data  set.  This  
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data  set  may  then  be  manipulated  to  show  thin  slices  along  any  chosen  axis  of  the  
body,  similar   to   those  obtained   from  other   tomographic   techniques   [187].  A  CT  
image   is   also   acquired   and   acts   as   a   guide   for   the   SPECT   rendering.   This  
combined  technique  is  referred  to  as  SPECT/CT.  
   However,   radiolabeling   via   chelators   has   several   limitations   that  
encouraged  us  to  pursue  a  different  labeling  strategy,  intrinsic  doping  of  111indium  
directly   into   the  cobalt   ferrite   core  particles.  First,   the  coordination  chemistry  of  
radioisotopes   varies   significantly.   Choosing   the   right   chelator   for   any   specific  
isotope  is  challenging,  as  there  are  none  that  can  bind  multiple  radioisotopes  [188].  
Second,  external  chelators  can  alter  the  hydrodynamic  size  and  surface  chemistry,  
which  will  alter  biodistribution  and  obscure  the  true  pharmacological  behavior  of  
the  particles  [189,  190].  This  fact  may  be  enhanced  as  the  radiolabel  could  become  
unbound   from   particle   leading   to   false   positive   results.   Chelator   free   labeling  
forgoes  the  need  for  chelating  moieties  and  therefore  the  native  pharmacological  
behavior  of   the  particle   is  maintained.  Third,   to  optimize   labeling   the  number  of  
chelating   moieties   conjugated   to   the   particle's   surface   should   not   impose   any  
limitations.  As  intrinsic  doping  places  radioisotopes  directly  into  the  lattice  sites  of  
the  particle's  metallic  core,  abundant  labeling  sites  are  available  which  results  in  
high  yields  with  enhanced  stability   [191].  Fourth,  with  chelator-­free   labeling,   the  
surface  of   the  particle  can  be  easily  modified  with   targeting   ligands,   therapeutic  
agents,  or  other  imaging  agents  because  no  surface  functional  groups  are  required  
for  the  radiolabel  [192].  Lastly,  chelator-­free  labeling  is  simple,  fast,  and  effective  
allowing  for  radiolabeling  with  a  broader  spectrum  of  isotopes,  including  72As  and  
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69Ge,  both  of  which  have  proven  extremely  challenging  to  radiolabel  via  chelator  
chemistry  [193].  
1.8.3  Fluorescence    
Fluorescence  is  the  emission  of  light  by  a  substance  that  has  absorbed  light  
or  other  electromagnetic  radiation.  It  is  a  form  of  luminescence.  In  most  cases,  the  
emitted   light   has   a   longer   wavelength,   and   therefore   lower   energy,   than   the  
absorbed  radiation.  Utilization  of  such  a  property  has  proven  useful  in  biological  
sciences,   as   application   of   fluorescent   materials   to   a   vehicle   allows   for   non-­
destructive  tracking  or  analysis  through  different  biological  pathways.  This  can  be  
performed  at  specific  emission  frequencies  in  which  there  is  no  background  from  
excitation  light,  as  very  few  biological  components  are  naturally  fluorescent.  Such  
“fluorescent  labeling”  can  be  done  via  a  very  large  variety  of  different  fluorophores  
such  as  dyes  and  fluorescent  proteins,  each  with  a  unique  excitation  and  emission  
wavelength,   molecular   weight,   and   quantum   yield   [194].      Additionally,   specific  
elements   exhibit   intrinsic   fluorescence.   Rare-­earth   doped   phosphors   such   as  
Terbium,  Cerium,  Lanthanum,  and  Europium  form  the  basis  for  fluorescent  lighting  
[195].   Incorporation   of   rare   earth   element   Eu3+   into   our   nanoparticle   vehicle  
proved  particularly  useful,   exhibiting   fluorescence  and  emission  wavelengths  at  
410   nm   and   660   nm,   respectively.   Europium   doping   within   the   spinel   ferrite  
structure  of   our   theranostic   nanoparticles   allowed   for   subcellular   tracking  using  
both  in  vitro  and  ex  vivo  confocal  microscopy,  as  described  in  chapter  2.  
  1.8.4  Nanoformulated  ARVs  
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   The   final   component   of   our   theranostic   nanoparticles   was   that   of  
nanoformulated  ARV  drug,  specifically   the  non-­nucleoside  reverse  transcriptase  
inhibitor,  rilpivirine.  Considerable  innovation  has  occurred  in  the  production  of  long-­
acting   ART   regimens   in   efforts   to   reduce   secondary   toxicities,   improved   drug  
adherence,   and   prevent   new   infections   [196].   Ultimately,   such   goals   center   on  
drastically   increasing   the   half-­life   of   ARV   drugs   by   improving   upon   their  
hydrophobicity.   Formation   of   cell   and   tissue   penetrate   nanocrystals   that   are  
protected  by  biodegradable  polymers  allow  the  establishment  of  drug  depots  within  
monocyte-­macrophages,   prolonging   drug   half-­life.   [196,   197]  However,   a  major  
drawback  of  developing   long-­acting  ARV  formulations   is   that  biodistribution  and  
pharmacokinetic   studies,   often   taking   weeks   to   months,   are   tedious   and  
burdensome.  Incorporation  of  long  acting  ARV  drug  into  theranostic  nanoparticles,  
in   conjunction   with   other   components,   allows   a  much  more   rapid   screening   of  
tissue  biodistribution  and  pharmacokinetics,  subsequently  resulting  in  much  more  
timely  pharmacodynamics  (PD)  improvements  and  drug  screening.    
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CHAPTER  2  
Synthesis,  characterization,  and  in  vitro  testing  of  
































The   development   of   effective   antiretroviral   therapy   (ART)   for   human  
immunodeficiency   virus   type   one   (HIV-­1)   infection   has   dramatically   reduced   disease  
morbidities  and  mortality   [198,  199].  ART’s  success,  over   the  past  several  decades,   is  
substantive  as  evidenced  by  the  treatment’s  ability  to  efficiently  reduce  circulating  plasma  
HIV-­1  loads  to  undetectable  levels.  In  so  doing  ART  protects  CD4+  T  cells  and  reduces  
comorbid   disease   [200,   201].   However,   current   treatment   limitations   include   drug  
pharmacokinetics  (PK)  and  biodistribution  profiles,  viral  mutations  and  drug  toxicities  [202,  
203]  .  All  affect  optimal  therapeutic  efficacy  [204].  Additionally,  short  antiretroviral  (ARV)  
drug  half-­lives  necessitate  daily  dosing  and  strict  regimen  adherence  [205].  Reduced  ARV  
access  to  virus  target  tissues  can  also  affect  the  maintenance  of  drug  levels  at  action  sites  
and   the  ability   to  contain  CD4+T  cell   infection   [206].   Innate   inflammatory  and  adaptive  
immune   responses   tied   to  HIV-­1   infection  continue  despite   therapeutic  drug   regimens,  
leading  to  diabetes,  osteoporosis,  cardiovascular  diseases  and  neurocognitive  disorders  
[207-­212].    Therefore,  a  major  unmet  need  in  the  treatment  of  human  immunodeficiency  
virus   type   one   (HIV-­1)   infection   rests   in   long-­term   adherence   to   antiretroviral   therapy  
(ART).   If   brought   into   clinical   practice,   long-­acting   ART   regimens   would   substantively  
improve  drug  adherence,  reduce  secondary  toxicities  and  prevent  new  infections.  These  
could  ultimately  facilitate  the  realization  of  an  AIDS-­free  world  [196,  213-­217].    
   Substantial   efforts   to  overcome   these   limitations  has   led   to   the  development  of  
longer  acting  nanoformulated  ART     and   recently   to   the  chemical  synthesis  of   lipophilic  
prodrug  nanocrystals  coined  long  acting  slow  effective  release  (LASER)  ART  which  has  
further  extended  drug  ARV  half-­lives  and  potencies  [151,  218,  219].  LASER  ART  rests  on  
four   pillars;;   creation  hydrophobic   prodrug  nanocrystals,   the  enhanced  drug   lipophilicity  
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associated   with   improved   cell   membrane   drug   penetration,   slow   drug   release   and  
hydrolysis,   and   facilitated   viral   reservoir   drug   penetrance.   These   transformative  
technologies   have   created   ARVs   that   best   penetrate   viral   reservoirs   and   increase   the  
drug’s  apparent  half-­life  creating  medicines  that  maximally  restrict  viral  growth  [154]  .    
In   order   to   realize   the   potential   of   long   acting   tissue   viral   reservoir   penetrating  
ARVs,   the   drugs’   pharmacokinetic   (PK)   and   pharmacodynamic   (PD)   profiles   must   be  
optimized  to  minimize  on  and  off-­target  effects.  However,  a  significant  obstacle  remains  
in  the  ability  to  rapidly  screen  drug  formulation  tissue  biodistribution  and  pharmacokinetics  
(PKs)   in  order  to  realize  substantive  PD  improvements.  This   is  of  particular   importance  
as,  while  the  half-­lives  of  each  of  the  few  existing  long-­acting  drugs  are  measured  in  weeks  
or   even   months,   drug   tissue   distribution   is   limited   [216,   220-­223].      Moreover,   while  
mathematical   descriptions   of   long-­acting   nanoformulated   drug   distribution   have   been  
developed,   these   cannot   reflect   the   diversity   of   chemical   alterations   and   physical  
characteristics   now   required   for   LASER   ART   nanoformulations   [224]   .   To   this   end  
multimodal   theranostic   ARVs   were   created   to   serve   as   effective   descriptor   for   drug  
biodistribution.  
   To   overcome   these   technical   and   biologic   challenges,   multimodal   decorated  
nanoparticles  were  produced  with  hydrophobic  ARVs  and  bioimaging  agents  encased  in  
a   single   nanoformulation.   All   were   placed   into   one   “multimodal   imaging   theranostic  
nanoparticle”  using  core-­shell  construction  methods  [225].  The  surface  of  the  particle  was  
coated  with   lipids  decorated  with   targeting  moieties,  while   the  drug,  along  with  SPECT  
and  MRI   image   contrast   agents   were   incorporated   into   a   polymeric   core.   Specifically,  
111indium   and   europium   (Eu3+)-­   doped   cobalt   ferrite   (CF,   111InEuCF)   crystals   and  
hydrophobic   drug   rilpivirine   (RPV)   were   packaged   in   a   polycaprolactone   (PCL)   core.  
Intrinsic  doping  of  the  radioisotope,  111indium  into  the  core  of  the  particle,  imparted  SPECT  
capabilities   while   also   providing   a   highly   stable   association   between   particle   and  
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radioisotope.  A  lipid  layer  coated  the  particle’s  “shell”.  L-­α-­phosphatidylcholine  (PC),  1,2-­
distearoyl-­phosphatidylethanolamine-­methyl-­polyethyleneglycol   conjugate-­2000   (DSPE-­
PEG2000)  and  1,2-­dioleoyl-­sn-­glycero-­3-­phosphoethanolamine  (DOPE)  lipids  enhanced  
particle   biocompatibility   and   lipophilicity,   facilitating   macrophage   targeting   [226]   .  
Nanoparticles   were   produced   with   consistent   size   and   stability,   and   were   readily  
phagocytosed   and   retained   by   macrophages   in   culture,   resulting   in   long-­acting   slow  
effective   drug   release   (LASER)   ART   profiles   [219,   227]   .   This   was   reflected   by   the  
multimodal  theranostic  particle’s  ability  to  effectively  inhibit  HIV  viral  growth  in  vitro  to  the  
same  degree  as  nanoformulated  RPV.  Together  these  properties  enable  depot  formation  
for  viral  reservoir  targeting  and  bioimaging  [227]  .    
  
2.2  Materials  and  Methods  
2.2.1  Reagents    
   Iron(III)   acetylacetonate   (Fe(acac)3),   cobalt(II)   acetylacetonate   (Co(acac)2),  
europium(III)  nitrate  hydrate  (Eu(NO3)3•5H2O,  oleic  acid,  oleylamine,  poly(vinyl  alcohol)  
(MW  30,000-­70,000,  87-­90%  hydrolyzed),  L-­a-­phosphatidylcholine  (PC)  (from  egg  yolk),  
3-­(4,5-­dimethylthiazol-­2-­yl)-­2,5-­diphenyltetrazolium  bromide  (MTT),  CF®633  succinimidyl  
ester  (CF®633),  poloxamer  407  (P407),  low  gelling  temperature  agarose,  SIGMAFASTTM  
3,3’-­diaminobenzidine  and  propidium  iodide  were  obtained  from  Sigma  Aldrich,  St.  Louis,  
MO,  USA.  Polycaprolactone  (PCL)  (MW  43,000-­50,000)  was  obtained  from  Polysciences,  
Inc.   Warrington,   PA,   USA.   1,20-­distearoyl-­phosphatidylethanolaminemethyl-­polyethyl-­
eneglycol   conjugate   2000   (DSPE-­PEG2000)   and   1,2-­dioleoyl-­sn-­glycero-­3-­
phosphoethanolamine   (DOPE)   were   obtained   from   Corden   Pharma   International,  
Plankstadt,  Germany.  Rilpivirine  (RPV)  was  acquired  from  Hangzhou  Bingo  Chemical  Co.,  
Ltd.   Hangzhou,   ZJ,   China.   111Indium   chloride   (111InCl3)   was   purchased   from   Cardinal  
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Health,  Dublin,  OH,  USA.   177Lutetium  chloride   (177LuCl3)  was  obtained   from  Oak  Ridge  
National  Laboratory,  Oak  Ridge,  TN,  USA.  Pluronicâ  F  108  Pastille  (P338)  was  bought  
from   BASF,   Florham   Park,   NJ,   USA.   Heat-­inactivated   pooled   human   serum   was  
purchased   from   Innovative   Biologics   (Herndon,   VA).   Dulbecco’s   Modified   Eagle  
Medium   (DMEM)   was   purchased   from   Corning   Life   Sciences   (Tewksbury,   MA).  
Monoclonal  mouse  HIV-­1  p24  (Clone  Kal-­1)  and  Dako  EnVision+  detection  system  HRP  
labeled  polymer  anti-­mouse  antibodies  were  purchased  from  Agilent  Technologies,  Santa  
Clara,  CA,  USA.  In  Situ  apoptosis  detection  kit  (ab206386)  was  purchased  from  Abcam  
(Cambridge,   UK)   and   assay   was   done   per   manufacturer's   instructions.   The   following  
primary  antibodies  were  obtained  from  Santa  Cruz  Biotechnology,  Inc.  (Dallas,  TX,  USA):  
Rab5  (D-­11)   (sc-­46692),  Rab7  (H-­50)   (sc-­10767),  Rab11  (C-­19)   (sc-­6565),  Rab14  (sc-­
98610)   (H-­55),   and   Lamp1   (sc-­19992)   (1D4B).   The   following  Alexa  FlourTM   secondary  
antibodies  were  purchased  from  Thermo  Fischer  Scientific  (Waltham,  MA,  USA):  594  goat  
anti-­rabbit  (A11037),  594  goat  anti-­mouse  (A11005),  488  chicken  anti-­mouse  (A21200),  
and  488  goat  anti-­rabbit  (A11008).  Optima-­grade  solvents  and  water  were  purchased  from  
Thermo   Fischer   Scientific.   Bovine   Serum   Albumin   (BSA)   purchased   from   Fischer  
Scientific.    
     
2.2.2  Synthesis  of  Rilpivirine  (RPV)  freebase  
RPV  freebase  was  prepared  by  using  as  received  RPV-­HCL.  To  a  500  mL  capacity  
beaker,  2g  of  RPV-­HCL  was  added  to  a  250  ml  mixture  of  ethyl  acetate  and  HPLC  grade  
water  (4:1  v/v)  stirred  on  ice.  After  30  min,  sodium  hydroxide  (1M)  was  carefully  added  
until   RPV  was   completely   dissolved   into   the   organic   layer.   Finally,   using   a   separation  
funnel,  organic  and  aqueous  layers  were  separated.  The  organic  layer  was  washed  with  
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50  mL  brine,  collected  and  dried  with  sodium  sulfate.  Solvent  evaporation  yielded  RPV  
freebase,  which  was  characterized  by  1H  NMR  and  HPLC.  
  
2.2.3  Preparation  of  Nanoformulated  RPV  (NRPV)  and  CF®633-­NRPV  
   Nanoformulated  RPV  (NRPV)  and  CF®633-­labeled  NRPV  (CF®633-­NRPV)  were  
prepared  by  high-­pressure  homogenization  (Avestin  EmulsiFlex-­C3;;  Avestin  Inc.,  Ottawa,  
ON,  Canada).  In  preparing  NRPV,  P338  (0.5%  w/v)  was  fully  dissolved  in  endotoxin-­free  
water.  For  NRPV-­CF®633  preparations,  a  1:5  (w/w%)  mixture  of  CF®633  and  P407  (total  
0.5%  w/v)  were  dissolved  in  endotoxin-­free  water.  Free-­base  RPV  was  then  added  (1.0%  
w/v),  and  the  mixtures  were  bath-­sonicated  for  15  min  and  mixed  overnight  at  high  speed.  
The  solutions  were   then  homogenized  at  20,000  psi  until   the  desired  particle  size  was  
reached  (~260  nm).  Suspensions  were  stored  at  4°C  and  vials  were  wrapped  in  foil   for  
protection  from  light.  
  
2.2.4  Preparation  of  Radiolabeled  111InEuCF-­RPV  Theranostic  Nanoparticles  
   Production  of  chelate  free,  non-­leachable  and  highly  stable  radiolabeled  111InEuCF  
nanocrystals  was   accomplished   by   intrinsically   co-­doping   the   radionuclide,   111In,   along  
with  europium  into  a  core  cobalt  ferrite  lattice  structure.    In  a  typical  synthesis,  Fe  (acac)3  
(706  mg,  2  mmol),  Co(acac)2  (257  mg,  1  mmol),  Eu(NO3)3_5H2O  (100  mg,  0.29  mmol),  
1,2-­hexadecanediol  (2.584  g,  10  mmol),  5  ml  of  oleic  acid,  5  ml  of  oleamine,  and  30  ml  of  
benzyl   ether  were  mixed   and   sonicated   for   2  min   using   a   probe   type   sonicator   (Cole-­  
Parmer,  Vernon  Hills,  IL,  USA).  Separately,  ~555  MBq  (~15  mCi)  of  111InCl3  was  mixed  
with  750  µL  of  benzyl  alcohol,  vortexed  and  stirred  for  30  min  at  room  temperature.  The  
two   mixtures   were   combined   and   slowly   transferred   into   a   Teflon   container   for  
hydrothermal   synthesis.   The   obtained   mixtures   of   metal   precursors,   surfactants,  
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protective  ligands  and  reducing  agents  were  added  to  a  Teflon  container  and  sealed  in  a  
high-­quality   stainless   steel   autoclave   reactor.   This   reactor   was   placed   in   a   preheated  
vacuum   oven   for   90   min   at   260°C   then   cooled   to   room   temperature.   111InEuCF  
nanocrystals   were   purified   by   washing   with   ethanol   and   collected   with   a   magnet.  
Radioactivity  of  111InEuCF  nanocrystals  was  quantitated  by  gamma  counting  (CRC®-­25R  
dose  calibrator,  Capintec,  Inc,  Florham  Park,  NJ,  USA).  The  encapsulations  of  111InEuCF  
nanocrystals  were  re-­suspended   in  chloroform  or  hexane   for   the  next   formulation  step.  
111InEuCF  and  RPV  in  PCL  and  further  coating  with  a  lipid  shell  was  accomplished  using  
a  modified  solvent  evaporation  process  [225,  228].    Specifically,  PCL  (400  mg),  RPV  (30  
mg)  and  111InEuCF  (20  mg)  were  dissolved  in  DCM,  methanol  and  chloroform  (oil  phase),  
respectively.  Fresh  lipid  mixtures  were  prepared  by  dissolution  of  PC  (50  mg),  mPEG2000-­
DSPE   (25   mg)   and   DOPE   (25   mg)   in   5   mL   of   chloroform   by   bath   sonication.   The  
111InEuCF-­RPV  primary  emulsion  was  prepared  by  mixing  EuCF,  PCL  and  RPV  solutions  
with  stirring  for  6-­8  h  at  140  ×  g  at  room  temperature.  The  secondary  emulsion  and  shell  
layers  for  core  nanoparticles  were  prepared  by  making  a  thin  film  of  lipids  (PC,  PEG2000-­
DSPE  and  DOPE)  in  a  round  bottom  flask  through  rotary  evaporation  (Büchi  Rotavapor  
R-­II,   New   Castle,   DE,   USA)   of   chloroform   followed   by   overnight   vacuum-­drying.   The  
primary  emulsion  of  111InEuCF-­RPV  was  then  transferred  into  30  mL  of  freshly  prepared  
1%  (w/v)  PVA  and  mixed  by  probe  sonication  (Cole-­Parmer,  Vernon  Hills,  IL,  USA)  at  20%  
amplitude  for  10  min  in  an  ice  bath.  The  PVA  served  as  a  surfactant  in  this  emulsification  
step.  The  core  nanoparticles  were  then  transferred  into  the  flask  containing  the  lipid  film.  
The  flask  was  steadily  rotated  with  the  core  nanoparticles  in  a  bath  sonicator  followed  by  
probe  sonication  at  20%  amplitude  for  10  min   in  an   ice  bath.  Evaporation  of  DCM  was  
carried  out  under  pressure  at  35°C  followed  by  overnight  stirring.  The  nanoparticles  were  
purified  by  centrifugation  of  the  suspension  at  55  ×  g  for  10  min,  followed  by  centrifugation  
of   the   supernatant   at   35,131  ×   g   for   30  min   at   10°C   (Sorvall,   Lynx-­4000   super   speed  
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centrifuge,  Thermo  Fisher  Scientific,  Waltham,  MA,  USA).  The  pellet  was  washed  twice  
with  PBS,  resuspended  in  PBS  and  stored  at  4°C.  Non-­radiolabeled  InEuCF  probes  were  
synthesized  by  similar  methods  except  that  stable  113InCl3  was  the  source  of  indium.  
  
2.2.5  Production  of  Ultra-­Small  Intrinsically  Radiolabeled  177LuEuCF  Nanoparticles  
   Particle  size  is  known  to  play  a  key  role  in  biodistribution,  however  the  effect  is  still  
not   completely   understood   [229,   230].   To   test   the   effect   of   construct   size   on   drug  
biodistribution   ultra-­small   (~5   nm)   177lutetium-­radiolabeled   EuCF   nanocrystals  
(177LuEuCF)  were  prepared.  Lipid  coated  177LuEuCF  nanocrystals  were  synthesized  with  
a   reaction   time  of   45  min.   177LuEuCF  nanocrystals   encapsulations  were   accomplished  
using  a  spectrum  of  lipid  film  composition  ratios.  Ultra-­small  177LuEuCF  nanocrystals  were  
coated  with  lipid  by  dehydration  processes.  The  lipid  film  was  prepared  from  solutions  of  
PC  (25  mg)  and  DSPE-­PEG2000  (12.5  mg)  in  chloroform  followed  by  rotary  evaporation.  
177LuEuCF  nanocrystals  were  dispersed  in  chloroform  by  sonication  for  30  min  and  then  
transferred  into  2%  Tween  80  (3  mL)  solution  to  make  oil   in  water  (o/w)  emulsion.  This  
emulsion  was  allowed  to  stir  for  one  hour  at  room  temperature  to  ensure  complete  removal  
of  chloroform,   then   transferred   into   the   round  bottom   flask  containing   the   lipid   film  and  
stirred  for  an  additional  five  hours.  Finally,  lipid  coated  ultra-­small  177LuEuCF  nanocrystals  
were  purified  by  centrifugation  at  35,136-­x  g  (18,000  rpm)  for  30  min  and  re-­suspended  in  
PBS.  
2.2.6  Particle  Characterizations  
The   structural   and   crystallinity   characteristics   of   particles   were   examined   by  
powder  X-­ray  diffraction  (XRD),  hydrodynamic  size  distribution,  polydispersity  index  (PDI)  
and   transmission   electron   microscopy   (TEM)   [196].   Powder   X-­ray   diffraction   (XRD)  
analysis   was   carried   out   in   the   2θ   range   of   2–70°   using   a   PANalytical   Empyrean  
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diffractometer  (PANalytical,   Inc.,  Westborough,  MA,  USA)  with  Cu-­Kα  radiation  (1.5418  
Å)  at  40  kV  and  45  mA.  A  mask  of  20  mm  and  divergence  slit  of  1/32°  were  used  on  the  
incident   beam  path.   A   thin   layer   of   the   powdered   nanoparticle  was   placed   on   a   zero-­
background   silicon   plate   and   continuously   spun   at   a   rate   of   22.5°/s.   The   solid   state  
PIXcel3D  detector   (PANalytical,   Inc.)  was  scanned  at  a  rate  of  0.053°/s.  The  PIXcel3D  
was  equipped  with  a  beam  monochromator  to  improve  the  signal-­to-­noise  ratio.  Stability  
of  the  EuCF-­DTG  nanoparticle  suspension  was  assessed  over  three  weeks  by  measuring  
hydrodynamic  diameter  and  nanoparticle  size  distribution  in  saline  on  a  Malvern  Zetasizer  
Nano-­Series   instrument   (Malvern   Instruments  Ltd.,  Malvern,  UK)  at   4   °C.  Nanoparticle  
morphology   and   structure   were   analyzed   by   transmission   electron  microscopy   (TEM).  
Nanoparticle  suspensions  were  dried  on  a  copper  grid  at   room   temperature  and  bright  
field   images  were   taken  with   exposure   times   of   2   s   using   the   Tecnai  G2  Spirit   TWIN  
electron  microscope  (FEI,  Houston,  TX,  USA)  operating  at  80  kV.  Images  were  acquired  
with   an   AMT   digital   imaging   system.   RPV   content   of   EuCF-­RPV   was   determined   by  
reversed-­phase   ultra-­performance   liquid   chromatography   (UPLC)   using   a   Waters  
ACQUITY  UPLC  H-­Class  System  with  TUV  detector  and  Empower  3  software  (Waters,  
Milford,  MA,  USA)  as  described  previously   [179].  Metal   quantitation  was  performed  by  
inductively  coupled  plasma  mass  spectrometry  (ICP-­MS)  at  the  University  of  Nebraska-­
Lincoln’s  Spectroscopy  and  Biophysics  Core  Facility,   using  an  Agilent  7500cx   ICP-­MS  
(Santa  Clara,  CA,  USA)  coupled  with  a  96-­well  plate  autosampler  Model  SC/DX4   from  
Elemental  Scientific,  Inc.  (Omaha,  NE,  USA),  operating  in  GasMix  mode  (3.5  mL  H2  and  
1.5  mL  He  per  min).    Other  conditions  were:  plasma  power,  1500  W,  carrier  Gas  flow,  1  L  
per  min.,  Makeup  Gas  glow,  0.15  L  per  min.,  sample  depth,  8  mm.  Concentrations  were  
calculated  against  an  external  calibration  curve  and  50  μg/L  of  Ga  was  used  as  internal  
standard  (IS)  throughout  (71Ga  isotope).  
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2.2.7  Radiolabeled  Particle  Stability  
   The  in  vitro  stability  of  111InEuCF-­PCL  particles  was  tested  in  PBS  and  rat  plasma  
solutions.   111InEuCF-­PCL   particles,   1.48   MBq   (40   μCi),   were   incubated   in   1.5   mL   of  
phosphate  buffered  saline  (PBS)  or  rat  plasma  at  4°C  and  37°C  for  3  days.  At  0,  24,  48  
and  72  hours,  the  samples  were  centrifuged  at  21,255-­x  g  (14,000  rpm)  for  30  min  at  10°C  
and  supernatants  were  collected.  The  radioactivity  of  the  supernatant  and  pellet  (particles)  
was  measured  by  gamma  counter  to  determine  the  percent  stability.  The  percent  stability  
was  calculated  using  the  equation  (Radiolabeling  stability  (%)  =  radioactivity  in  pellet  /  total  
radioactivity  X  100).  
  
2.2.8  Isolation  and  Culture  of  Monocyte-­Derived-­Macrophages  (MDM)  
Human  peripheral  blood  monocytes  were  obtained  by  leukapheresis  from  hepatitis  
B   and   HIV-­1/2   seronegative   donors,   and   were   purified   by   counter-­current   centrifugal  
elutriation   [196].   Cells   were   cultured   in   Dulbecco’s   modified   Eagle’s   medium   (DMEM;;  
Invitrogen,   Grand   Island,   NY,   USA)   with   10%   heat-­inactivated   pooled   human   serum  
(Innovative  Biologics,  Herndon,  MA,  USA),   1000  U/mL  macrophage   colony   stimulating  
factor,   1%   glutamine,   50   μg/mL   gentamicin,   and   10   μg/mL   ciprofloxacin   for   7   days   to  
promote  monocyte  macrophage  differentiation  [231].  
  
2.2.9  Properties  of  Particles  in  vitro:  Cell  Vitality,  Uptake  and  Retention  in  MDMs  
Cell  vitality  evaluation  of  native  RPV,  EuCF-­RPV,  111InEuCF-­RPV  and  NRPV  was  
performed  using   the  3-­(4,5-­dimethylthiazol-­2-­yl)-­2,5  diphenyltetrazolium  bromide   (MTT)  
assay[232].  In  brief,  105  human  monocytes  per  well  were  seeded  on  a  flat-­bottomed  96-­
well  polystyrene  coated  plate  and  incubated  for  seven  days  at  37°C  in  a  5%  CO2  incubator  
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for   differentiation   into   MDM   as   stated   in   section   2.2.8.   Serial   dilutions   of   EuCF-­RPV,  
111InEuCF-­RPV   and   NRPV   particles   (0.2-­200   μM   based   on   RPV   concentration   or  
1.987X10-­3  to  8.14  MBq)  in  media  were  added  to  the  cells  in  triplicate.  Native  RPV  was  
dissolved  in  dimethyl  sulfoxide  (DMSO)  and  diluted  in  media  (0.1%  v/v)  for  MDM  treatment  
control.  After  treatment,  the  media  was  removed  and  100  µL  of  MTT  solution  (0.5  mg/mL)  
was  added  to  each  well.  Plates  were  incubated  at  37°C  for  45  minutes.  The  MTT  solution  
was   removed  after   incubation  and  100  µL  of   sterile  DMSO  was  added   to  each  well   to  
dissolve  formazan  crystals.  The  plates  were  read  immediately  in  a  SpectraMax®  M3  Multi-­
Mode  Microplate  Reader  (Molecular  Devices,  LLC,  Sunnyvale,  CA,  USA)  at  absorbance  
of  490  nm.  Wells  with  DMSO  but  without  cells  were  used  as  blanks.  Untreated  MDM  and  
cells  treated  with  EuCF-­RPV  and  NRPV  for  8  hours  were  evaluated  by  the  MTT  assay  to  
assess  cell  vitality.  
MDM  uptake  and   retention  of  EuCF-­RPV  and  NPRV  particles  were  determined  
according  to  published  reports  with  noted  modifications  [179,  233].  MDM  were  plated  in  
12  well  plates  at  a  density  of  1.5  ×  106  cells/well  with  half  media  exchanges  every  other  
day.  After  seven  days,  6.25  µM,  12.5  µM  and  25  µM  concentrations  of  EuCF-­RPV  and  
NPRV  particles  were  added  to  the  cells  and  incubated  for  2,  4,  8  and  12  hours  to  evaluate  
particle  uptake.  Cell  particle  retention  was  determined  by  treating  MDM  with  25  μM  EuCF-­
RPV  or  NRPV  for  8  hours  followed  by  washing  the  cells  and  adding  fresh  medium  without  
particles.  Cell  samples  were  collected  on  days  1,  3,  5,  7,  11,  12  and  15  following  treatment.  
At  each  time  point,  the  media  was  removed,  cells  were  washed  three  times  with  PBS  then  
counted  and  harvested  following  centrifugation  at  21,255  x  g  (14,000  rpm)  for  10  min.  Cell  
pellets  were  stored  at   -­80°C   for  metal  analysis.  The  cell  pellet  was  digested  with   fresh  
diluted   nitric   acid.   Iron   and   cobalt   concentrations   were   determined   by   ICP-­MS   and  
reported  as  iron  or  cobalt  concentration  per  million  cells  as  previously  described  [179].  For  
RPV  analysis  100  μL  of  methanol  was  added  to  the  cell  pellet  followed  by  sonication  for  2  
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min.     The  mixture  was   then  centrifuged  at  21,255-­x  g   (14,000   rpm)   for  10  min  and   the  
supernatant   was   collected.   RPV   concentration   in   the   supernatant   was   determined   by  
UPLC  with  UV/Vis  absorption  as  previously  described  [234].  
  
2.2.10  Transmission  Electron  and  Atomic  Force  Microscopy  (TEM  and  AFM)  
The  uptake  of  EuCF-­RPV  and  NPRV  particles  in  MDMs  along  with  associated  cell  
surface  topological  changes  were  visualized  by  transmission  electron  microscopy  (TEM)  
and  atomic  force  microscopy  (AFM).  For  TEM  analysis  MDMs  (1.5  x  106  cells/mL)  were  
incubated  for  8  h  with  EuCF-­RPV  and  NRPV  particles  (RPV  content:  25  µM).  For  TEM,  
MDM  were  fixed  in  a  solution  of  2%  glutaraldehyde  and  2%  paraformaldehyde  in  0.1  M  
Sorenson’s  phosphate  buffer  (pH  6.2)  for  24  h  at  4°C.  Samples  were  washed  three  times  
with  PBS.  During  processing  samples  were  postfixed  in  a  1%  aqueous  solution  of  osmium  
tetroxide  for  30  minutes.  Subsequently,  samples  were  dehydrated  in  a  graded  ethanol  and  
propylene   oxide   used   as   a   transition   solvent   between   the   ethanol   and   araldite   resin.  
Samples  were  allowed  to  sit  overnight  in  a  50:50  propylene  oxide:resin  solution  until  all  
the  propylene  oxide  had  evaporated   then   they  were   incubated   in   fresh   resin   for  2  h  at  
room   temperature  before  embedding.  Polymerization   took  place  at  65°C   for  24  h.  The  
staining  procedure  was  10  minutes  in  2%  (w/v)  uranyl  acetate,  washed  3  times  in  distilled  
water,  10  minutes  in  Reynolds  Lead  Citrate,  and  washed  3  times  in  distilled  water.  Thin  
sections  (100nm)  made  with  Leica  UC6  Ultracut  ultramicrotome  were  placed  on  200  mesh  
copper  grids,  and  examined  on  the  Tecnai  G2  Spirit  TWIN  (FEI)  operating  at  80kV.  Images  
were  acquired  digitally  with  an  AMT  imaging  system.  
For  AFM  Cells  were  cultured  on  glass  coverslips  in  12  well  plates  at  a  density  of  
1.5  X  106  cells/  well  and  incubated  for  seven  days  at  37°C  and  5%  CO2  to  differentiate  into  
MDM  as  described  previously.  MDM  were   treated  with  EuCF-­RPV  and  NRPV  particles  
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(25  μM  based  on  RPV)  for  8  hours.  After  particle  incubation,  cells  were  fixed  with  ice-­cold  
4%  paraformaldehyde  (PFA)  in  PBS  at  room  temperature  for  30  min.  Coverslips  with  fixed  
cells  were  removed  from  wells  and  mounted  on  a  slide  for  AFM  analysis.   Images  were  
acquired  in  air  using  an  MFP-­3DTM  system  (Asylum  Research,  Santa  Barbara,  CA,  USA)  
operating  in  tapping  mode.  AFM  probes  MSNL-­F  with  a  nominal  spring  constant  ~0.6  N/m  
were   used   for   imaging.   Image   processing   was   performed   using   Femtoscan   software  
(Advanced  Technologies  Center,  Moscow,  Russia).  
  
2.2.11  Immunocytochemistry  (ICC)  and  Flow  Cytometry  Assessments    
Subcellular   localization   of   particles   taken   up   by   MDM   was   accomplished   via  
immunocytochemistry   using   fluorescent   secondary   antibodies   as   previously   described  
with  some  modifications  [235,  236].  Briefly,  after  EuCF-­RPV  and  NRPV-­CF®633  particle  
treatment  of  MDM,  cells  were  washed  with  PBS  and  fixed  with  ice  cold  4%  PFA  at  room  
temperature   for  30  min  and   rinsed   three   times  with  PBS.  MDM  were   then   treated  with  
0.5%  v/v  Triton-­X-­100  for  15  min  to  permeabilize  the  cells  and  again  washed  with  PBS.  A  
mixture  of  5  %  w/v  bovine  serum  albumin  (BSA)  in  PBS  and  0.1%  v/v  Triton-­X-­100  was  
used  as  a  blocking  solution  for  1  hour  and  50  mM  NH4Cl  was  used  as  quenching  solution  
for  15  min  and  washed  once  with  0.1%  Triton-­X-­100  in  PBS.  MDM  were  next  treated  with  
primary   antibodies   against   either   lysosomal-­associated  membrane   protein   1   (LAMP-­1;;  
Novus  Biologicals,  Littleton,  CO,  USA)  for  lysosome  identification,  Rab  5  and  Rab  7  for  
late  endosomes,  or  Rab  11  and  Rab  14  (Santa  Cruz  Biotechnology,  Dallas,  TX,  USA)  for  
recycling   endosomes.   Primary   antibodies   were   diluted   1:25   (v/v)   antibody:blocking  
solution  and  incubated  overnight  with  shaking  at  4°C  as  previously  described  [179].  MDM  
were   then   treated  with  secondary  antibody   in  blocking  solution   (1:50)   (AlexaFluor-­  488  
and   594   for   NRPV-­CF®633   and   EuCF-­RPV,   respectively;;   Thermo-­Fischer   Scientific,  
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Waltham,  MA,  USA)   for  2  hours  at   room   temperature.  MDM  nuclei  were  stained  using  
ProLong   Gold   AntiFade   reagent   with   DAPI   (4′,6-­diamidino-­2-­phenylindole;;   Thermo-­
Fischer  Scientific,  Waltham,  MA,  USA).  Cells  were  imaged  using  a  63  X  oil  objective  on  a  
LSM  710  confocal  microscope  (Carl  Zeiss  Microimaging,   Inc.,  Dublin,  CA,  USA).  Zeiss  
LSM  710  Image  browser  AIM  software  version  4.2  was  used  to  determine  the  number  of  
pixels  and  the  mean  intensity  of  each  channel.    
NRPV  uptake  at  select  drug  concentrations  was  analyzed  and  validated  by  flow  
cytometry  [237,  238].  Briefly,  5  x  106  MDM  were  cultured  in  suspension  in  50  mL  Teflon  
flasks  containing  20  mL  of  cell  culture  media.  After  7  days  of  culture,  cells  were  treated  
with  NRPV-­CF®633  at  25  µM  and  50  µM  RPV  or  vehicle  control  for  8  hours.  After  8  hours,  
cells  were  centrifuged  976  x  g  (3,000  rpm)  for  10  minutes  at  4°C  following  which  treatment  
media  was  removed.  Cells  were  re-­suspended  in  cold  PBS  and  centrifuged  again  at  the  
same  conditions.  After  washing,  cells  were  again  re-­suspended  in  PBS  at  a  concentration  
of   1.0   x106   cells/mL.   Before   flow   analysis,   cells   were   incubated  with   the   viability   dye,  
propidium   iodide   (PI),   for   30  minutes.  Analysis  was   completed  with   a  BD  LSR   II   Flow  
Cytometer   (BD  Biosciences,   Franklin   Lakes,  NJ,  USA).  Cells  were   gated   according   to  
viability  and  only  live  cells  were  selected  for  analysis  of  NRPV-­CF®633  uptake.  Unlabeled  
cells  were  used  to  calculate  the  background  fluorescence  and  MDM  without  any  treatment  
served   as   a   negative   control   in   every   measurement.   The   percentage   of   cells   that  
internalized   NRPV-­CF®633   was   determined   using   BD   FACSDiva   8.0.1   software   (BD  
biosciences,  Franklin  Lakes,  NJ  USA).  
  
2.2.12  Particle  T2  Relaxivity  Measurements  
   T2  relaxivity  measurements  of  EuCF-­RPV  particles  were  determined  in  two  sets  of  
samples   over   a   concentration   range   of   3.58   to   35.81   μM   iron.   EuCF-­RPV   particle  
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suspensions  were  prepared  in  PBS.  A  1.5%  (w/v)  agar  gel  was  prepared  by  heating  agar  
powder  dissolved  in  PBS  at  70°C  for  30  min.  In  250  μL  eppendorf  tubes,  100  μL  of  EuCF-­
RPV  particle  suspensions  were  mixed  with  100  μL  of   the  1.5%  (w/v)  agar  solution  and  
solidify  in  an  ice  bath.  The  second  set  of  samples  were  prepared  with  EuCF-­RPV  particle  
loaded  MDM.  In  order  to  measure  the  T2  relaxivity  in  MDM,  cells  were  seeded  onto  100  
mm  culture  plates  at  a  concentration  of  1  x  106  cells/mL.  MDM  were  incubated  with  EuCF-­
RPV  particles  in  media  (5  μg/mL  based  on  iron)  for  8  hours.  After  treatment,  the  media  
was   removed   and   cells   were   washed   three   times   with   PBS.   Cells   were   collected   by  
centrifugation  at  976  x  g  (3,000  RPM)  for  10  min  at  4°C  and  re-­suspended  at  various  cell  
concentrations  in  PBS  containing  1.5%  (w/v)  agar  in  250  μL  eppendorf  tubes.  T2  relaxtivity  
was   measured   using   a   7T/16   cm   Bruker   PharmaScan   scanner   (Bruker;;   Ettlingen,  
Germany)  with  set  parameters  described  previously  [196].  Relaxivity  in  MDM  was  used  to  
generate  a  standard  curve  correlating  cellular  iron  content  to  T2  relaxation  time  to  be  used  
for  in  vivo  quantitation  of  tissue  iron  concentration  by  MRI.  
  
2.2.13  Measurements  of  Particle  Antiretroviral  Activities      
   Antiretroviral  activities  of  EuCF-­RPV,  NRPV  and  native  RPV  were  evaluated  by  
measures   of   reverse   transcriptase   (RT)   activity   and   HIV-­1p24   staining   according   to  
previously  described  protocols  with  modifications  [153].  In  brief,  MDM  were  treated  with  
6.25  µM,  12.5  µM,  or  25  µM  (RPV  content)  native  RPV,  NRPV  or  EuCF-­RPV  particles  for  
8  hours.  MDM  were  then  cultured  in  fresh  medium  without  particles.  At  days  1  and  5  post-­
treatment,  MDM  were  challenged  with  HIV-­1ADA  for  16  hours  at  a  multiplicity  of  infection  
(MOI)  of  0.1  infectious  virions  per  cell.  MDM  were  cultivated  for  10  days  after   infection.  
Culture  supernatants  were  collected  and  analyzed   for  progeny  virion  production  by  RT  
activity  assay  [239].  At  the  same  time,  cells  were  washed  with  PBS  and  fixed  in  4%  PFA  
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for   15   min   for   HIV-­p24   staining   [151].   Images   were   analyzed   using   a   Nikon   TE300  
microscope  with  a  20X  magnification  objective.  
  
2.3  Results  
2.3.1   Synthesis   and   Physical   Characterizations   of   Multimodal   Theranostic  
Nanoparticles  
   EuCF   particles   were   prepared   by   solvothermal   techniques   using   cobalt  
acetylacetonate;;   iron   (III),   acetylacetonate,   and   europium   (III)   nitrate   hydrate   in   the  
presence  of  oleic  acid  and  oleylamine.  To  create  SPECT/CT  capable  nanoparticles  with  
a   highly   stable   radiolabel,   radioactive   indium   chloride   (111InCl3)   or   lutetium   chloride  
(177LuCl3)  was  slowly  added  into  the  reaction  mixture.  Benzyl  alcohol  served  as  solvent  
and  protective  ligand,  while  1,2-­hexadecanediol  was  used  as  a  reducing  agent  [240].  A  
schematic   of   this   synthesis   is   shown   in  Figure   2.1A.   The   stability   of   the   radiolabeled  
111InEuCF-­PCL   particles  
was   assessed   in   PBS   and  
rat  plasma  at  4°C  and  37°C  
and  was  found  to  be  >97.4  ±  
0.26%   after   24   hours.  
Plasma   stability   studies  
confirmed   that   the  
radioactive   isotope  
remained   particle   bound  
over   3   days   (Table   2.1).   For   physical   characterizations,   non-­radioactive   InEuCF  
nanoparticles  were  used.  Preparation  of  NRPV  was  accomplished  using  high-­pressure  
  
Figure   2.1   Synthesis   of   Multimodal   Theranostic   Nanoparticles   and  
NRPV.  A  schematic  illustration  of  the  design  of  multimodal  EuCF-­RPV  core-­
shell   nanoparticles   as   well   as   a   schematic   illustrating   the   production   of  
NRPV  is  presented  in  (A)  and  (B),  respectively.    
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homogenization  of  RPV  in  the  presence  of  polaxamer  338  [204,  241].  A  schematic  of  this  
process  is  shown  in  Figure  2.1B.  RPV  drug  loading  into  the  EuCF-­RPV  was  determined  
to  be  ~  5.5%  (w/w).  The  hydrodynamic  size  of  monodispersed  NRPV,  EuCF-­RPV,  and  
111InEuCF  is  shown  in  Figure  2.2A.  RPV  nanocrystals  had  an  average  hydrodynamic  size  
of  260  nm,  which  was  similar  to  that  of  the  EuCF-­RPV  and  111InEuCF-­RPV  particles  that  
measured  220  nm.  As  expected,   intrinsic  doping  of   111Indium  had  no  effect  on  particle  
hydrodynamic  size.  Additionally,  EuCF-­RPV  and  111InEuCF-­RPV  particle  sizes  remained  
constant  in  a  variety  of  different  media.  As  shown  in  Figure  2.2D,  The  PDI  of  all  particles  
was  ~0.2.  The  size  and  PDI  of  NRPV  were  stable  in  water  for  four  weeks  at  both  4ºC  and  
25ºC.   Additionally,   the   size   and  PDI   of   111InEuCF-­RPV   and  EuCF-­RPV   particles  were  
evaluated  daily  over  a  week  with   incubation   in  a  variety  of  solutions   including,  distilled  
water,  150  mM  NaCl  in  water,  distilled  water  adjusted  to  a  pH  of  3,  5,  7,  9  and  11,  PBS  
containing  2%  BSA,  and  MDM  cell  media.  Size  and  PDI  of  both  particles  in  all  solutions  
were  unchanged  after  a  week  indicating  that  these  particles  are  stable  and  thus  suitable  
for  further  studies.  
   In   addition,   the   crystalline   properties   of   nanoformulations   could   also   influence  
particle   stability   and   the   in   vivo   drug   pharmacokinetics   and   biodistribution   parameters  
[151,  242].  Undesirable  in  vivo  burst  release  PK  patterns  and  ultimately  rapid  clearance  
from   tissues   and   plasma   depend   on   variables   that   include   type   of   drug,   surfactants,  
process  and  duration  of  making  nanoformulations  [243].    These  changes  vary  depending  
  
Table  2.1  Radiolabeling  stability  in  vitro.    
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on  the   type  of  drug,  surfactant  used,  pressure  and   time  to  make  the  nanoformulations.  
Therefore,  before  and  after  particle  size  reduction,  XRD  analysis  was  conducted  to  assess  
whether  the  initial  crystalline  state  was  preserved.  Figure  2.2B  shows  the  results  of  each  
of  the  XRD  patterns  of  
RPV,   NRPV,   CF,  
EuCF   and   InEuCF.  
The   powder   X-­ray  
diffraction   study   of  
NRPV   showed  
significant  shifts  in  the  
main   peaks,  
compared  with  coarse  
RPV.   RPV   showed  
characteristic  
diffraction   peaks   at  
12.42°,   13.93°,  
17.57°,   20.0°,   25.68°,  
27.87°   and   32.70°   at  
2θ  positions.  Whereas  
NRPV   showed  
characteristic  
diffraction   peaks   at  
31.80°,   45.5°   and  
56.62°  at  2θ  positions.  
This   shift   from   lower  
2θ  angles  to  higher  2θ  
  
  
Figure   2.2   Characterization   of   particles.   (A)   Hydrodynamic   size   distribution   of  
NRPV,  EuCF-­RPV  and  111EuCF-­RPV  particles.  (B)  XRD  pattern  of  RPV,  NRPV,  CF,  
EuCF  and  InEuCF  particles.  (C)  TEM  image  of  NRPV  and  EuCF-­RPV.  (D)  Stability  
of  particles’  hydrodynamic  size  distribution  measurements  of  NRPV  in  PBS  (average  
particle  sizes  of  ~260  nm),  and  111InEuCF-­RPV  and  EuCF-­RPV  in  various  conditions  
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angles  can  be  attributed  to  the  formation  of  a  different  molecular  structure  from  the  more  
amorphous  parent  RPV.  From  these  values,  it  is  clear  that  NPRV  is  crystalline  in  nature  
after  high-­pressure  homogenization.  In  the  XRD  pattern  of  CF,  EuCF  and  InEuCF  shown  
values   that  closely  matched   that  of  our  own  previously  published   reports   reflecting   the  
inverse  spinel  to  the  spinel  ferrite  structure  [196].  We  observed,  from  the  XRD  results,  that  
intrinsically  doping  indium  or  europium  into  the  cobalt  ferrite  lattice  produced  no  significant  
structural  changes  to  the  crystalline  lattice  of  atomic  planes.    
   TEM   images   of  NRPV  and  EuCF-­RPV  particles   are   presented   in  Figure   2.2C.  
NRPV  crystals   have  a  well-­defined   rod   like  morphology  while  EuCF-­RPV  particles  are  
spherical  and  multiple  components  can  be  visualized.  The  black  punctate  structures  in  the  
TEM  image  of  EuCF-­RPV  represent  electron  dense  EuCF  nanocrystals  embedded  in  the  
less  electron  dense  PCL  core  (white  on  image),  which  also  contains  RPV.  A  faint,  almost  
translucent  ring  around  each  particle  in  the  TEM  image  represents  a  “shell”  of  lipids  that  
surrounds  the  EuCF-­RPV  particles.  
     
2.3.2  In  vitro  Evaluations  of  Theranostic  Nanoparticles  
   Macrophages  are  the  effector  cells  of  the  innate  immune  system  that  have  a  large  
capacity   to   phagocytose   bacteria,   dead   cells,   debris,   tumor   cells,   and   foreign  material  
[244].  Recent  studies  demonstrated   that  macrophages  differentiate   from  hematopoietic  
stem  cell-­derived  monocytes  and  embryonic  yolk  sac  macrophages.  The  former  mainly  
gives   rise   to   “wandering”  macrophages  which  circulate   through   the  body  until  cytotoxic  
signaling  draws  them  to  sites  of  inflammation,  while  the  latter  mainly  gives  rise  to  tissue  
resident  macrophages  [245].    Tissue  resident  macrophages  exist  in  all  tissues,  including  
tissue  reservoirs  of  HIV  that  have  proven  restrictive  to  ARV  medications.  These  include  
the   nervous,   pulmonary,   cardiovascular,   gut   and   renal   organs   [246].   Additionally,  
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macrophages  are  known  cellular  reservoirs  of  HIV  which  herald  viral  spread  to  neighboring  
CD4+  T  cells,   the  principal  host  cell  of   the  virus   [214].  Because  of   these  cells  ability   to  
readily   phagocytose   and   store   a   large   amount   of   particles   of   nanometer   size,   their  
circulation  through  the  body,  ability  to  penetrate  and  take  up  long-­term  residence  in  tissue  
reservoirs   of   HIV,   and   their   status   as   an   HIV   cellular   reservoir,   make   these   cells   an  
attractive  depot  to  target  for  our  theranostic  nanoparticles.  Success  in  the  area  would  see  
macrophages  used  as  Trojan  horse  carriers  of  theranostic  nanoparticles.    
In   order   to   study   the   interactions   between   our   theranostic   nanoparticles   and  
macrophages,   the   uptake,   retention,   subcellular   localization,   as   well   as   cytotoxicity   of  
nanoparticles   were   determined   in   vitro   in   monocyte-­derived   macrophages.   We   first  
determined   the  effects  of  EuCF-­RPV  particle  administration  on  MDM  cell  vitality.  MDM  
were   treated   with   native   non-­formulated   RPV,   NRPV   or   EuCF-­RPV   particles   at  
concentrations  ranging  from  0.2  µM  to  200  µM  (based  on  RPV  concentration)  for  12  hours  
before  cell  vitality  was  measured  by  MTT  assay.  As  shown  in  Figure  2.3A,  native  RPV,  
NRPV  and  EuCF-­RPV  particles  had  little  effect  on  cell  vitality  up  to  50  µM.  At  the  highest  
concentration  tested,  200  µM,  NRPV  and  EuCF-­RPV  less  effected  cell  vitality  than  native  
RPV   (82.9%,   56.9%   and   37.9%,   respectively).   Replicate   MDMs   were   treated   with  
111InEuCF-­RPV  particles  to  assess  the  radioisotope’s  effect  on  cell  vitality.  111InEuCF-­RPV  
treated  cells  demonstrated  a  ~80%  cell  viability  at  8  h  at  the  highest  concentration  of  8.14  
MBq  (220  μCi)  (Figure  2.3B).      
We  then  examined  the  uptake  kinetics  of  NRPV  and  EuCF-­RPV  in  MDM.  Figure  
2.3C   shows   the   RPV   concentrations   in   MDMs   treated   with   various   concentrations   of  
NRPV  (6.25  µM,  12.5  µM,  and  25  µM).  At  2,  4,  8,  and  12  hours  post  treatment  the  media  
containing  RPV  was   removed,  cells  were  washed  with  PBS,  centrifuged,  collected   into  
1mL  PBS  and  counted.  RPV  concentration  per  106  cells  was  determined  by  UPLC-­with  
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UV/Vis  detection  at  285  nm   [234].     Maximal  uptake  at  all  concentrations  occurred  at  8  
hours  post  treatment  (12.1  µg/106  cells  at  25  µM)  and  this  value  remained  stable  until  12  
hours.  We  then  investigated  retention  time  of  NRPV  by  MDM.  After  treating  with  25  µM  
NRPV   for   8   hours,   excess  NRPV  was   removed   and   replaced  with   normal   cell  media.  
Initially,   MDM   contained   approximately   7.5   µg   RPV/   106   cells   24   hour   post-­treatment  
(Figure  2.3D).  By  day  5,  the  amount  of  NRPV  in  cells  decreased  to  3.2  µg  RPV/106  cells.  
NRPV  was  slowly  released  between  day  5  and  day  15  with  approximately  0.9  µg  RPV/  
106  cells  remaining  at  15  days  post  treatment.    
Next,  we  evaluated  the  uptake  and  retention  of  EuCF-­RPV  particles  in  MDM.  For  
uptake  experiments;;  cells  were  treated  at  25  µM  RPV  equivalents  for  up  to  12  hours.  At  
various  times  treatment  was  removed  and  cells  were  washed  and  collected  for  drug  and  
metals  analyses  by  UPLC-­UV/Vis  and  ICP-­MS.  As  shown  in  Figure  2.3E,  the  amount  of  
RPV  taken  up  at  8  hours  was  similar  to  that  of  NRPV  (Figure  2.3C)  (14  µg/106  cells  and  
12.1  µg/106  cells,  respectively).  It  is  possible  that  particles  break  down  in  the  macrophage,  
releasing  some  components  of  the  particle  and  not  others.  We  therefore  also  examined  
the  uptake  and  retention  of  the  metal  components  of  the  nanoparticles.  We  measured  iron  
and  cobalt  levels  in  these  cells  and  found  that  at  8  hours  cells  contained  9.5  µg  iron  /106  
cells  and  2.9  µg  cobalt  /106  cells.  Retention  of  EuCF-­RPV  particles  in  MDM  was  examined  
for  15  days.  After  treating  MDM  with  EuCF-­RPV  particles  for  8  hours  at  a  concentration  of  
25  µM  RPV,  treatment  media  was  removed  and  replaced  with  fresh  media.  After  24  hours  
post  treatment,  cells  retained  9.6  µg/106  cells  of  RPV,  3.6  µg  of  iron  /106  cells  and  1.0  µg  
cobalt  /106  cells.  After  7  days  the  cells  had  released  most  particles,  retaining  2.0  µg/106  
cells  RPV,  0.7  µg  iron  /106  cells  and  0.2  µg  cobalt  /106  cells.  Release  of  particles  slowed  
by  day  15  when  RPV,  iron  and  cobalt  was  retained  in  cells  and  measured  at  0.8  µg,  0.4  
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µg   and   0.1   µg/106   cells,   respectively   (Figure   2.3F).  Figure   2.3G   shows   atomic   force  
microscopy  topological  images  of  cells  treated  with  vehicle  control,  EuCF-­RPV,  or  NRPV.  
  
Figure  2.3  In  vitro  assessments  in  human  monocyte-­derived  macrophages.  (A)  MTT  cell  viability  assay  of  
MDMs  treated  with  non-­radioactive  particles  for  12  hours.  (B)  MTT  cell  viability  assay  of  MDM  cells  treated  with  
111InEuCF-­RPV  particles  for  12  hours.  (C)  Uptake  of  NRPV  particles  was  determined  in  MDM.  NRPV  and  EuCF-­
RPV  particles  were  added  to  MDM  at  6.25,  12.5  and  25.0  μM  RPV.  Stars  denote  significant  differences  compared  
to  12.5  μM  RPV  (****P  <  0.0001)  (D)  6  Retention  of  NRPV  added  to  MDM  at  25μM  RPV   for  8h.  (E)  Uptake  of  
EuCF-­RPV   particles   was   performed   at   25μM   RPV.   RPV,   Iron,   and   Cobalt   concentration   (μg/10   cells)   were  
determined  after  2,  4,  8  and  12  h  of  treatment.  (F)  Retention  of  EuCF-­RPV  particles  over  15  days.  MDMs  were  
treated  with  25  μM  (by  RPV)  of  EuCF-­RPV  particles  for  8  h  before  treatment  was  removed.  Cells  were  analyzed  
for  RPV,  iron  and  cobalt  concentration  (μg/106  cells)  at  1,  3,  5,  7,  12,  15  days  post  treatment  removal.  (G)  atomic  
force  microscopy 
 74 
Interestingly,   even   though   these   cells   uptake   a   large   number   of   particles   the   surface  
topography  of  the  cells  remained  unchanged.    
In   order   to   evaluate   the   magnetic   sensitivity   of   our   particles   and   to   provide   a  
standard   curve   by  which   to   estimate   iron   concentration   from  MR   imaging   data,   the  T2  
relaxivity   (r2)   of   EuCF-­RPV   particles   was   determined   for   particles   suspended   in   PBS  
(Figure  2.4A)  as  well  as  for  particles  loaded  within  MDM  (Figure  2.4B)  by  using  a  7T  MRI.  
The  T2   relaxation  rates  (R2)  showed  a   linear  correlation  (R2=  0.98)  with   increasing   iron  
concentration   in   MDM.   Using   the   slope   of   this   correlation   we   found   that   EuCF-­RPV  
particles  have  an  intracellular  relaxivity  of  r2  =  750.4μM-­1s-­1.    
    
2.3.3  Subcellular  Particle  Localization  Studies  
   We  next  determined  the  intracellular  fate  of  NRPV  or  EuCF-­RPV  particles  in  MDM.  
This  was  accomplished  through  qualitative  assessments  of  particle  subcellular  localization  




Figure  2.4  T2  Relaxivity  Phantoms  in  PBS  and  MDMs.  (A)  Relaxivity  phantoms  in  PBS.  EuCF-­PCL  particles  
were  suspended  in  agar  at  variant  concentrations  of  iron.  T2  relaxation  rates  (R2)  increased  linearly  with  increasing  
iron  concentration  (R2=0.9873).  (B)  MRI  signal  enhancement  effects  of  EuCF-­RPV  particles  were  determined  by  
calculating  particle  relaxivity  (μM-­1s-­1)  in  human  monocyte-­derived  macrophages  (MDM)  at  various  concentrations  
of  iron.  (R2  =  0.98389).  
A                                                                                                    B  
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performed   for   quantitative   measurements.   In   order   to   visualize   NRPV   by   confocal  
microcopy  and  for  flow  cytometry,  we  synthesized  CF®633  labeled  poloxamer  407  (P407)  
as  per  our  previous  report  [247].  This  CF®633-­P407  was  used  for  coating  during  NRPV  
formulation   to   create  NRPV-­CF®633.  Cells  were   treated  with   25   μM  NRPV-­CF®633   or  
EuCF-­RPV  particles  at  a  concentration  equivalent  to  25  μM  RPV  for  8  hours.  At  this  time  
the  treatment  was  removed,  the  cells  were  washed  with  PBS,  and  then  fixed  in  4%  PFA  
before  immunostaining  with  markers  for  early  endosomes  (Rab5),  late  endosomes  (Rab7),  
recycling  endosomal  compartments   (Rab11  and  14),  and   lysosomes  (LAMP-­1).  Figure  
2.5A   shows   that   the   majority   of   NRPV   localizes   in   the   late   and   recycling   endosomal  
compartments  enriched  in  Rab7,  11,  and  14.  To  a  lesser  degree  NRPV  can  be  found  in  
early  endosomal  compartments  enriched  in  Rab5,  and  little  co-­localization  with  LAMP-­1  
was   detected.   Together,   these   data   suggest   the   retention   of   NRPV   in   macrophage  
endosomal  compartments  with  minimal  lysosomal  degradation.  Similar  results  were  found  
in  cells  treated  with  EuCF-­RPV  (Figure  2.5B)  with  the  exception  that  there  was  greater  
co-­localization  with  Rab5  and  7.   Interestingly,  EuCF-­RPV  particles  also  showed  no  co-­
localization   with   LAMP-­1,   suggesting   that   these   particles   are   also   retained   within  
macrophage   endosomal   compartments   without   significant   lysosomal   degradation.   We  
used  TEM   to   further  confirm   the   intracellular   fate  of  NRPV  and  EuCF-­RPV  particles   in  
greater   detail.   MDM  were   treated   at   25   μM   RPV   equivalents   of   EuCF-­RPV   or   NRPV  
crystals   for   8   hours   before   removal   and   cells   were   fixed   for   TEM   analysis.   Large  
accumulations   of   EuCF-­RPV   or   NRPV   are   observed   in   intracellular   subcompartments  
within  the  cytoplasm  of  MDM  (Figure  2.5C).  Selected  intracellular  depots  of  EuCF-­RPV  
and  NRPV  are  outlined  in  dotted  lines  in  column  (i)  and  then  shown  at  a  higher  resolution  
in  columns  (ii)  and  (iii).  The  EuCF  nanocrystals  are  clearly  visible  as  dark  spots  near  the  
edge  of  the  crystals.  Further,  the  uptake  potential  of  MDM  was  confirmed  by  quantitative  
measurements  of  NRPV  by  FCM  analysis.  The  viability  dye,  propidium  iodide  was  mixed  
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with   treated   cells   prior   to   analysis   so   that   only   viable   cells   were   analyzed   for   NRPV  
content.   As   shown   in   Figure   2.5D,   we   observed   that   treatment   with   25   μM   RPV  
approximately   68.7%   of   MDM   take   up   NRPV-­CF®633,   while   at   50   μM   approximately  
  
Figure  2.5  Immunocytochemistry,  transmission  electron  microscopy  and  flow  cytometry.  Representative  
images  of  MDMs  treated  with  Alexa-­Fluor  488  secondary  antibody  against  Rab5,  Rab7,  Rab11,  Rab14,  or  LAMP-­
1   primaries   (green)  with   (A)  NRPV-­CF®633   (red)  or   (B)   EuCF-­RPV  (green)  Nuclei  are   blue   (DAPI).   (C)   TEM  
ultrastructural  evaluation  of  macrophage  particle  uptake  and  subcellular  distribution.  Areas  of  interest  are  bordered  
with  black  dotted  lines  and  are  presented  in  corresponding  high-­resolution  images  (ii–iii)  (D)  Flow  cytometry  results  
for  control  MDM  (left  panel)  and  MDM  exposed  to  NRPV  particles  (right  panels)  are  shown.  (i)  Population  of  cells  
analyzed  by  scattering  analysis  plot  of  control  MDM  and  NRPV  treated  MDM.  (ii)  Single  cell  gate,  (iii)  Live/dead  
MDM  gated  using  propidium  and  (iv)  CF®633-­NRPV  uptake  in  MDM.      
for  RPV,  iron  and  cobalt  concentration  (μg/106  cells)  at  1,  3,  5,  7,  12,  15  days  post  treatment  removal.  (G)  atomic  
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80.7%  of  MDM  take  up  NRPV-­CF®633.  Overall  these  results  demonstrate  that  MDM  can  
uptake  large  amounts  of  NRPV.    
  
  
2.3.4  Antiretroviral  Activity  Measurements  
   The  antiretroviral  properties  of  EuCF-­RPV  were  assessed  and  compared  to  native  
RPV  and  NRPV  in  MDM  challenged  with  HIV-­1ADA,  a  prototypical  macrophage-­tropic  strain  
of  HIV   [231].  Cells  were   treated  with  6.25  µM,  12.5  µM  or  25  µM  equivalents  of  native  
RPV,  NRPV,  or  EuCF-­RPV  for  8  hours  and  removed  from  cultures.  At  1  and  5  days  post  
treatment,  cells  were  challenged  with  HIV-­1ADA  for  16  hours  at  a  MOI  of  0.1.  Cells  were  
maintained  for  10  days  post   infection,  at  which  time  progeny  HIV  virion  production  was  
determined  by  assaying  RT  activity  in  the  cell  culture  media.  Remaining  cells  were  fixed  
in   4%   PFA   and   immunostained   for   HIV-­1   p24   antigen   expression.   At   the   lowest  
concentration   (6.25   µM)   NRPV   and   EuCF-­RPV   showed   a   significant   reduction   in   RT  
activity  at  day  1  compared  to  native  RPV,  which  provided  only  a  small  degree  of  protection  
(Figure   2.6A).   At   5   days   post-­infection,   native   RPV   and   NRPV   provided   virtually   no  
protection,   but   EuCF-­RPV   provided   a   slight   but   significant   reduction   in   RT   activity  
compared  to  positive  control.  For  cells  treated  with  12.5  µM  RPV  equivalents,  native  RPV,  
NRPV  and  EuCF-­RPV  provided  significant  reduction  in  RT  activity  compared  to  positive  
control  at  day  1.  By  day  5,  native  RPV  provided  no  protection,  yet  RT  was  significantly  
decreased  for  NRPV  and  EuCF-­RPV  with  EuCF-­RPV  showing  the  least  RT  activity.  At  the  
highest  concentration  tested,  25  µM,  treatments  with  all  3  modalities  provided  significant  
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protection  at  days  1  
and  5.  However,  by  
day   5   protections  
with   NRPV   and  
EuCF-­RPV   was  
greater   than   native  
RPV   alone.   These  
results   were  
confirmed   by   the  
p24  
immunostaining,  
which   shows   less  
p24  staining  in  cells  
treated   with   NRPV  
or   EuCF-­RPV  
particles   compared  
to   native   RPV  
(Figure  2.6B).    
  
2.4  Discussion  
The   potential   of   LASER   ART   in   the   prevention,   treatment   and   eradication   of  
HIV/AIDS  is  of  the  highest  significance  [151].  This  is  linked,  in  part,  to  improvements  of  
drug   penetration   into   target   organs,   reduced   systemic   toxicities,   simplified   regimens,  
reduced  pill  burdens,  and  enabling  the  availability  of  drug  to  larger  numbers  of  patients  
[155].    However,  to  realize  the  full  potential  of  LASER  ART,  formulations  in  development  
Figure  2.6  Antiretroviral  assessments  in  human  monocyte-­derived  macrophages.  
(A)   Progeny  HIV   virion   production  was   determined   by  HIV   reverse   transcriptase   (RT)  
Statistical  differences  were  determined  using  two-­way  ANOVA  among  groups;;  we  used  
Bonferroni's  post  hoc  test  to  correct  for  multiple  comparisons.  **p  <  0.01;;  ***p  <  0.001;;  
****p   <   0.0001.   (B)   HIV   p24   staining   (brown)   counterstained   with   hematoxylin   (blue)  
(scale  bar  =  200  μm).    
 79 
must   be   appropriately   screened   based   upon   drug   biodistribution   and   ease   of   drug  
penetration  into  tissue  viral  reservoirs.  While  computerized  simulations  were  developed  
due  to  the  inherent  complexity  of  particle  drug  parameters  this  has  not  proven  beneficial  
[248,  249].  This  is  based  on  broad  differences  in  the  drug  properties,  the  size,  shape  and  
charge  of  the  composed  particle,  the  prodrug  lipophilicity,  composition  and  hydrophobicity,  
the   drug   loading,   encasement   and   decorations   and   the   inherent   tissue   and   cell  
physicochemical   properties   [250,   251].      While   others   and   we   have   developed   such  
schemes  the  needs  to  track  particle  distribution  at  the  cellular  and  tissue  level  to  predict  
drug   particle   efficacy   knows   no   substitutions   from   direct   measurements   [179,   252].  
Therefore,  there  is  a  clear  need  to  develop  such  direct  screening  platforms.  To  overcome  
this  obstacle,  we  demonstrated  that  the  biodistribution  of  ARV  loaded  theranostic  particles  
by  SPECT/CT  and  MRI  imaging  modalities  effectively  correlates  with  LASER  ART  drug  
cell   and   tissue   biodistribution.   Our   newly   crafted,   intrinsically   radiolabeled   multimodal  
theranostic   particles   provide   a   platform   to   expedite   the   development   of   efficient   and  
effective   long-­acting   ART.   However,   we   acknowledge   the   inherent   limitations   of   the  
system.  Indeed,  studies  are  now  being  implemented  that  will  address  the  remaining  hurdle  
including   matching   the   inherent   properties   (size,   shape   and   surface   charge)   of   the  
theranostic  particles  with  those  particles  that  would  be  scaled  up  for  human  use  [179,  253].  
Second,  as  of  yet  the  success  of  screening  theranostic  particles  decorated  with  ligands  
that  serve  to  facilitate  optimal  drug  entry  into  the  most  relevant  tissue  viral  reservoirs  such  
as  lymphoid  tissues  and  the  brain  remains  unproven  [254,  255].  The  third  rests  in  the  use  
of   subcellular   drug   localizations   to  maximally   restrict   targeted   components   of   the   viral  
replication  cycle  [236].  Fourth  is  the  predictive  value  of  not  simply  measuring  drug  depots  
in   macrophages   but   also   assessing   ARV   entry   and   distribution   into   the   more  
pathobiologically  relevant  viral  target,  the  CD4+  effector  memory  T  cell  [256].    All  must  be  
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taken  into  account  and  careful  consideration  of  particle  design  is  required  with  concomitant  
evaluations  of  its  predictive  value.    
In  efforts  to  meet  such  needs,  we  have  taken  a  “next  step”  in  our  research  activities  
to  build  upon  an  already  successful  theranostics  platform  that  is  based  upon  a  “core-­shell”  
system  composed  of  europium-­doped,  cobalt-­ferrite  nanocrystals  (EuCF),  encased   in  a  
PCL   core,   and   encapsulated  within   a   lipid   shell   [179].   The  EuCF  nanocrystals   have   a  
number   of   properties   that   can   meet   the   requirements   of   assessing   of   LASER   ART  
activities.   Notably,   the   particles   sizes   are   similar   to   LASER   ART   and   possess   strong  
superparamagnetic   properties.   This   allows   their   efficient   use   as   a   T2-­weighted   MRI  
contrast   agents   [257].   As   MRI   tests   are   broadly   available   in   medical   practice   and  
commonly   used   in  medical   imaging   it   certainly   offers   the  needed   spatial   and   temporal  
resolution   and   tissue   contrast   to   permit   adequate   determination   of   EuCF-­drug   particle  
distribution  in  tissues  [258].    
However,  MRI  lacks  sensitivity  for  determining  precise  drug  particle  concentrations  
in  tissue  [259].  Indeed,  imaging  alternatives  to  MRI  could  improve  visualization  of  particles  
at   low  concentrations  [260].  Moreover,  no  single   imaging  modality   is  currently  available  
that   offers   both   highly   sensitive   detection   and   excellent   spatial   resolution   [261].   This  
inspired  our  use  of  nuclear  medicine  imaging  modalities  (SPECT/CT),  which  provides  the  
highest   degree   of   sensitivity   [261,   262].   Additionally,   radioactive   imaging   provides   the  
ability  to  accurately  quantify  the  concentration  of  particles   in  tissue  noninvasively  [262].  
Therefore,   combining   MRI   and   SPECT/CT   takes   advantage   of   the   strengths   of   both,  
enabling  a  clearer  evaluation  of  any  of  our  developed  long-­acting  ARVs.    
The   stability   of   the   radiolabel   is   critical   for   accurate   determinations   of   particle  
distribution  by  SPECT/CT  as  the  particle  locale  is  assessed  indirectly  via  a  radionucleotide  
signal  [263].  If  the  radiolabeling  strategy  can  be  carefully  designed  to  create  a  highly  stable  
radiolabel,  both  its  sensitivity  and  specificity  can  be  optimized.  To  meet  such  a  challenge,  
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we  intrinsically  doped  the  radioisotope  directly  into  the  EuCF  nanocrystal  lattice.  This  is  
different   from  more   common   radiolabeling   strategies   as   it   does   not   involve   the   use   of  
exogenous   chelators   in   forming   stable   complexes   [263,   264].   There   are   a   number   of  
considerations   in   generating   an   optimal   labeling   strategy   [188].  First,   the   coordination  
chemistry  of  radioisotopes  varies  significantly.  Choosing  the  right  chelator  for  any  specific  
isotope   is   challenging,   as   there   are   none   that   can   bind   multiple   radioisotopes   [265].  
Second,  incorporation  of  chelators  can  alter  the  hydrodynamic  size  and  surface  chemistry,  
which   will   alter   biodistribution   and   obscure   the   true   pharmacological   behavior   of   the  
particles  [189,  190].  This  fact  may  be  enhanced  as  the  radiolabel  could  become  unbound  
from  particle  leading  to  false  positive  results  [189,  190,  266].  Chelator  free  labeling  forgoes  
the  need  for  chelating  moieties  and  therefore  the  native  pharmacological  behavior  of  the  
particle   is   maintained.   Third,   to   optimize   labeling   the   number   of   chelating   moieties  
conjugated  to  the  particle’s  surface  should  not  impose  any  limitations.  As  intrinsic  doping  
places  radioisotopes  directly  into  the  lattice  sites  of  the  particle’s  metallic  core,  abundant  
labeling   sites   are   available   which   results   in   high   yields   with   enhanced   stability   [191].  
Fourth,  with  chelator-­free  labeling,  the  surface  of  the  particle  can  be  easily  modified  with  
targeting   ligands,   therapeutic   agents,   or   other   imaging   agents   because   no   surface  
functional   groups   are   required   for   the   radiolabel   [192].   Last,   chelator-­free   labeling   is  
simple,  fast,  and  effective  allowing  for  radiolabeling  with  a  broader  spectrum  of  isotopes,  
including  72As  and  69Ge,  both  of  which  have  proven  extremely  challenging  to  radiolabel  
via  chelator  chemistry  [267,  268].  Thus,  in  the  current  report  we  intrinsically  doped  111In  
into  the  core  structure  of  the  EuCF  nanocrystals.  To  facilitate  the  production  of  the  particle,  
we   simply   added   the   radioisotope   precursor   111InCl3   during   the   synthesis   of   the  EuCF  
nanocrystal  core.  This  simple  method  embeds  the  radioisotope  into  the  crystal  lattice  of  
the  core  resulting  in  an  intrinsically  radioactive  particle  whose  radiolabel  was  >  97%  stable  
and  able  to  accurately  measure  particle  accumulation  at  targeted  sites.    
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Any   consideration   of   predictive   modeling   of   the   diversity   of   LASER   ART  
physiochemical   properties,   excipients,   size,   shape,   charge,   encasements  and   complex  
pharmacological  behaviors  (for  example,  drug  subcellular,  cellular  and  tissue  distribution,  
hydrolysis   and   antiretroviral   activities)  must   include   accurate   predictive  modeling   [179,  
269-­271].   These   assessments   must   include   subcellular,   cellular   and   tissue   drug  
distribution   studies   [179,   253,   270].      Moreover,   before   any   animal   injection,   the   drug  
particle   properties   such   as   uptake,   retention,   subcellular   location,   toxicities,   and  
antiretroviral  activity  were  investigated  in  macrophages  and  served  as  confirmation  of  the  
current  data  sets  [151,  272].  Dynamic  light  scattering  showed  that  the  hydrodynamic  size  
of   the   EuCF-­RPV   particles   was   similar   to   that   of   NRPV.   This   was   confirmed   by   TEM  
imaging   of   both   particles.  Additionally,   encapsulated   drug   retained   potent   antiretroviral  
activities  as  evidenced  by  RT  and  HIV-­1p24  activity  and  staining,  respectively.  Importantly,  
the   intrinsic   fluorescence   of   Eu   allowed   for   visualization   of   particle   uptake   along   with  
subcellular   identification  of  EuCF  particles  within  endosomal  compartments   identical   to  
those  where  active  viral  replication  occurs  which  was  consistent  with  our  previous  reports  
[179,  235,  273,  274].    
Overall,  111InEuCF-­RPV  “multimodal  imaging  theranostic  nanoprobes”  were  made  
to  facilitate  the  development  of  targeted  LASER  ART.  The  lipid-­encapsulated,  intrinsically  
radiolabeled  111InEuCF  nanoparticles  can   fulfill   this   role  by  providing  a   flexible  platform  
with  the  highest  degree  of  spatial  accuracy  and  sensitivity  for  the  design  of  diagnostic  and  
therapeutic  applications 
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CHAPTER  3  
In  vivo  Biodistribution  of  Theranostic  
Nanoparticles.  





To   realize   the   potential   of   long   acting   viral   reservoir   penetrating   drugs,  
pharmacokinetic   and   pharmacodynamic   profile   assessment   must   be   performed   to  
minimize  on  and  off-­target  effects.  Because  of   the  greatly  extended  half-­lives  of  newly  
emerging  LASER  ART  nanoformulations.  Current  PK  and  PD  experimental  assessments  
often  take  weeks  to  months  to  perform,  and  with  multiple  innovative  strategies  coming  to  
the   forefront   of   development,   such   timeframes   have   proven   too   tedious   and   time  
consuming.  Another  limitation  of  current  PK  and  PD  analysis  is  that  for  tissue  drug  levels  
to  be  determined,  the  animal  must  be  sacrificed.  Therefore,  a  screening  platform  that  could  
be  used  to  assess  current  and  predict  future  drug  biodistribution,  in  living  animals,  would  
be  of  great  value  in  assessing  new  treatments.    While  mathematical  descriptions  of  long-­
acting  nanoformulated  drug  distribution  have  been  developed,   these  cannot   reflect   the  
diversity  of  chemical  alterations  and  physical  characteristics  now  required  for  LASER  ART  
nanoformulations  [224].  To  overcome  these  technical  and  biologic  challenges,  multimodal  
decorated  nanoparticles  were  produced  where  hydrophobic  ARVs  and  bioimaging  agents  
were  encased  in  a  single  nanoformulation.  Highly  stable  europium  cobalt-­ferrite  (EuCF)  
nanocrystals,   intrinsically   radiolabeled   with   111indium   were   loaded   with   the   ARV   drug,  
rilpivirine  (RPV),  creating  an  all-­in-­one  “multimodal  imaging  theranostic  nanoparticle”.    
The  newly  minted  drug  particles  facilitated  real-­time  non-­invasive  detection  of  drug  
and  antiretroviral  drug  biodistribution  and  screening  by  both  MRI  and  SPECT/CT  imaging  
modalities.   Combining   spatial   specificity   of   MRI   with   the   quantitative   sensitivity   of  
SPECT/CT  allowed  for  precise  assessments  of  drug  distribution  and  drug  concentration  
in  real  time.    These  findings  forge  a  significant  improvement  over  first  generation  EuCF-­
PCL   particles   [179]   by   extending   ARV   encapsulations   and   bioimaging   capabilities   to  
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assess   drug   biodistribution.   In   vivo  MRI   and   SPECT/CT   imaging   and   quantification   of  
111InEuCF-­RPV  particle  distribution  over  a  week  provided  strong  correlations  with  tissue  
RPV   levels   up   to   one   month   post   intravenous   injection.   Validation   of   this   predictive  
potential   is   provided   by   ultra-­performance   liquid   chromatography   tandem   mass  
spectrometry  (UPLC-­MS/MS)  and   inductively  coupled  plasma  mass  spectrometry  (ICP-­
MS)  made   possible   by   the  metals   encased   in   the   particles.   TEM  analysis   of   reservoir  
tissues   showed   accumulation   of   theranostic   particles   in   tissue   resident   macrophages.  
Histological  evaluations  of  various  tissues  after  treatment  with  particles  show  no  significant  
deviations   from   tissue   derived   from   untreated   animals.   This   provides   evidence   that  
particles  are  non-­toxic.     The  data  demonstrate,   for   the  first   time,   that   theranostics  ARV  
particles  can  provide  a  platform  to  facilitate  clinically  effective  LASER  ART  development.  
  
3.2  Materials  and  Methods  
3.2.1  Animals  
Male  Balb/cJ  (6-­7  weeks  old)  were  purchased  from  Jackson  Laboratories  (Bar  
Harbor,  Maine,  USA).  Animals  were  housed  in  the  University  of  Nebraska  Medical  
Center  (UNMC)  laboratory  animal  facility  according  to  the  Association  for  Assessment  
and  Accreditation  of  Laboratory  Animal  Care  guidance.  All  protocols  related  to  animal  
experiments  were  approved  by  the  UNMC  Institutional  Animal  Care  and  Use  Committee  
and  met  the  requirements  and  ethical  guidelines  set  forth  by  the  National  Institutes  of  






3.2.2  Tissue  Biodistribution  of  Multimodal  Theranostic  Nanoparticle  
   For  multimodal  imaging  and  biodistribution  studies;;  111InEuCF-­PCL/RPV,  ultra-­
small  lipid  coated  177LuEuCF  and  NRPV  particles  were  injected  intravenously  into  mice  
at  variant  concentrations  of  drug  or  radioisotope  (Table  3.1).  As  shown,  male  Balb/cJ  
mice  (6-­7  weeks  old)  were  divided  into  eight  groups  (n=  10  to  15  mice  per  group)  and  
intravenously  injected  with  various  doses  of  theranostic  and/or  NRPV  particles.  The  first  
group  (G1)  received  NRPV  particles  at  45  mg  RPV/kg.  The  second  group  (G2)  received  
NRPV  particles  at  a  lower  dose  of  5  mg  RPV/kg.  The  third  group  (G3)  received  EuCF-­
PCL  particles  (2mg/kg  iron)  only.  The  fourth  group  (G4)  was  administered  EuCF-­RPV  
particles  (2  mg/kg  iron).  The  fifth  (G5)  and  sixth  (G6)  groups  received  two  sequential  
injections,  first  EuCF-­PCL  particles  (2  mg/kg  iron)  and  then  NRPV  particles  (45  mg  
RPV/kg  for  G5  and  5  mgRPV/kg  for  G6,  respectively).  The  seventh  group  (G7)  
underwent  SPECT/CT  imaging  after  receiving111InEuCF-­PCL  particles  ~  22.2  MBq  (600  
μCi)  and  the  final  group  (G8)  was  treated  with  ultra-­small  lipid  coated  177LuEuCF  
particles  ~  74  MBq  (2000  μCi)  to  assess  the  effect  of  particle  size  on  biodistribution.  For  
plasma  drug  quantitation,  100  µL  whole  blood  was  collected  by  cheek  puncture  into  
lithium  heparin  coated  tubes  at  1,  3,  5,  7,  14,  21,  and  28  days  post  injection.  For  tissue  











2,  5  and  28  days  post  treatment  and  eight  tissues  were  dissected  (liver,  spleen,  lung,  
gut,  brain,  axillary  and  popliteal  lymph  nodes  and  kidneys).    
3.2.3  UPLC-­MS/MS  Analysis  of  RPV  in  Plasma  and  Tissues  
   For  analysis  of  RPV  in  plasma,  to  25  µl  of  plasma,  10  µL  of  internal  standard  (IS)  
solution   (250   ng/mL   indinavir   and   500   ng/ml   lopinavir;;   final   concentration   25   ng/ml  
indinavir,   50   ng/ml   lopinavir)   was   added   along   with   1   ml   of   ice-­cold   Optima-­grade  
acetonitrile.  Samples  were  then  vortexed  and  centrifuged  at  17,000  g  for  10  min  at  4°C.  
Supernatants   were   evaporated   using   a   Thermo   Scientific   Savant   Speed   Vacuum  
(Waltham,  MA,  USA)  and   reconstituted   in  100  µL  50%   (v/v)   optima-­grade  methanol   in  
optima-­grade  water.  Standard  curves  were  prepared  in  blank  rat  plasma  in  the  range  of  
0.2–2000  ng/mL  RPV  with  10  µL  of  IS  added.  For  tissue  analyses,  100  mg  of  tissue  was  
homogenized  in  4  volumes  of  90%  (v/v)  Optima-­grade  methanol  in  Optima-­grade  water  
using  a  Qiagen  Tissue  Lyzer  II  (Valencia,  CA,  USA).  To  100  µL  of  tissue  homogenate,  80  
µL  of  100%  Optima-­grade  methanol,  10  µL  of  50%  Optima-­grade  methanol  (v/v)  in  MS-­
grade  water,   and   10   µL   IS  was   added.   Standard   curve   samples  were   prepared   using  
equivalent  tissue  matrix  dilutions,  to  which  were  added  80  µL  of  Optima-­grade  methanol,  
10  µL  of  50%  Optima-­grade  methanol  (v/v)  in  Optima-­grade  water  spiked  with  standard  
drug  concentrations  and  10  µL  of  IS.  Chromatographic  separation  of  10  µL  of  plasma  or  
tissue  samples  was  achieved  with  an  ACQUITY  UPLC-­BEH  Shield  RP18  column  (1.7  µm,  
2.1   mm   x   100   mm)   using   a   7-­min   gradient   of   mobile   phase   A   (7.5   mM   ammonium  
bicarbonate  in  Optima-­grade  water  adjusted  to  pH  7  using  acetic  acid)  and  mobile  phase  
B  (100%  Optima-­grade  methanol)  at  a  flow  rate  of  0.25  mL/min.  The  initial  mobile  phase  
composition  of  70%  B  was  held  for  4.75  min  and  was  increased  to  95%  B  in  0.25  min  then  
held  constant  for  0.75  min.  Mobile  phase  B  was  reset  to  70%  in  0.25  min  and  the  column  
was  equilibrated  for  1.0  min  before  the  next  injection.  RPV  was  detected  at  a  cone  voltage  
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of  92  volts  and  collision  energy  of  56  volts.  Multiple  reaction  monitoring  (MRM)  transitions  
used  for  rilpivirine,  indinavir  and  lopinavir  were  367.032  >  127.859,  614.14  >  97.023,  and  
629.177  >  155.031  m/z,  respectively.  Spectra  were  analyzed  and  quantified  by  MassLynx  
software  version  4.1  using  the  ratio  of  analyte  peak  area  to  IS  peak  area.  Tissue  cobalt  
was  analyzed  by  ICP-­MS  as  described  previously  [275].    
  
3.2.4  MRI  Analysis  of  the  Biodistribution  of  Theranostic  Nanoparticles  in  Mice  
   EuCF-­RPV  (G4)  and  EuCF-­PCL  biodistribution  studies  were  performed  with  co-­
injected  NPRV  particles  (G5).  These  experiments  were  performed  using  male  Balb/cJ  
mice  (6-­7  weeks  old,  n  =  10).  MRI  scanned  mice  immediately  prior  to  intravenous  
injection  of  particles  to  provide  a  baseline  scan  for  comparisons.  MR  images  were  
acquired  2  and  5  days  after  treatment  using  a  7T/16  cm  Bruker  PharmaScan  and  a  
home-­built  RF  coil  for  signal  transmitting  and  receiving.  T2  mapping  was  used  to  
determine  the  biodistribution  of  EuCF-­RPV  particles  as  previously  described  [276]  with  
the  following  modified  scanning  parameters.  For  T2  mapping,  a  CPMG  phase  cycled  3-­
dimensional  multi-­echo  sequence  data  acquired  with  24  echoes  (echo  times  TEn  =  n  x  
2.638  ms;;  n  =  1,  2,  3...  up  to  24),  400  ms  repetition  time,  120  ×  144  ×  58  acquisition  
matrix,  40  ×  40×  22  mm  field  of  view  (FOV),  one  average,  for  a  total  acquisition  time  of  
56  min.  After  post  scans,  mice  were  anesthetized  with  isoflurane,  sacrificed  via  cardiac  
puncture,  and  perfused  with  sterile  PBS.  Organs  were  then  collected  for  drug  and  metals  
content  analysis  (liver,  spleen,  kidney,  lung,  GALT,  and  brain).  Additionally,  mice  were  
bled  via  facial  vein  puncture  after  the  day  2  and  5  post-­scans.  Blood  was  collected  into  
lithium  heparin  coated  tubes  and  centrifuged  at  2,000  x  g  for  10  min  to  collect  plasma  for  




3.2.5  Theranostic  Nanoparticle  Biodistribution  by  SPECT/CT  
   In  vivo  biodistribution  of  111InEuCF-­PCL  particles  was  determined  in  male  Balb/cJ  
mice   (6-­7  weeks   old,   n=   10,  G7)   via  SPECT/CT.  On   day   0   all  mice   received   a   single  
intravenous   injection   of   ~22.2   MBq   (600   µCi)   of   111InEuCF-­PCL   particles.   Image  
acquisition  was  performed  at  4,  12,  24,  48,  and  120  hours  post  injection  by  a  hybrid  single  
photon   emission   computed   tomography   system   and   x-­ray   computed   tomography  
(SPECT/CT)  (Flex  Triumph,  TriFoil  Imaging,  Northridge,  CA,  USA)  fitted  with  a  five  pinhole  
(1.0  mm  per  pinhole)  collimator.  First  CT  images  were  acquired  using  360  projections  over  
360°  with  an  x-­ray  tube  current  of  140  mA  and  voltage  of  75  kilovoltage  peak  (kVp)  at  a  
magnification   of   2.0   (field   of   view   =   59.2   mm2).   Immediately   after,   SPECT/CT   image  
acquisition  was  performed  with  the  following  parameters;;  64  projections  at  10  seconds  per  
projection  over  360°  using  a  radius  of  rotation  (ROR)  of  48  mm  (field  of  view=  59  mm2).  
Co-­registration   of   anatomical  CT   images  and   functional  SPECT  was  performed  by   3D  
visualization  and  analysis  software,  VivoQuant  3.5  (Invicro  Boston,  MA,  USA).  Regions  of  
interest  (ROIs)  were  drawn  over  various  organs  and  the  radioactivity  and  organ  volume  
were  determined  to  calculate  gamma  counts  per  cubic  millimeter  (mm3).  After  days  2  and  
5  scans,  mice  were  sacrificed  and  various  organs  including  the  heart,  lung,  liver,  pancreas,  
stomach,  spleen,  small   intestine,  large  intestine,  kidneys,  bladder,   lymph  node,  muscle,  
bone,  brain,  injection  site  (tail),  remaining  carcass  and  blood  were  collected,  weighed,  and  
analyzed  ex   vivo   for   radioactivity   using   gamma   scintillation   spectrometry.   Additionally,  
animals   were   individually   caged   so   that   excreted   signal   could   be   measured   from   the  
bedding.   Signal  measured  was   back   calculated   to   the   time   of   injection   to   account   for  
radioactive  decay  of  111In  (t1/2  =  67.2  h).  Signal  from  each  organ  was  divided  by  the  sum  
of  total  counts  from  all  sources  and  then  divided  again  by  the  weight  of  the  organ  to  obtain  
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percent-­injected  dose  per  gram  of   tissue  (%  ID/g).  For   the  ultra-­small   (~  5  nm)  particle  
biodistribution  study,  15  male  Balb/cJ  mice  (6-­7  weeks  old)  were  intravenously   injected  
with   ~   74   MBq   (2,000   µCi)   of   lipid-­coated   177LuEuCF   particles   (G8).   Mice   were   then  
scanned   by   SPECT/CT   using   the   same   parameters   as   previously   described   for   the  
111InEuCF-­PCL  particles  at  6,  24,  48,  and  120  hours  post  injection.  After  scanning  at  24,  
48,  and  120  hours,  5  mice  were  sacrificed  and  organs  were  collected  for  ex  vivo  gamma  
counting   in  the  same  manner  as  for  111InEuCF-­PCL  particles  except   that   the  half-­life  of  
177Lu  (t1/2  =  6.64  days)  was  used  for  back  calculating  radioactivity.  
  
3.2.6   Theranostic   Nanoparticles   for   Prediction   of   Long-­Term   Rilpivirine  
Biodistribution    
For   multimodal   imaging,   non-­invasive   MRI   and   SPECT/CT   were   performed   to  
assess   theranostic   particle   biodistribution.   As   shown   in   Figure   3.1   First,   MRI   was  
performed  on  mice  receiving  EuCF-­RPV  (G4)  and  EuCF-­PCL  plus  NRPV  (G5)  at  2  and  5  
days   post   injection.   These   images   were   quantified   for   approximate   iron   concentration  
using  phantom  relaxivity  data  acquired  in  MDM.  SPECT/CT  imaging  was  performed  on  
mice  that  received  ~22.2  MBq  (600  µCi)  of  111InEuCF-­PCL  (G7)  and  ~  74  MBq  (2000  μCi)  
of   ultra-­small  
lipid   coated  
177LuEuCF  
(G8)   particles.  
For   ex   vivo  




Figure   3.1   Schematic   diagram   of   treatment   groups   used   in   the   in   vivo  
pharmacokinetic/bio-­distribution   correlation   study.   Figure   display   groups   injected   with  
EuCF-­RPV,  EuCF-­PCL  and/or  NRPV,  111InEuCF-­PCL  or  177LuEuCF  particles  in  Balb/cJ  mice.  
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was  performed  on   tissues   recovered   from  mice   injected  with   111InEuCF-­PCL   (G7)   and  
ultra-­small  177LuEuCF  (G8)  particles.  The  degree  of  correlation  between  the  following  data  
sets  was  determined;;  RPV  concentration  in  tissues  as  determined  by  UPLC-­MS/MS,  iron  
concentration   by   MRI,   radioactivity   by   SPECT/CT,   ex   vivo   gamma   scintillation  
spectrometry,  and  cobalt  concentration  determined  by  ICP-­MS.  To  assess  in  vivo  toxicity  
of  the  injected  particles,  the  mice  were  sacrificed  at  28  days,  and  liver,  spleen  and  kidney  
were   collected   and   fixed   in   10%   neutral   buffered   formalin   for   histological   analysis.   To  
determine   the   real   time   drug   biodistribution   prediction   capabilities   of   the   particles,   the  
results  from  advanced  molecular  imaging  techniques  were  correlated  with  drug  and  metal  
quantitative   results   from   independent   groups.   For   the   first   set   of   comparisons,   RPV  
concentration   (ng/mL),   iron   concentration   (ng/mL),   cobalt   concentration   (µg/mL),  
SPECT/CT  signal  (counts/mm3),  or  gamma  counts  (%  ID/g)  were  each  averaged  across  
all  groups  by  tissue  (liver,  spleen,  lymph  node)  and  Pearson’s  correlation  coefficients  for  
each  2  parameter  comparison  (for  example:  RPV  in   liver  vs.  SPECT/CT  signal   in   liver)  
were   determined.   For   the   second   set   of   comparisons,   each   group   was   considered  
separately.  For  each  group,  these  data  were  averaged  by  tissue  and  day  of  sacrifice.  The  
tissue  per  day  averages  were  then  compared  to  the  same  tissue  per  day  averages  from  
every  group  and  Pearson’s  correlation  coefficients  were  calculated  for  each  comparison.  
Statistical  differences  were  determined  using  a  two-­way  ANOVA  among  groups  followed  
by  Bonferroni  multiple  comparison  test.  P  values  ≤  0.05  were  considered  significant.    
  
3.2.7  Autoradiography  
   Liver,  lungs  and  spleen  were  excised  at  1,  2  and  5  days  post  injection  from  mice  
treated  with  111InEuCF-­PCL  or  177LuEuCF  particles.  Collected  tissues  were  washed  with  
deionized   water   and   immediately   embedded   into   optimal   cutting   temperature   (O.C.T)  
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compound  (Fischer  HealthCare,  Waltham,  MA,  USA).  Cryostat  sections  (10  µm)  of  tissue  
samples  were  prepared  and  exposed  to  a  phosphor  screen  for  5  days  in  the  dark  (Leica  
CM1850,   Leica   Biosystems   Inc,   Buffalo   Grove,   IL,   USA).   The   phosphor   screen   was  
subsequently   imaged  by  a  Typhoon  FLA  9500  variable  mode  imager  (GE  Lifesciences,  
Pittsburg,  PA,  USA)  at  25  µm  resolution.      
  
3.2.8  Tissue  Localization  and  Toxicity  
   Particle  distribution  within  the  spleen  and  liver  from  mice  treated  with  EuCF-­PCL  
(G3)  and  NRPV  (G5)  was  evaluated  via  TEM.  For  TEM  examination,  tissue  samples  were  
fixed   in   TEM   buffer   at   room   temperature.   Tissue   processing   and   sectioning   were  
performed  as  previously  described  [276].  In  vivo  toxicity  of  the  EuCF-­RPV  particles  was  
determined  by  histological  examination.  For  histological  examination,  5  μm  sections  of  
paraffin-­embedded  tissues  were   fixed  to  glass  slides  and  stained  with  hematoxylin  and  
eosin   and   a   TUNEL   assay   was   performed   as   per   as   per   manufacturer's   instructions.  
Images  were  captured  with  a  Nuance  EX  multispectral  imaging  system  affixed  to  a  Nikon  
Eclipse  E800  microscope  (Nikon  Instruments,  Melville,  NY,  USA)  using  a  20×  objective.  
Histopathological   assessment  was   conducted   in   accordance  with   the  guidelines  of   the  
Society  of  Toxicologic  Pathology.    
  
3.2.9  Statistical  Analyses    
For   all   studies,   data   were   analyzed   using   GraphPad   Prism   7.0   software  
(GraphPad,  La  Jolla,  CA,  USA)  or  Statistica  v9  (Statsoft,  Inc.,  Tulsa,  OK,  USA)  and  are  
presented   as   the  mean  ±   standard   error   of   the  mean   (SEM).   For   comparisons   of   two  
groups,  Student’s  “t”  test  (two-­tailed)  was  used.  Experiments  with  multiple  time  points  were  
analyzed  using  two-­way  ANOVA,  to  assess  treatment  versus  control  groups  over  multiple  
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time  points  and  Bonferroni’s  post  hoc  tests  for  multiple  comparisons.  
  
3.3  Results  
3.3.1  Real  Time  in  vivo  Biodistribution  Tests  in  Mice  
3.3.1.1  MRI  Modality  
   The  goal  of  these  studies  is  to  use  multimodal  theranostics  for  non-­invasive  real  
time   tracking   of   drug   biodistribution   in   animals   by   using  MRI   and  SPECT/CT   imaging.  
Figure  3.2A  depicts  the  experimental  timeline  for  the  MRI  and  SPECT/CT  studies.  MRI  
pre-­scans  were  taken  before  injection  of  EuCF-­RPV  (G4)  or  EuCF-­PCL  plus  NRPV  (G5)  
to  establish  a  baseline  signal  and   representative  pre-­scans  are  shown   in  Figure  3.2B.  
MRI  was   chosen  as   the   first  modality   because  of   its   superior   spatial   resolution,  which  
provides   the  most   accurate   information  about   the   localization  of   these  particles   in   soft  
tissues   [259].   Post-­injection   MR   images   were   acquired   2   and   5   days   after   particle  
intravenous   administration   (Figure   3.2B).   After   2   days   post-­administration   mice   were  
scanned  again  and  the  resulting  images  were  analyzed  for  the  presence  of  particles.    T2  
signals  were  decreased  in  both  liver  (outlined  in  red)  and  spleen  (outlined  in  green),  which  
visually  confirms  the  presence  of  supraparamagnetic  particles.  A  similar  decrease  in  T2  
was  observed  5  days  post-­injection  signifying   the  retention  of  particles   in   those  organs  
over  time.    
  
3.3.1.2  Nuclear  Imaging  Modality  
   Taking  advantage  of  increased  sensitivity  over  MRI,  SPECT/CT  imaging  was  also  
performed.  By  combining  MRI  and  SPECT/CT  modalities  the  distribution  of  particles  can  
be  accurately  determined  with  a  high  degree  of  spatial  resolution  and  sensitivity.  To  make  
the   EuCF-­PCL   particles   suitable   for   SPECT/CT   imaging,   Indium-­111   (111In)   was  
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intrinsically   labeled   directly   into   the  EuCF  nanocrystal   lattice   (111InEuCF-­PCL).   For   the  
SPECT/CT  experiment,  10  mice  were   injected  at  a  dose  corresponding   to  ~  22.2  MBq  
(600   µCi)   and   subsequently   scanned   at   4,   12,   24,   48,   and   120   hours   (5   days)   post  
injection.  In  mice  scanned  4  hours  post-­injection,  the  majority  of  particles  localized  to  the  
 
Figure  3.2  Multimodal  theranostics  tests.  (A)  Time  line  of  the  experimental  procedure  in  mice  is  shown  (NP:  
nanoparticles).   (B)   Representative   pre-­scan   and   post-­scan  T2  maps   of   mice   2   and   5   days   after   intravenous  
injection  administration  of  EuCF-­RPV  (2  mg  iron/kg)  particles  (G5)  (yellow:  lung;;  red:  liver;;  green:  spleen;;  orange:  
kidney).   (C)   Two-­dimensional   image   representations   of   three-­dimensional   SPECT/CT   scan   of   mice   treated  
intravenously  with  ∼22.2  MBq   (600  μCi)  of  111InEuCF-­PCL  particles.  (D)  Autoradiographic   images  of   liver  and  
spleen  sections  from  mice  sacrificed  2  and  5  days  post  injection  with  111InEuCF-­PCL  particles.    
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liver,  spleen,  and  axillary  lymph  nodes,  with  modest  accumulation  in  the  popliteal  lymph  
nodes   (Figure  3.2C).  By  12  hours  post-­administration,   the  popliteal   lymph  nodes  were  
clearly  visible  and  persisted  until  day  5.  Particles  continued  to  accumulate  in  the  spleen,  
liver,  and  lymph  nodes  until  48  hours  post-­injection.  Intense  labeling  can  be  seen  in  the  
upper   thoracic   region  which  most   likely   represent   axillary   lymph   nodes.  Axillary   lymph  
nodes  were  dissected  out  and  radioactivity  was  confirmed  by  gamma  scintillation,  ex  vivo.  
By  5  days  post-­injection,   particle   concentrations  had  decreased   in   the   liver   and   lymph  
nodes.  However,  particle  accumulation  in  the  spleen  slightly  increased  by  day  5  compared  
to  day  2,  but  did  not  rise  to  significance.  After  the  2  day  and  5  day  SPECT/CT  scans,  mice  
were  sacrificed  so  that  the  livers  and  spleens  could  be  excised,  flash  frozen  and  fixed  for  
autoradiographic   imaging.  Autoradiography  analysis  of   liver  and  spleen   tissues  visually  
confirmed  the  slight  decrease  in  liver  signal  between  2  and  5  days  as  well  as  the  increase  
in   spleen   signal   over   the   same   time   period   (Figure   3.2D).   Location   of   particles   in   the  
spleen  appears  diffuse  on  day  2,  but  the  signal  coalesces  into  discrete  areas  by  day  5.  
This  most  likely  represents  a  transfer  of  particle  from  the  red  pulp  of  the  spleen  into  the  
marginal  zones  and  white  pulp,  which  are  the  primary  locations  of  splenic  macrophages  
[277].  
The   biodistribution   of   particles   was   dependent   on   surface   chemistry,   size,   and  
shape  [229].  To  this  end  we  prepared,  ultra-­small,  lipid-­coated  lutetium  (177Lu)  intrinsically  
radiolabeled   EuCF   nanocrystals   (177LuEuCF)   with   an   average   size   of   ~   5   nm   for  
SPECT/CT  to  investigate  differential  biodistribution  by  modulating  the  size  of  the  particles.  
Mice  underwent  SPECT/CT  scanning  at  6,  24,  48  and  120  hours  (5  days)  post-­intravenous  
administration  of  ~  74  MBq  (~2000  μCi)  of  lipid-­coated  177LuEuCF  particles  (Figure  3.3A).  
At  each  time  point,  representative  images  of  SPECT/CT  scans  were  acquired  of  the  torso  
and  of  the  thoracic  cavity  at   lower  radius  of  rotation  (higher  magnification).  The  images  
show   preferential   early   distribution   of   these   particles   into   the   lungs   at   6   hours   post-­
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administration   with   a   small  
amount   in   the   liver   and  
spleen.   At   24   hours  
accumulation   in   the   lungs  
peaked  and  was  beginning  in  
the   spleen   and   liver.   By   48  
hours,   the   signal   in   the   lung  
began  to  decrease,  indicating  
a   clearance   of   particle   from  
lung  tissue.  At  the  same  time,  
accumulation   in   the   liver  was  
clearly  visible  as  well  as  in  the  
spleen.  Interestingly  this  trend  
continued  to  day  5  with  more  
accumulation   in   the   liver  and  
a   sharp   decrease   in   lung  
signal  (Figure  3.3B).  Signal  in  
the  spleen  remained  relatively  
constant  between  days  2  and  
5.   These   observations   were  
supported  by  3D  quantitation  of   the  SPECT/CT  signal  (counts  per  mm3)  (Figure  3.3C).  
For  additional  verification  of  these  results,  mice  were  sacrificed  after  24,  48,  and  120  hour  
scans  and  various  organs  were  collected  which  included,  but  not  limited  to,  lung,  liver,  and  
spleen.  All  organs  were  weighed  and  the  radioactivity  measured  to  calculate  the  percent-­
injected  dose  per  gram  (%ID/g)  for  each  tissue.  As  shown  in  Figure  3.3D,  176  %ID/g  of  
the  particle  accumulated   in   the   lungs,  38  %ID/g  had  accumulated   in   the   liver  and  34.5  
 
Figure  3.3  Effect  of  ultra-­small   particle  size  on   theranostic  particle  
biodistribution  determined  by  SPECT/CT.  In  vivo  biodistribution  of  ultra-­
small  lipid  coated  177LuEuCF  particles  (∼74  MBq)  was  assessed  in  mice  by  
SPECT/CT.   (A)   Experimental   timeline   for   177LuEuCF   particles  
biodistribution   study.   (B)   Representative   images   of   3D   SPECT/CT  
acquisitions  (C)  Left:  3D  quantification  of  SPECT  signal  using  VivoQuant  
software   displayed   in   counts/mm3.   Right:   Ex   vivo   radioactivity  
biodistribution  by  gamma  counting.  
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%ID/g  was  found  in  the  spleen  
by  24  hours.  At  48  hours   the  
amount  of  particles  in  the  lung  
had   dropped   to   153   %ID/g  
while  particle  accumulation  in  
the   liver   and   spleen   had  
increased  to  40  and  55  %ID/g,  
respectively.   By   day   5   more  
than   half   of   particles   had  
cleared  from  the  lung  leaving  
73%  ID/g.  However,  signal  continued  to  increase  in  the  liver  (63%  ID/g)  and  held  steady  
in   the   spleen   (56%   ID/g).   This   ex   vivo   radioactivity   was   verified   by   autoradiographic  
evaluation  of  the  liver,  spleens  and  lungs  from  these  mice  sacrificed  1  and  2  days  post  
injection  as  shown  in  Figure  3.4..  Additionally,  we  could  not  detect  ultra-­small  particles  in  
any   lymph  nodes  however,   the  most  striking   feature  of   these   images   is   the   increase   in  
signal   seen   in   the   spleen   from   24   hours   to   48   hours.   Overall,   we   conclude   that  
intravenously  injected  particles  must  be  of  appropriate  size  in  order  to  effectively  penetrate  




3.3.2   Predictive   Capabilities   of   Theranostic   Nanoparticles   for   Rilpivirine  
Biodistribution  
   Long-­term   prediction   of   disease   progression,   drug   biodistribution   and   dose  
optimizations   for   long-­acting  HIV  medications   is  difficult,   laborious  and   time  consuming  
 
Figure  3.4  Ex  vivo  autoradiography.  Autoradiographic  images  of   lung,  
liver  and  spleen  sections  from  mice  sacrificed  1  and  2  days  post  injection  
with  ultra-­small  177LuEuCF  particles.  Most  notable  is  the  strong  increase  in  
signal  in  the  spleen  between  days  1  and  2.  
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using   conventional   pharmacokinetics   and   biodistribution   assessments   [151,   153].  
Therefore,  a  theranostic  imaging  platform  would  be  advantageous  to  build  a  data  library  
that   can   be   used   to   predict   drug   biodistribution   in   patients   with   more   precision   than  
traditional  pharmacokinetics  analysis  without  invasive  isolation  of  tissues  samples  [179,  
196].   We   hypothesized   that   imaging   data   acquired   from   our   multimodal   theranostic  
imaging  platform  would  correlate  with  drug  concentration  and  provide  information  about  
the  long-­term  biodistribution  of  long-­acting  antiretroviral  medications.  In  order  to  test  this  
hypothesis,  we  examined  the  pharmacokinetic  and  biodistribution  profiles  of  eight  different  
treatment  groups,  each  group  containing  10  to  15  Balb/cJ  mice  over   the  course  of  one  
month.  All  treatments  were  administered  via  intravenous  injection  to  healthy  Balb/cJ  mice.  
As   shown   in  Figure  3.1  and  Table  3.1   two  groups   received  only  NRPV  at   a   high   (45  
mg/kg)   (G1)  or   low  (5  mg/kg)  dose  (G2).  The   third  group  was  administered  EuCF-­PCL  
particles  (2  mg/kg  iron)  (G3)  and  the  fourth  was  injected  with  EuCF-­PRV  particles  (2  mg/kg  
iron)  (G4).  Groups  5  and  6  received  a  dual  injection  of  EuCF-­PCL  particles  (2  mg/kg  iron)  
and  NRPV  at  45  mg/kg  (G5)  or  5  mg/kg  (G6).  In  each  group  five  mice  were  sacrificed  at  
days  2,  5  and  28.  At  the  time  of  sacrifice,  organs  were  excised  and  analyzed  by  UPLC-­
MS/MS  and  ICP-­MS  for  drug  and  metal  content,  respectively.  Plasma  was  also  collected  
from  mice  at  days  1,  2,  3,  5,  7,  14,  21,  and  28  and  analyzed  for  drug  and/or  metal  content  
to  build  a  complete  biodistribution  profile  for  each  treatment  group.  We  then  compared  this  
month   of   pharmacokinetic   and   biodistribution   results   to   the   bioimaging   data   obtained  
within  the  first  five  days  post  injection  from  MRI  scans  of  G4  and  G5.  Lastly,  111InEuCF-­
PCL  or  lipid  coated  177LuEuCF  particles  were  given  intravenously  to  groups  7  (G7)  and  
group  8   (G8),   respectively,   for  SPECT/CT  analysis.  We   then  used   these  data   sets   for  
correlation  analyses  comparing  drug  versus  metals  content  or  signal  quantified  through  
imaging  to  estimate   the  ability  of  our  multimodal  particles   to  rapidly  assess  and  predict  
long  term  biodistribution  of  long-­acting  antiretroviral  medications.    
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By  MRI  analysis,  EuCF-­
RPV   particles   (G4)   showed  
similar  biodistribution  as  EuCF-­
PCL   particles   injected  
alongside  NRPV  (G5)  on  day  2  
and   day   5   post   injections  
(Figure   3.5A).   The   amount   of  
iron   present   in   the   liver   and  
spleen   at   2   and   5   days   was  
quantified   using   phantom  
relaxivity   standard   curves  
generated   from   EuCF-­RPV  
particles   in   MDM   at   varying  
concentrations   of   particles   (by  
iron)  as  shown  in  Figure  2.2H  
and  Figure  2.2I.  In  both  groups  
iron   concentrations   decreased  
between   days   2   and   5   in   the  
liver.   This   decrease   was   not  
significant   for   EuCF-­RPV   (2.4  
to  2.1  ng/mL)  but  was  significant  for  EuCF-­PCL  plus  NRPV  (1.9  ng/mL  to  1.1  ng/mL).  In  
contrast,  there  was  a  slight  increase  in  iron  concentration  in  the  spleen  over  the  same  time  
in  both  groups.  Iron  levels  in  the  spleen  increased  from  1.0  to  1.6  ng/mL  for  EuCF-­RPV  
and   from   1.0   to   1.4   ng/mL   for   EuCF-­PCL   plus   NRPV.   G7   mice   were   administered  
111InEuCF-­PCL  particles  and  assessed  by  SPECT/CT  at  4,  12,  24,  48,  and  120  hours  post-­
injection.  Acquired  images  were  reconstructed  to  3-­D  renditions,  regions  of  interest  (ROI)  
 
Figure   3.5   Biodistribution   and   pharmacokinetic   analyses.   (A)  
Quantification  of  iron  content  in  liver  and  spleen  by  MRI.  (B)  Left:  %ID/g  
radioactivity   in   liver,   spleen,   and   lymph  nodes   from  mice   treated   with  
111InEuCF-­PCL.  Right:  Quantification   of  SPECT/CT   signal   by   3D   (C)  
RPV  drug  levels  in  plasma,  liver,  spleen,  and  lymph  nodes  from  days  2,  
5,   and   28   as   determined   by   UPLC-­MS/MS.   (D)   Cobalt   content   from  
groups   (G3,   G4,   and   G5)   treated   with   EuCF-­PCL/RPV   and   NRPV  
particles   in   liver,   spleen,   and   lymph   node   from   days   2,   5,   and   28   as  
determined  by  ICP-­MS.  *p  <  0.05,  **p  <  0.01,  ****P  <  0.0001.  
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were   electronically   drawn   to   encompass   organs,   and   relative   activity   counts   per   cubic  
millimeter   for   each   tissue  were   determined.   Activity   in   liver,   spleen,   and   lymph   nodes  
(axillary  and  popliteal)  increased  until  48  hours  post  injection  with  the  majority  of  particles  
localizing  in  the  liver  (Figure  3.5B).  By  five  days  post  injection,  activity  in  liver  and  lymph  
nodes  decreased  slightly  while  splenic  activity   increased.  The  SPECT/CT   results  were  
confirmed  by  determining  tissue  drug  levels  in  mice  after  scans  on  days  2  and  5.  All  organs  
were  removed  and  particle  biodistribution  measured  by  gamma  scintillation  spectrometry.  
The  results  are  presented  in  Figure  3.5B  as  %  ID/g.  There  was  a  significant  accumulation  
of  particles  in  the  Liver  (73.5%  ID/g),  Spleen  (41.1%  ID/g),  and  axillary  or  popliteal  lymph  
nodes  (13.5%  ID/g).  Interestingly,  at  5  days  post  injection  there  was  a  large  increase  in  
distribution  of  these  particles  to  the  spleen  (63.3%  ID/g)  with  modest  clearance  from  the  
liver   and   small   increases   in   the   lymph   nodes   by   day   5   (62.6%   ID/g   and   18.0%   ID/g,  
respectively).    
In   all   animal   groups   that   received   NRPV   or   EuCF-­RPV   particles,   drug   levels   were  
measured  in  plasma  collected  on  days  1,  2,  3,  5,  7,  14,  21,  and  28  after  treatment.  Tissues  
were  collected  from  mice  on  days  2,  5,  and  28  for  UPLC-­MS/MS  determination  of  drug  
levels.  Drug  levels  in  plasma  and  tissues  for  the  EuCF-­RPV  treatment  group  were  lower  
than  those  found  in  groups  treated  with  NRPV  at  45  mg/kg  or  EuCF-­PCL  particles  with  a  
co-­injection  of  NRPV  at  45  mg/kg   (Figure  3.5C).  The  values  observed  were  similar   to  
values   obtained   from   groups   treated   with   the   lower   concentration   of   NRPV   (5  mg/kg)  
(Figure  3.6).    
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In   groups   that  
received  theranostic  particles,  
(G3,   G4,   G5,   and   G6)   mice  
were  sacrificed  on  days  2,  5,  
and  28,  and  their  organs  were  
removed   and   analyzed   by  
ICP-­MS   for   cobalt  
concentration.  Cobalt  content  
was  fairly  consistent  across  groups  in  the  various  tissues  at  each  time  point  in  groups  G3,  
G4,  and  G5  (Figure  3.5D).  Liver  cobalt  content  on  day  2  was  similar  for  groups  treated  
with  EuCF-­PCL  particles  (G3),  EuCF-­RPV  particles  (G4),  or  dual  injection  of  EuCF-­PCL  
and  NRPV  (G5)   (1.08,  1.12,  and  1.64  µg/g,   respectively).  The  same  was  observed   for  
spleen  (0.90,  0.92,  1.17  µg/g)  and   lymph  nodes  (0.33,  0.35,  and  0.51  µg/g).  By  day  5,  
cobalt  content  in  the  liver  had  dropped  similarly  in  each  group  (10.3%,  21.8%,  and  16.0%,  
respectively),  but  cobalt  content  in  the  spleen  had  increased  (18.8%,  25.5%  and  16.8%).  
Cobalt  concentration  in  the  lymph  nodes  remained  consistent  or  increased  slightly  from  
day  2  to  day  5  in  all  groups.  After  28  days  post  injection  of  particles,  the  liver,  spleen,  and  
lymph  nodes  still  retained  a  small  amount  of  particles,  but  the  majority  had  been  cleared  
from   tissues   as   evidenced   by   the   much   lower   cobalt   concentrations.   However,   the  
percentage   of   particles   cleared  was   similar   between   groups   for   each   tissue.   For   liver,  
cobalt  concentrations  decreased  by  81.9%,  84.3%,  and  86.5%  from  day  5  to  day  28  for  
groups  3,  4,  and  5,  respectively.  In  the  spleen,  cobalt  concentration  dropped  by  87.0%,  
81.0%,  and  82.6%.  Lymph  nodes  also  showed  a  significant  decrease  from  day  5  to  day  
28  of  83.8%,  90.5%,  and  79.6%.    
  
 
Figure   3.6  Pharmacokinetics   and  biodistribution   of   the   co-­injected  
EuCF-­PCL  (2  mg/kg  iron)  and  NRPV  (5  mg/kg  RPV)  particles  (G6)  
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3.3.3  Biodistribution  Confirmations  
We  assessed  the  various  result  parameters  (Figure  3.7A)  by  correlation  analysis  
across   groups   to   test   the   estimated   predictive   value   for   long-­term   biodistribution.  
Pearson’s  correlation  coefficients  for  two  parameter  comparisons  were  averaged  for  RPV  
concentrations,   cobalt   concentrations,   and   SPECT/CT   radioactivity   measures   in   liver,  
spleen,  and  lymph  nodes.  Means  of  absolute  “r”  values  with  p  ≤  0.05  were  displayed  in  
each  cell  and  used  to  generate  a  heat  map  of  relative  strength  of  correlation  (Figure  3.7B).  
Across   all   groups   the   strongest   correlation   (highest   r   value)   was   between   cobalt  
concentration  and  RPV  concentration   in   lymph  node  (r=0.93).  Similarly,  an  absolute  “r”  
value  of  0.81  was  obtained  for  between  SPECT/CT  signal  in  the  lymph  node  and  cobalt  
concentration  in  the  lymph  nodes.  In  the  spleen,  RPV  concentration  correlated  with  cobalt  
concentration   with   r   =   0.54.   For   the   liver,   RPV   concentration   correlated   with   cobalt  
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concentration   and   gave  
an   “r”   value  of   0.65.  Also  
in   the   liver,   SPECT/CT  
radioactivity   and   cobalt  
concentration   correlated  
with   an   “r”   value   of   0.66.  
Lower  Pearson  correlation  
coefficients  were  recorded  
in   liver   than   spleen   and  
lymph   nodes.   However,  
such   differences   likely  
reflect   tissue   processing  
as   whole   lymph   nodes  
and  spleens  were  used  for  
analysis  while  subregions  
of  liver  were  analyzed.  We  
also   determined  
correlations   between  
groups,   tissues   and   test  
measures.   Mean   %ID/g  
from   ex   vivo   gamma  
counts   of   111InEuCF-­PCL  
(G7)   in   liver,   spleen,   and  
lymph  node  on  days  2  and  
5   exhibited   a   strong   correlation   with   SPECT   activity   (r   =   0.93)   (Figure   3.7C),   which  
validated   the  accuracy  of  our  SPECT/CT  quantification.  Also   the  mean  cobalt   levels   in  
 
Figure   3.7   Coordination   and   correlation   of   metadata   analysis.   (A)  
Schematic   showing   parameters   used   for   correlation   analysis.   (B)   Correlation  
matrix.  For  each  tissue  (liver,  spleen,  lymph  nodes)  RPV,  cobalt,  or  radioactivity  
(by  SPECT/CT)   content  was   summed   across   groups   and   then   compared   to  
each  other.  Shown  are  average  correlation  coefficients  across  treatment  groups  
for  correlations  with  a  p-­value  ≤  0.05.  Pearson's  correlation  from  days  2  and  5  
between   (C)   ex  vivo   radioactivity   (%ID/g)   and   in  vivo  SPECT/CT  signal   from  
liver,  spleen,   and   lymph  nodes;;   (D)  cobalt  content  and   ex  vivo   radio-­  activity  
(%ID/g)   from   liver,   spleen   and   lymph   nodes;;   (E)   cobalt   content   and   in   vivo  
SPECT/CT  signal  quantitation  in  spleen  and  lymph  nodes;;(F)  between  in  vivo  
drug  content  and  SPECT/CT  signal  in  spleen  and  lymph  nodes;;  
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liver,  spleen,  and  lymph  nodes  from  EuCF-­RPV  (G4)  treated  mice  were  strongly  correlated  
to  mean   gamma   scintillation   counts   from   111InEuCF-­PCL   (G7)   treated  mice   (r   =   0.92)  
(Figure   3.7D),   indicating   that   the   amount   of   radioactivity   in   these   samples   positively  
correlates  with  cobalt  concentration.  We  found  that  in  spleen  and  lymph  nodes  on  days  2  
and  5  post-­administration,  mean  cobalt  concentrations  in  EuCF-­RPV  (G4)  were  strongly  
correlated  with  SPECT/CT  radioactivity  (r  =  0.99)  (Figure  3.7E).  Finally,  for  days  2  and  5  
post-­administration  =  in  spleen  and  lymph  nodes  from  mice  treated  with  EuCF-­RPV  (G4),  
mean  RPV  concentrations  were  strongly  with  radioactivity  measured  by  SPECT/CT  signal  
(r  =  0.96)  (Figure  3.7F).  These  data,  taken  together,  show  that  the  amount  of  antiretroviral  
accumulation  into  reticuloendothelial  organs  can  be  estimated  accurately  using  imaging  
data  obtained  from  a  multimodal  theranostic  platform.      
3.3.4  Particle  Trafficking  in  Mouse  Tissue  Macrophages  
To   determine   cellular   distribution   of   particles   in   tissues,   following   the  MRI   and  
SEPCT/CT  scan  animas  
was   euthanized   for  
collection   of   tissues.  
Tissues   were   fixed   in  
TEM   buffer,   embedded  
in   resin,   and   TEM  
analysis   [179].  
Representative   TEM  
images   of   liver   and  
spleen   show  
macrophages   in   liver  
and  spleen   tissues   from  
 
Figure   3.8   TEM   of   liver   and   spleen   tissue   sections.   Column   (0)   shows  
representative   images   of   tissue   sections   containing  macrophages   loaded   with  
particles.  Columns  (i-­iii)  display  magnified  images  of  selected  sections    
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day  2  and  day  5  and  are  denoted  by  red  roman  numerals  i,  ii,  and  iii.  (Figure  3.8,  column  
0)  and  are  magnified  (columns  I,  ii,  and  iii,  respectively).  Moreover,  large  accumulations  
of  light-­colored  NRPV  crystals  can  be  found  alongside  dark  clusters  of  EuCF  nanocrystals.  
Histological  analyses  showed  normal  tissue  structure  in  particle-­treated  mice,  thus  ruling  
out   the   possibility   of   particle-­associated   pathological   events   at   the   microscopic   level  
(Figure   3.9).   Together   these   data   confirm   that   particles   administered   intravenously   to  
mice  were   indeed  sequestered  by  macrophages  (TEM)   in   target  organs  without  readily  





































Figure  3.9  Histological  assessments  of  tissues  treated  with  particles.  (A)  Hematoxylin  and  eosin  
(H&E)  staining  of   liver  and  spleen  sections   in   treated  mice.  Livers  and  spleens  from  each   treatment  
group  (non-­radioactive  treatment  groups)  were  excised  at  28  days  post  injections.  (B)  TUNEL  stains  of  
liver  and  spleen  sections  of  the  same  mice.  
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3.4  Discussion  
   Synthesized   theranostic   nanoparticles   contain   individual   functional   components  
that  improve  their  diagnostic  and  therapeutic  potential.  First,  the  CF  component  enhances  
MRI   signal   sensitivity   and   specificity   measures   [196].   The   images   show   excellent   T2  
relaxivity.  As  such,  they  can  be  readily  used  for  ARV  biodistribution  studies.  High  relaxivity  
results  in  enhanced  sensitivity  for  ferrite  quantification.  Second,  the  nanoparticle’s  unique  
spinel  structure  permits  the  incorporation,  in  a  formed  lattice,  of  rare  earth  elements.  This  
includes,  but   is  not   limited   to,  neodymium,   In3+,  Eu3+  and  gadolinium   [196].  Third,  Eu3+  
provides  magnetic  and  fluorescence  capabilities.  Fourth,  intrinsic  doping  of  111In  imparted  
SPECT/CT   imaging   capabilities,   Fifth   translational   potential   is   realized   through   the  
nanoparticle’s  biocompatibility  [196].  This  is  facilitated  through  the  outer  “soft”  lipid  layer  
of   the   111InEuCF-­RPV   nanoparticles   [226,   278].   Sixth,   the   formed   111InEuCF-­RPV  
nanoparticles  are  highly  stable  and  as  such  can  be  made  for  systemic  use.  Seventh,  the  
111InEuCF-­RPV   nanoparticles   are   hydrophilic   with   a   narrow   size   distribution.   Each  
contains  a   “hard”   inner  matrix  of  an  organic-­inorganic  hybrid  of  EuCF  and  PCL,  which  
enables   the  nanoparticles   to  be   loaded  with  hydrophobic  ARVs  and  have   limited   to  no  
toxicities.  Eighth,  the  nanoparticles  unique  physicochemical  properties  facilitate  entry  into  
cells.  Indeed,  the  core  is  made  up  of  111InEuCF,  PCL  and  RPV,  while  the  outer  lipid  layers  
are   formed  with  PC,  DSPE-­PEG2000  and  DOPE.  The   lipid  surrounding   the  111InEuCF-­
RPV   core   serves   to   facilitate   rapid   uptake   by   macrophages   and   as   such   effectively  
distribute  drug   into   tissue  viral   reservoirs.  Ninth,   the  nanoparticle’s  size  and  shape  are  
comparable  to  that  of  LASER  ART  being  developed  for  clinical  use  [153,  219].    
   In  the  present  study  we  compared  the  pharmacokinetics  and  biodistribution  
of  metal   and  drug   to   imaging  data  acquired   from  MRI  and  SPECT/CT  modalities   from  
plasma,  liver,  spleen  and  lymph  nodes  of  NRPV,  111InEuCF-­PCL,  and  EuCF-­RPV  treated  
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Balb/cJ   mice.   The   addition   of   the   SPECT/CT   modality   to   our   already   sensitive   MRI  
particles   was   a   significant   improvement   as   it   allowed   for   the   visualization   and  
quantification  of  particle  accumulation  in  the  axillary  and  popliteal  lymph  nodes  which  were  
not  visible  via  MR  imaging.  Importantly,  the  SPECT/CT  imaging  data  acquired  within  the  
first   week   after   111InEuCF-­PCL   particle   administration   showed   a   very   high   Pearson’s  
correlation  with   the  coordinate   tissue  cobalt  and  RPV   levels   found   in   lymph  nodes  and  
spleens  of  mice  treated  with  EuCF-­RPV  particles  (r  =  0.9875  and  0.966,  respectively).  The  
results  demonstrated  the  potential  of  this  platform  to  accurately  screen  the  biodistribution  
of   long-­acting   formulations   in   the   reticuloendothelial   system.      However,   several   of   the  
correlations   made   had   moderate   Pearson’s   correlation   coefficients   but   were   not  
statistically  significant.  The  limitation,  in  part,  reflects  the  particle  biodistribution  based  on  
size.  Indeed,  our  own  ultra-­small  177LuEuCF  particles  localized  primarily  to  the  lung  before  
a  liver  and  spleen  signal  could  be  visualized.  We  believe  this  system  can  be  accurately  
developed  to  closely  match  and  improve  upon  the  performance  of  our  current  and  future  
LASER  ART   formulations.     The  creation  of  particles  with   increased  aspect   ratios   is  an  
area  of  active   research  and   rod  shaped  particles  may  be  advantageous   for  a   cell   and  
tissue  based  drug  delivery  system  [279].    
   In   addition   to   serving   as   a   screening   tool,   these   particles   can   facilitate   drug  
penetrance  into  reservoir  sites  by  a  “Trojan  horse”  mechanism  by  creating  drug  depots  
[214].   The   ability   to   deliver   therapeutics   to   the   exact   subcellular   site   of   HIV   infection  
provides  opportunities  for  disease  prevention  and  treatment.  Further  optimization  opens  
the  possibility  of  combining  multiple  ARVs  into  a  single  particle,  encapsulating  CRISPR  
Cas9   for   excision   of   integrated   HIV   DNA   from   tissue   sites   of   latent   infection   [280]   or  
delivering  latency  reversal  agents  like  toll-­like  receptor  (TLR)  7  agonists  which  were  shown  
to  be  capable  of  reducing  viral  reservoirs  in  simian  immunodeficiency  virus-­infected  rhesus  
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macaques  [281],  while  simultaneously  imaging  the  real  time  ARV  particle  biodistribution  
and  therapeutic  efficacy.  
In  conclusion,  the  multimodal  particles  provide  the  basis  for  a  flexible  platform  to  
rapidly  assess  tissue  and  cell  drug  biodistribution  of  long-­acting  ARVs  by  SPECT/CT  and  
MRI   in   real   time.   Currently,   plasma   drug   levels   remain   the   gold   standard   for  
pharmacokinetics   analysis,   which   is   cumbersome   for   long-­acting   formulations.  
Importantly,  the  biocompatibility  of  these  particles  was  confirmed  and  when  loaded  with  
ARVs  they  maintain  therapeutic  efficacy.  Thus,  these  theranostic  particles  can  accelerate  
the  discovery  of  LASER  ART  and  optimize  therapeutic  use  profiles  for  an  infected  human  
viral  host.    
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CHAPTER  4  




4.1  Summary  and  conclusions    
  
The  successful  development  of   combination  antiretroviral   therapy   for   the  
treatment  of  HIV-­1  undoubtedly  changed  the  course  of  human  history,  as  millions  
of  infected  people  can  now  anticipate  a  prolonged  lifespan  instead  of  a  certain  and  
painful  death.  However,   the  persistence  of  virus  and  the  continued  strain  of   the  
pandemic  on  global  healthcare  has  resulted   in  HIV-­1  research  to  develop  novel  
strategies   to   improve   upon   current   antiretroviral   therapy.   Improvements   in  
pharmacodynamic  and  pharmacokinetic  profiles  have  shown  remarkable  promise  
in  increasing  drug  adherence,  reducing  secondary  toxicities,  and  preventing  new  
infections.  Our  laboratory  has  shown  that  the  enhancement  of  the  hydrophobicity  
of  current  ARVs  via  nanocrystals  encased  in  biodegradable  polymers  allows  for  
the   establishment   of   drug   depots   within   monocyte-­macrophages,   significantly  
prolonging   drug   half-­life.   But   experimentation   of   such   nanoformulations   within  
animal   models   has   proved   cumbersome,   with   biodistribution   measurements  
extending  weeks  or  even  months  proving  particularly  tedious.    
This  study  assessed  the  use  of  our  theranostic  nanoparticle  platform  and  
its   ability   to   accumulate   within   monocyte-­macrophages   as   well   as  
reticuloendothelial   tissues.   Theranostic   nanotechnology   has   allowed   the   rapid  
screening   of   drug   tissue   biodistribution   and   pharmacokinetics   which   allows   for  
pharmacodynamic   improvements.   Our   theranostic   nanoparticle   platform   was  
developed  with  careful  consideration  of  components  that  allowed  assessment  of  
particle  presence  as  well  as  component  concentration  within  cells  and  tissues  in  
vitro,  in  vivo,  and  ex  vivo.  Encasement  of  hydrophobic  ARVs  and  imaging  contrast  
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agents  within  a  single  nanoformulation  produced  theranostic  nanoparticles  with  a  
multitude   of   modalities,   allowing   for   validations   of   the   multiple   measurements  
performed.  Incorporation  of  Eu3+  into  the  nanoparticles  allowed  for  confirmation  of  
particle   presence   within   cells   and   tissues   via   fluorescence   confocal   imaging.  
Cobalt  ferrite  provided  a  highly  sensitive  paramagnetic  material  necessary  for  T2  
contrast   which   allowed   us   to   take   advantage   of   the   great   spatial   resolution  
provided  by  MRI.  Intrinsic  doping  of  the  radioisotope,  111inidum  gave  us  the  ability  
to   accurately   determine   the   concentration   of   particles   in   vivo   by   SPECT/CT  
imaging.  SPECT/CT  imaging  is  known  for  having  greater  sensitivity  than  MRI,  but  
less   spatial   resolution.  By   combining  both   imaging  modalities,  we  were  able   to  
create   both   a   highly   sensitive   and   specific   probe.   Altogether,   our   theranostic  
nanoparticle  platform  allowed  for  real  time  assessment  of  ARV  biodistribution  and  
activity  that  would  otherwise  not  be  possible  with  traditional  plasma  post-­mortem  
tissue  concentration  analysis.  If  fully  realized,  these  particles  could  be  used  pre-­
clinically  to  screen  new  drug  candidates  early  in  development.  As  a  first  step  drug  
biodistribution   and   pharmacokinetic   analysis,   these   particles   would   provide  
information   about  whether   a   therapy   is   reaching   disease   sites   at   a   therapeutic  
concentration.   This   could   speed   drug   development,   bringing   more   effective  
medications  to  patients.    
  Upon   synthesis,   111InEuCF-­RPV   nanoparticles   showed   remarkably  
consistent  size,  magnetism,  fluorescence,  and  proper  ARV  drug  loading  as  well  as  
drug   release   in   PBS.      Administration   of   InEuCF-­RPV   to   in   vitro   macrophage  
cultures   resulted   in   consistent   cellular   uptake   of   nanoparticles,   showing  
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significantly  higher  uptake  than  NRPV.  Uptake  of  InEuCF-­RPV  nanoparticles  did  
not  affect  cellular  viability  in  these  studies.  Furthermore,  confocal  microscopy  of  in  
vitro   macrophages   displayed   InEuCF-­RPV   nanoparticles   localizing   within  
subcellular   components,   with   a   high   proportion   of   nanoparticles   residing  within  
recycling   endosomes.   Perhaps   most   importantly,   InEuCF-­RPV   nanoparticles  
exhibited   antiretroviral   activity   (similar   to   NRPV)   upon   administration   to   HIV-­1  
infected   in   vitro   cellular   cultures,   confirming   the   therapeutic   effects   of   our  
theranostic  nanoparticle  platform.    Real  time  in  vivo  MR  and  SPECT/CT  imaging  
of   mice   administered   111InEuCF-­RPV   nanoparticles   via   IV   injection   confirmed  
nanoparticle  presence  within  reticuloendothelial  tissues,  including  liver,  spleen  and  
axillary  and  inguinal  lymph  nodes  up  to  5  days  post  administration.  Quantification  
of  iron  concentrations  within  liver  and  spleen  was  performed  by  MRI  T2  mapping.  
Post-­mortem  tissue  concentrations  of  cobalt  and  RPV  were  measured  by  ICP-­MS  
and   UPLC-­   MS/MS,   respectively.   RPV   and   cobalt   levels   following   injection   of  
nanoparticles   showed   coordinate   tissue   and   plasma   drug   and   cobalt   levels.  
Furthermore,  quantification  of  SPECT/CT  imaging  data  from  the  first  5  days  post  
injection  proved  predictive  of  drug  and  cobalt  concentrations  up  to  28  days  post  
injection.   Post-­mortem   tissue   confocal   microscopy   confirmed   the   presence   of  
InEuCF-­RPV   nanoparticle   within   recycling   endosomal   compartments   in  
macrophages,  mirroring  results  found  in  in  vitro  confocal  microscopy  studies.  
Overall,  such  data  suggests   that   the  amount  of  drug   that  accumulates   in  
tissues  can  be  estimated  in  real  time  by  in  vivo  MRI  and  SPECT/CT  by  using  the  
known  signal-­to-­drug  ratio  of  111InEuCF-­RPV  nanoparticles.  This  imaging  data  can  
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then  be  used  to  predict  drug  pharmacokinetics  and  biodistribution  up  to  28  days  
post  administration  of  particles  which  can  greatly  help  and  speed  up  the  production  




A  major  limitation  of  our  111InEuCF-­RPV  theranostic  nanoparticle  platform  
was  that  of  drug  loading.  Indeed,  the  ability  to  load  adequate  amounts  of  drug  into  
a   nanoscale   system   while   still   containing   the   necessary   contrast   agents   and  
fluorescent  components  is  particularly  challenging.  111InEuCF-­RPV  nanoparticles  
exhibited   a   drug   loading   percentage   of   ~5.5%   weight/weight;;   while   such  
concentrations  were  adequate  to  exhibit  antiretroviral  activity  in  vitro,  it  is  unlikely  
that  such  drug  levels  would  have  much  of  a  therapeutic  effect  on  HIV-­1  replication  
in  vivo.  While  this  platform  provided  a  good  proof-­of-­concept  that  theranostic  ARVs  
can  predict  future  biodistribution,  several  of  the  correlations  made  had  moderate  
Pearson's   correlation   coefficients,   but   were   not   statistically   significant.   The  
limitation,   in  part,   reflects   the  particle  biodistribution  based  on  size.   Indeed,  our  
own  ultra-­small  177LuEuCF  particles   localized  primarily  to  the  lung  before  a   liver  
and  spleen  signal  could  be  visualized.  We  believe  this  system  can  be  accurately  
developed  to  closely  match  and  improve  upon  the  performance  of  our  current  and  
future  LASER  ART  formulations.  The  creation  of  particles  with  increased  aspect  
ratios  is  an  area  of  active  research  and  rod  shaped  particles  may  be  advantageous  




4.3  Future  Directions  
Potential   future  applications  of  HIV-­1   theranostic   technology  are  exciting  
and  are   rapidly   expanding.  Advancements   in   the   fields   of   chemistry,  molecular  
biology   and   engineering   have   facilitated   the   design,   development,   and  
implementation  of  numerous  sophisticated  theranostic  nanosystems  for  a  variety  
of  diseases  [282].  Additionally,  theranostics  is  being  applied  to  explore  variability  
in  therapeutic  responses  in  patients  adhering  to  different  medications,  vaccines,  
and  lifestyles  [283].  Despite  its  potential  to  drive  the  evolution  of  precise  diagnostic  
and  drug  delivery  agents  at  the  molecular  level,  theranostic  medicine  is  still  in  its  
infancy  and  optimal  systems  are  yet  to  be  developed.  Further  exploration  of  cellular  
dynamics,   disease   pathogenesis,   biomaterials,   genetic   engineering,   and   the   in  
vivo  behavior  of  nanomaterials  has  the  potential  to  uncover  solutions  to  challenges  
drug  delivery  systems  currently  face.    
In  addition  to  the  delivery  of  therapeutics,  nanosystems  are  often  employed  
for  screening  the  biodistribution  of   long-­acting  nanoformulated  drugs  [179,  284].  
This  is  of  particular  importance  as  the  half-­lives  of  each  of  the  few  existing  long-­
acting  drugs  measure  in  weeks  or  even  months  and  so  would  require  extensive  
and  cumbersome   traditional  pharmacokinetic   testing   [216,  220-­223,  285].   In  an  
effort   to   overcome   this   technical   and   biologic   challenge,   multimodal   decorated  
nanoparticles  have  been  produced   in  which  hydrophobic  ARVs  and  bioimaging  
agents  are  encased  within  a  single  nanoformulation.  The  bioimaging  agents  allow  
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for  visualization  by  SPECT,  PET,  fluorescence,  photoacoustic,  MR  imaging,  or  a  
combination   thereof.   This   enables   a   sensitive,   rapid   and   non-­invasive  
measurement  of  drug  location  and  concentration  in  the  body.  If  realized,  this  would  
be  a  significant  improvement  over  traditional  biodistribution  and  pharmacokinetic  
assays  that  require  animal  sacrifice  and  end  point  organ  removal.    
Successful  establishment  of  a  theranostic  nanoparticle  platform  would  allow  
more  advanced  drug  delivery  and  targeting  schemes  for  HIV-­1  eradication  to  be  
evaluated  more  efficiently.  Experimentation  that  traditionally  took  months  or  years  
could   be   performed  within  weeks,   allowing  more   time   and   resources   to   be   put  
towards   innovative   nano-­technological   developments.   Additionally,   further  
refinement   of   theranostic   nanoparticles   is   a   tangible   possibility   for   the   future.  
Recently,  we  have  begun  experimenting  with  nanoparticles  with  increased  aspect  
ratios,  such  as  bismuth  sulfur  nanorods   that  have   the  same  shape  and  size  as  
nanoformulated  ARVs.  These  particles  have  proven   to  provide  better  predictive  
power   in   terms   of   future   BD   and  PK   of   nanoformulated   drugs   than   older   ARV  
nanoformulations,  presumably  due  to  their  shape  and  surface  characteristics  more  
closely  matching  that  of  the  delivered  drugs.    
Alterations   in   nanoparticle   components   and   size   could   lead   to   specific  
targeting  of  other  HIV-­1  reservoirs,  such  as  the  brain  or  lymphoid  systems.  Many  
researchers  are  currently  using  a  variety  of  targeting  techniques  to  reach  cells  and  
tissues   of   interest.   In   the   case   of   HIV   infection,   strategies   that   actively   target  
therapeutics  to  anatomical  and  cellular  reservoirs  of  latent  infection  could  facilitate  
the   eradication   of   HIV   within   a   patient   entirely.   CD4   receptor-­targeted  
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nanoparticles   are   designed   to   deliver   therapeutics   to   T   cells   through   surface  
functionalization  with  targeting  molecules  such  as  monoclonal  antibodies  (mAb),  
peptides,  or  aptamers  and  have  been  used  in  various  diagnostic,  therapeutic,  and  
vaccine  applications  [286-­293].  CD4+  T  cells  are  the  major  target  for  HIV  infection,  
and  resting  memory  CD4+  T  cells  are  considered  the  primary  reservoir  of  latent  
HIV-­1  provirus  that  is  ineradicable  by  current  anti-­HIV  therapy.  Targeted  delivery  
of   antiretroviral   drugs  and   latency-­reversing  agents   to   these  CD4+  T  cells  may  
improve   drug   efficacy   and   minimize   toxicity   and   off-­target   effects   [294-­296].  
Although,   conventional   antibodies   have   been   used   to   target   nanoparticles,  
limitations   such   as   immunogenicity   and   nonspecific   uptake   by   the  
reticuloendothelial  system  may  reduce  effectiveness  [297,  298].    
An   interesting   and   novel   solution   to   these   limitations   would   be   use  
replication   incompetent  HIV  envelope  as  a  nanocarrier   of   therapeutics.  From  a  
biotechnological   point   of   view,   viruses   are   nature's   own   targeted   delivery  
nanoparticles   perfected   by   evolution   and   could   bring   improved   solubility,  
pharmacokinetics,  biodistribution,  and  designed  specificity  when  compared  with  
small  molecule  drugs.  Viruses,  structurally  can  be  defined  as  a  capsid,  which  is  a  
shell   of   proteins   and   lipids   that   encloses   genetic   material   needed   to   produce  
progeny  virus  in  target  cells  transcriptional  and  translational  machinery.  Virus-­like  
nanoparticles,  however  are  produced  from  DNA  plasmids  containing  only  genes  
for   the   capsid   proteins   and   lack   genes   for   replication   enzymes   as   integrase,  
reverse  transcriptase,  or  polymerases.  The  result  is  a  nanoparticle  that  targets  the  
same  cells  and  tissues  as  the  original  virus  without  creating  an  infection  [299,  300].  
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Virus-­like  particles  (VLPs),  are  rigid  and   firm  structures   that  can  be   loaded  with  
drug  molecules  in  a  confined  nanosized  spatial  distribution  [301].  These  are  well-­
defined  protein  based  geometries  at  the  atomic  level  with  attractive  self-­assembly  
properties  that  are  alterable  by  genetic  manipulation.  The  capsid  of  viruses  act  as  
protein  cages  in  which  drugs  can  be  loaded  in  a  controlled  manner  and  precisely  
delivered  due  to  their  ideal  size  for  endocytosis.    
In   the   context   of   a   cure   for  HIV,   it  was   recently   reported   that   sequential  
treatment   with   LASER   ART   and   CRISPR-­Cas9   (targeted   to   the   long   terminal  
repeat  region  of  the  gag  gene)  demonstrated,  for  the  first  time,  viral  eradication  in  
HIV  infected,  humanized  mice  [302].  Nested  and  digital-­droplet  PCR,  as  well  as  
RNAscope   tests  were  unable   to   detect   virus   in   latent   infectious   viral   reservoirs  
such   as   blood,   lymphoid   tissues,   bone   marrow   and   brain.   In   the   study   an  
adenovirus  was  used   to   deliver   the  CRISPR-­Cas9   system,   but   such  a  delivery  
system   has   inherent   limitations   including   target   specificity   and   potential   for  
immunogenicity.   The   ideal   delivery   vehicle   for   these   treatments   is   yet   to   be  
realized,  but   in   theory,  an  HIV-­like  nanoparticle,  whose  surface  consists  of  HIV  
envelope   glycoproteins   (gp120   and   gp41)   present   as   trimers   and   whose   core  
encases  both  LASER  ART  and  CRISPR-­Cas9  protein   (with   its  associated  RNA  
guide)  would  serve  as   the   ideal  HIV   reservoir   targeted   therapy  and  could  bring  
eradication  of  HIV  to  humans.  Additionally,  like  other  types  of  nanoparticles,  VLPs  
can   be   designed   for   bioimaging   techniques   through   incorporation   of   PET   or  
SPECT   radioisotopes,   quantum   dots,   or   MRI   contrast   agents   to   track   particle  
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biodistribution  and  serve  as  confirmation  of  particle  localization  to  anatomical  and  
cellular  targets.    
In  1900,  German  Nobel  laureate  Paul  Ehrlich  envisioned  a  scientific  concept  
he  termed,  “the  magic  bullet”.  He  envisioned  that,  just  like  a  bullet  fired  from  a  gun  
to  hit  a  specific  target,  there  could  be  a  way  to  specifically  target  invading  microbes  
in  the  body  without  harming  the  body  itself.  Nanotechnology  has  the  potential  to  
bring  magic  bullet  type  cures  to  almost  any  disease  and  could  usher  in  an  era  of  
personalized   medicine   where   treatment   and   diagnosis   are   accomplished   with  
single  agents.  The  therapeutic  index  of  drugs  delivered  via  nanoparticles  can  be  
greatly  enhanced  as  drug  and   imaging  agents  are  brought  directly   to  cells  and  
tissues   affected   by   disease.   This   allows   for   the   sparing   of   healthy   cells   and  
reduced  off-­target  toxicities.  In  the  context  of  HIV,  nanoparticles  can  increase  the  
concentration  of  drug  at  anatomical  sites  that  current  orally  administered  drugs  do  
not  reach  in  therapeutic  concentrations.  The  distribution  of  these  platforms  can  be  
tracked   non-­invasively   to   ensure   proper   biodistribution   of   therapies.   Overall,  
nanotechnology   will   continue   to   be   a   major   driver   of   pharmacological  
advancements  in  healthcare  in  the  foreseeable  future.    
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